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ABSTRACT
In the field of biomaterials, naturally-derived and synthetic polymers are
utilized individually or in combination with each other, to create bio-inspired or
biomimetic materials for various bioengineering applications, including drug delivery
and tissue engineering. Natural polymers, such as proteins and polysaccharides, are
advantageous due to low or non-toxicity, sustainable resources, innocuous byproducts,
and cell-instructive properties. Synthetic polymers offer a variety of controlled
chemical and physical characteristics, with enhanced mechanical properties. Together,
natural and synthetic polymers provide an almost endless supply of possibilities for the
development of novel, smart materials to resolve limitations of current materials, such
as limited resources, toxic components and/or harsh chemical reactions. Herein is
discussed the synthetic-biological material formation for cell-instructive tissue
engineering and controlled drug delivery. We hypothesized that the combination of
hydrogel-based scaffold and engineered nanomaterials would assist in the development
or regeneration of tissue and disease treatment.
Chemically-modified alginate was formed into alginate-based nanoparticles
(ABNs) to direct the intracellular delivery of proteins (e.g., growth factors) and small
molecular drugs (e.g., chemotherapeutics). The ABN surface was modified with celltargeting ligands to control drug delivery to specific cells. The ABN approach to
controlled drug delivery provides a platform for studying and implementing nontraditional biological pathways for disease (e.g., osteoporosis, multiple sclerosis) and
cancer treatment.
Through traditional organic and polymer chemistry techniques, and materials
engineering approaches, a stimuli-responsive alginate-based smart hydrogel (ASH) was
developed. Physical crosslinks formed based on supramolecular networks consisting of
β-cyclodextrin-alginate and a tri-block amphiphilic polymer, which also provided a
reversible thermo-responsiveness to the hydrogel. The hydrogel was shear-thinning,
and recovered physical crosslinks, i.e., self-healed, after un-loading. The ASH
biomaterials provide a platform for injectable, therapeutics for tissue regeneration and
disease treatment. Indeed, various hydrogel constituents and tunable mechanical
properties created cell-instructive hydrogels which promoted tissue formation.
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CHAPTER 1: CONPREHENSIVE LITERATURE REVIEW
PREFACE
In the field of bioengineering, the essence and motivation for research are
ultimately driven by fundamental questions in biology. To provide technical support in
the discovery of significant biological (and medical) findings, bioengineers contribute
methodologies and tools, to perform research in a safe and controllable manner. In
order to do so, bioengineers must have an understanding of, and appreciation for, the
work of biologists and doctors. Herein, my thesis has introduced and discussed relevant
biology in order to provide context for my work, and the motivation for my research
projects.
The contributions of my PhD thesis research are highlighted in detail below, in
regards to the collaborative publications in the field of biomaterials and biomedical
engineering:
Throughout the 4 years of my PhD research, I designed a natural-based
polysaccharide (i.e., alginate) nanoparticle platform for targeted and controlled delivery
of a variety of therapeutics, in order to meet treatment requirements for different
diseases, including: osteoporosis, lung cancer and multiple sclerosis. Various chemical
modifications of the polysaccharide core nanoparticle, and surface conjugation
chemistries, were utilized, characterized, and in some respects quantified, to enhance
the functionality of the nanoparticles. 1) I synthesized an alginate-graft-poly(ethylene
glycol) copolymer in order to form nanoparticles via water/oil emulsions; the sidechain addition of poly(ethylene glycol) (PEG) onto the alginate backbone was designed
to partially neutralize the nanoparticle. 2) I performed dithioldipyridine modification of
the alginate backbone in order to conjugate a targeting peptide (i.e., arginine-glycineaspartic acid, RGD) onto the surface of the nanoparticles. 3) I helped design the
emulsion of double-crosslinked hydrogel nanoparticles to prolong the release profile of
small molecules. In addition, I also performed flow cytometry to verify the nanoparticle
cellular uptake, and designed and completed the statistical analysis of the nanoparticle
data. The shared nanoparticle fabrication, and cell culture, was performed by Spencer
Fenn, a fellow graduate student in the Oldinski Laboratory. 4) I designed and
implemented an avidin coating on the nanoparticles, to allow subsequent conjugation of
any biotinylated antibody (e.g., a cell surface marker) to target drug delivery to
selective cell types. The remainder of the targeting efficacy verification in vitro and in
vivo were done by Abbas, in the Cory Teuscher Ph.D. Laboratory, and Dr. Dimitry
Krementostov. 5) I quantified the encapsulation efficiency and drug release profiles
over 14 days, for vascular endothelia growth factor A (VEGF-A), fibroblast growth
factor 2 (FGF-2), doxorubicin, bovine serum albumin (BSA). I quantified the
nanoparticles’ size and surface charge with dynamic light scattering, and characterized
the surface morphology with scanning electron microscopy. I created an efficient
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fluorescent labeling procedure to efficiently tag nanoparticles with Alexa-647, which
can be tracked and traced in vitro and in vivo. I also used these tagged nanoparticles to
semi-quantitatively determine how cells are internalized by cells, and how they are
transported inside cells. I cultured the nanoparticles with cancer cells, human epithelial
cells, and human mesenchymal stem cells. I was able to induce osteogenic
differentiation using MSC treated with VEGF-A loaded nanoparticles, and able to slow
down lung cancer proliferation using FGF-2 loaded nanoparticles.
The other significant part of my PhD research was to design an injectable
thermo-responsive hydrogel, based on alginate, for tissue regeneration and disease
treatment, specifically, drug delivery and cell transplantation. I synthesized and
characterized the mechanical properties of the hydrogels. I also conjugated RGD, a proadhesion peptide, onto the alginate backbone, mixed with cells, injected the material
into a tissue culture dish, and verified cell viability.
In the project of poly vinyl alcohol (PVA) /gelatin scaffold, I was able to create
porous hydrogels using freeze/thaw methods. I also synthesized theta-gels consisting of
PVA, gelatin and PEG. I quantified the mechanical properties of the hydrogels using
rheometry and scanning electron microscopy. I also performed a chondrogenesis assay
using the PVA/gelatin scaffold to verify the efficacy of using this material to regenerate
articular cartilage.
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1.1. Introduction to Polysaccharides
Natural-based polysaccharides from different sources attract much attention
from various industrial fields, such as the food and feed industries, and medical and
pharmaceutical industries[1]. Polysaccharides comprise a groups of molecules known
as carbohydrates. Along with oligosaccharides, they are one of the most abundant
group of materials in the class of biopolymers to be involved in many biological
structural building blocks and processes[2]. The basic structure for polysaccharides
consists of a monosaccharide repeating unit with hydroxyl groups, such as cellulose
and amylose. Some polysaccharides have other functional groups in addition to basic
hydroxyl groups, such as chitosan’s amine group, and alginate’s carboxyl groups,
offering more functionality compared to more basic polysaccharides (Figure 1-1). Due
to similar biochemical properties compared with human extracellular matrix (ECM),
polysaccharides are readily recognized and accepted by the body, and are viewed as
biocompatible. In addition, these polymers are susceptible to enzymatic and/or
hydrolytic degradation in biological environments, resulting in innocuous byproducts,
which can either be reused by the human body or cleared by the immune system[3].
Modern nanotechnology has boosted the development of drug delivery systems
to enhance the therapeutic efficacy for different type of diseases. With the tunable small
sizes that researchers can achieve, micro/nanoparticles can travel through the smallest
capillary vessels while avoiding clearance by phagocytes, resulting in a prolonged
blood stream residence time. The small size also facilitates their ability to penetrate
3
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tissue and cell gaps, and to even be internalized by targeted cells for efficient drug
delivery. Furthermore, the availability of additional chemical conjugation techniques
provides controlled–release drug profiles to target cells with different triggers, such as
pH, ion and/or temperature[4].
Compared to other type of polymers, polysaccharides have several advantages
for controlled drug delivery. First, the backbone structure of polysaccharides,
particularly hydroxyl and amine groups, yield high aqueous solubility, and are better
absorbed by the human body, and undergo hydrolysis to degrade into innocuous simple
sugar molecules. Second, many polysaccharides possess innate bioactivity, particularly
mucoadhesive, antimicrobial, and anti-inflammatory properties[5]. For example,
chitosan, which is the only natural positively charged polysaccharide, is capable of
attaching to negatively charged mucosal layers via electrostatic interactions[6]. Another
example is hyaluronic acid, which binds to CD44 sites in the extracellular domain[7].
Third, polysaccharide-based nanoparticles exhibit biocompatible and biodegradable
properties. Finally, polysaccharides are extremely amenable to chemical modification.
For example pegylation, peptide conjugation, and antibody coatings provide various
physiological behaviors and bioactivities for different applications[8].
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Figure 1-1. Structures of repeating units of some of the polysaccharides discussed in this
review. Branching is not shown for dextran. The structures of alginate and hyaluronic
acid are shown as two linkage types rather than a formal repeating unit. The chitin and
chitosan structures represent extremes of a continuum of structures.

1.2. Structures and Modifications of Polysaccharides
1.2.1. Alginate
Alginates are non-branched polysaccharides consisting of 1→4 linked β-Dmannuronic acid (M) and its C-5 epimer α-L-guluronic acid (G), extracted from algae
(such as kelp), or an exopolysaccharide of bacterial origin including Pseudomanas
aeruginosa. Commercially available alginates are most often derived from brown
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algae[9]. With the widely found extrusion source as well as the low cost of purifying
techniques, alginate has been applied in the food, biochemical, and biomedical
industries. The U.S. Food and Drug Administration (US-FDA) recognizes alginate as a
“Generally Referred As Safe (GRAS)” material[10].
Referring to the backbone structure of alginate, two functional groups have been
used for chemical conjugation. One is the common hydroxyl group from
polysaccharides and the other is the carboxyl group. The hydroxyl group can be reacted
with methacrylic anhydride via esterification, which can then be crosslinked upon
exposure to long-wave UV light in the presence of a photoinitiator[11]. Jeon et al. have
also developed a protocol using 2-aminoethyl methacrylate to react with the carboxyl
groups on alginates, providing alternatives for designing alginate-based photo-sensitive
materials[12].
Hydroxyl groups can also be oxidized to create more reactive groups and
increase the rate of degradation[13-15]. The periodate oxidation of alginate, which
chemically breaks the carbon-carbon bond of the cis-diol group in the urinate residue
and changes the chain conformation, results in promotion of hydrolysis of alginate in
aqueous solutions[13]. Jeon et al. also suggested that photo-crosslinked oxidized
methacrylated alginate hydrogels can promote enhanced cell adhesion and spreading
compared to those prepared with alginate that had not been oxidized[16], due to the
free aldehyde groups on photo-crosslinked oxidized methacrylated alginate hydrogels
forming bonds with amines present on cell surface or ECM proteins[16, 17].
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The carboxyl group also offers potential variations of alginate-based materials.
The most common strategy is to react the carboxyl group with an amine group to form
peptide bond using water-based reaction, which is catalyzed by 1-ethyl-3-(3dimethylaminopropyl)-carbodiimide (EDC) and N-hydroxysulfosuccinimide (sulfoNHS)[18-20]. While the water-based reaction is capable of directing bioconjugation
without prior organic solvent dissolution, excess reagent and byproducts can be easily
removed by dialysis or gel-filtration. The high reaction efficiency allows researchers to
conjugate polymers[20-22], peptides[23, 24] and proteins[25] onto alginate. In addition
to aqueous reactions, carbodiimide chemistry can also be performed in organic solvent,
rendering alginate soluble in organic solvent. The organic-based carbodiimide
chemistry was performed with (benzotriazol-1-yloxy)tris(dimethylamino) phophonium
hexa-fluorophosphate (BOP)[26]. To render alginate soluble in organic solvent, Pawar
et al. dissolved tetrabutylammonium (TBA) salts of alginic acid in polar aprotic
solvents containing tetrabutylammonium fluoride (TBAF)[27], which react with
alginates homogeneously in organic solvents, including dimethyl sulfoxide (DMSO)
and dimethylformamide (DMF).
Alginate particles have the ability to deliver proteins such as growth factors[9]
and cytokines[28], chemotherapeutics such as doxorubicin[29] and paclitaxel[30],
small molecules drugs[28] and nucleic acids including DNA[31] and RNA[32] (Figure
1-2). Thus, alginate shows great potential for the development of innovative drug
delivery systems.
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Figure 1-2. Schematic representation of alginate particulates for surface medication and
encapsulated drugs.

1.2.2. Chitosan/Chitin
Chitin is one of the most abundant polysaccharides in the natural world, and is
the supporting material for crustaceans, insects, etc., where it represents the major
component of their exoskeleton. The structure of chitin consists of 2-acetamido-2deoxy-β-D-glucose through a β (1→4) linkage[33]. Chitosan is the N-deacetylated
derivative of chitin, which consists of β(1-4)-linked D-glucosamine and N-acetyl-Dglucosamine, though this N-deacetylation is almost never complete[33, 34].Chitosan
has been used in the pharmaceutical industry for almost three decades, inspiring both
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academic and industrial researchers to create various therapeutic systems. In contrast to
all biodegradable polysaccharides, chitosan is cationic, based on its primary amino
groups. The polycations can be used to promote mucoadhesion, because the mucus gel
layer contains anionic sub-structures including sialic acid and sulfonic acid. Based on
the ionic interactions between the cationic primary amino groups of chitosan and the
anionic sub-structures of mucus, mucoadhesion can be achieved. In addition,
hydrophobic interactions may also contribute to the mucoadhesive properties [34, 35].
The solubility of chitosan in water is relatively poor, which limits its application in the
pharmaceutical industry. To facilitate dissolution, researchers have utilized acidic
solution with pH below 6.5 to increase the repulsion between different polymer
chains[36]. The backbone of chitosan contains multiple hydroxyl groups, capable of
supporting many reactions including methacylation[37]. Chitosan also contains amine
groups, which can react with carboxylate groups via carbodiimide chemistry catalyzed
by NHS/EDC. Rafat et al. reported using poly(ethylene glycol) dibutylaldehyde (PEGDBA) and short-range amide-type cross-linkers (EDC and NHS) to crosslink collagen
and chitosan molecules, which enhanced the mechanical strength and elasticity[38].
The unique properties of chitosan make it useful for developing drug delivery
systems for various applications. Studies have shown that chitosan can assist oral drug
delivery, ocular drug delivery, nasal drug delivery, vaginal drug delivery, buccal drug
delivery, parenteral drug delivery, intravesical drug delivery and vaccine delivery[34].
The commercially available chitosan derivative “Ciclopoli®” has been registered and
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we foresee more commercially available chitosan derivative products boosting the
pharmaceutical industry[34].

1.2.3. Hyaluronic Acid
Hyaluronic acid (HA) is a naturally occurring linear polysaccharide with
repeating units of D-glucuronic acid and N-acetyl-D-glucosamine disaccharide (Figure
1-1). It was first isolated from the vitreous humor of bovine eyes by Meyer and
Palmer[39, 40]. Due to the presence of carboxyl group on each of the repeat units, HA
is usually associated with cations at pH=7. As with other polysaccharides, HA is highly
hydrophilic, capable of absorbing large amounts of water and swelling up to 1000 times
[39, 41]. The unique character of HA that is different from other polysaccharides is that
it is capable of interacting with cell receptors, i.e. hyaluronan binding proteins, such as
CD44, RHAMM, LYVE-1, IVd4 and LEC receptors, since it is a major constituent of
skin and ECM[7, 42]. The inherent bioactivity of HA makes it a desirable biomaterial
for tissue engineering and drug delivery (Figure 1-3)[39, 43, 44].
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Figure 1-3. Schematic representation of advantages of HA in drug delivery [44]
(Adapted from reference).
HA contains a carboxyl group on each repeat unit, making it an anionic polymer
at neutral pH. Similar to alginate, the available hydroxyl and carboxyl groups on HA
are subject to a series of modifications including methacrylation[45] and carbodiimide
conjugation[46]. Methacrylated HA can be photo-crosslinked with either ultraviolet
(UV) light[46] or visible light[46]. The -NHCOCH3 group, which is distinctive in HA,
is available for deacetylation and amidation activated by hydrazine sulfate[47]. There is
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a trend of conjugating other polysaccharides onto hyaluronic acid for tissue
regeneration. Rodell et al. reported a shear-thinning hydrogel based on the guest-host
interactions of adamantine modified HA and β-cyclodextrin modified HA. The physical
crosslinked hydrogels show potential as a minimally invasive injectable hydrogel for
biomedical applications [48]. Owing to the unique and valuable physico-chemical
property of HA, researchers have designed and synthesized innovative HA derivatives
for various biomedical applications.

1.2.4. Dextran
Dextran consists of repeat units of branched glucans of varying lengths, which
is medically applied as an antithrombotic to reduce blood viscosity, or as a volume
expander for hypovolaemia. Dextran is produced by numerous types of bacteria,
including Leuconostocmesenteroids. Similar to other type of polysaccharides, the
properties of dextrans are strongly dependent on their structure including molecular
weight and degree of branching. Dextran is soluble in water, formamide and DMSO,
and insoluble in alcohol and acetone[49]. Only normal hydroxyl groups from the sugar
repeat unit are present on the dextran backbone; therefore, reactions which modify
hydroxyl groups are applicable to dextran. Maia et al. have investigated the degree of
oxidation of dextran using sodium periodate[50].
Cyclodextrin is one type of dextran obtained from the enzymatic degradation of
starch, belonging to the family of cage molecules (Figure 1-1). Supramolecular
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hydrogels utilizing interactions between macrocyclic host and guest polymers to form
inclusion complexes have drawn attention in the biomedical field[51]. The most
common host polymer is cyclodextrin, of which there are three types with different
numbers of sugar units on the ring[52]. The 3-dimensional structure of cyclodextrin
(CD) reveals an inner hydrophobic cavity, The core of cyclodextrin is composed of a
dimensionally stable hydrophobic cavity, able to trap and encapsulate other molecules,
making it a valuable material for drug delivery[53]. However, the smaller size of CD
limits its application. Therefore, there is a great need to conjugate CDs onto other
polysaccharides, such as alginate. Rodell et al. conjugated β-CD onto HA to form
supramolecular hydrogels. Alginate is also a popular polysaccharide to react with CD.
Pluemsab et al. reported a coupling reaction between α-CD and alginate at the hydroxyl
groups of alginate via the Cyanogen bromide (CNBr) method. After ionically
crosslinking with CaCl2, alginate-CD microparticles were generated approximately 500
µm in diameter[54]. Researchers have also reported using carbodiimide chemistry to
synthesize alginate-CD, providing alternatives for similar formulations[55]. Dextran
modification yielded other polymers with different molecular weights, shapes,
structures and various coupling groups, which is helpful in achieving controlled drug
delivery and release[56].

1.3.

Preparation of Polysaccharide-Based Particles

To maintain the network of polysaccharide particles while avoiding dissolution

13
·

of the hydrophilic polymer chains/segments into the aqueous phase, crosslinking is
performed. In general, labile bonds are introduced to form the crosslinked network.
However, these bonds are subjected to degradation either enzymatically or chemically.
Both chemical and physical crosslinking methods have been applied in forming
polysaccharide particulates[57].

1.3.1. Crosslinking Reaction
1.3.1.1. Physical Crosslinking
The advantage of physical crosslinking is that it can avoid using toxic
crosslinkers, which need to be extracted from particles before application in vivo. The
most common physical interactions are ionic. Alginate is a well-established material
that has been extensively studied to form nanoparticles. As stated above, the
mannuronic and guluronic repeat units on an alginate backbone contain carboxyl
groups, which can be crosslinked by calcium ions. The reaction is simple and fast, and
can be performed at room temperature. It occurs through the exchange of sodium ions
from the guluronic acid blocks with multivalent cations, such as Ca2+, forming a
characteristic “egg-box” structure [58]. The higher the percentage of guluronic acid, the
tighter the ionically crosslinked network, resulting in a prolonged drug release
profile[58]. The mild gelation method has enabled particle-based delivery of pDNAs,
growth factors or even live cells[28]. The formation of ionic crosslinks is reversible,
and the addition of a chelating agent will destabilize the crosslinked network, causing
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particle degradation.
An example of Ca2+ crosslinked alginate microspheres was generated from a
microfluidic device by Chen et al. They reported on a versatile droplet microfluidics
method to fabricate alginate microspheres while simultaneously immobilizing antiMycobacterium tuberculosis complex IgY and anti-Escherichia coli IgG antibodies on
the porous alginate microspheres for specific binding and binding affinity
tests[59].They showed that calcium crosslinked alginate microspheres were generally
round with undulating membranes.

1.3.1.2. Covalent Crosslinking
The water solubility of polysaccharides comes from the presence of functional
groups, including hydroxyl groups, carboxyl groups and amine groups, which can also
react to form new bonds in order form crosslinked networks. Yoon et al. developed
photo-crosslinked HA nanoparticles (c-HANPs) with improved stability for tumortargeted drug delivery[60]. The photo-crosslinking reaction was triggered by UV-Vis
activation of acrylate groups in the polymer backbone. c-HANPs showed significantly
higher stability in a physiological buffer and prolonged the release profile of a
chemotherapeutic, paclitaxel, enabling long circulation in the body with enhanced
tumor targeting ability. Researchers compared the near infrared fluorescence (NIRF)
imaging of SCC7 tumor-bearing mice treated with FPR675-labeled HANP and cHANP. C-HANP showed longer body circulation and higher tumor accumulation
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compared to NHNP without crosslinking, with lower excretion within 24 h postinjection of PR674-labeled nanoparticles[60].

1.3.2. Methods
1.3.2.1. Emulsions
Emulsions have been widely applied in the design of drug delivery particles and
pharmacotherapy. Emulsions provide a number of attributes, such as optical clarity,
ease of preparation, thermodynamic stability, and increased surface area. Phase
behavior studies have shown that the size of the droplets is determined by the surfactant
phase structure (bicontinuousmicroemulsion or lamellar) at the inversion point induced,
by either material composition or temperature[61]. Since polysaccharides are usually
water soluble, water/oil emulsions are most applicable in the fabrication of
polysaccharide nanoparticles. Machado et al. prepared calcium alginate nanoparticles
using w/o nano-emulsions. The emulsions were produced from mixtures of nonionic
surfactant tetraethylene glycol monododecyl ether (C12E4), decane, and aqueous
solutions of up to 2 wt % sodium alginate by means of the phase inversion temperature
(PIT) emulsification method. This method produced finely dispersed emulsions without
a large input of mechanical energy[62].
To ensure evenly sized nanoparticles, a homogenizer is often used in the
emulsion process to reduce the size of droplets in liquid-liquid dispersions, thus
generating stable homogenized particles. However, the inherent random emulsion
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process is not ideal for industry. Microfluidics have shown unparalleled advantages for
the synthesis of polymer particles and have been utilized to produce hydrogel particles
with a well-defined size, shape and morphology. Most importantly, during the cell
encapsulation process, microfluidics can control the number of cells per particle and the
overall encapsulation efficiency. Therefore, microfluidics is becoming a powerful
approach for cell microencapsulation and construction of cell-based drug delivery
systems[63].

1.3.2.2. Microfluidic Device
Microfluidic devices utilize the science of manipulating and controlling fluids
and particles at micron or sub-micron dimensions to exploit a wide range of biological
applications such as high-throughput drug screening, single cell or molecular analysis
and manipulation, drug delivery and advanced therapeutics, biosensing, and point of
care diagnostics, among others[64]. Fluid flow in microchannels is diffusion-based
laminar flow due to low Reynolds numbers[65]. Several materials have been cast to
make microfluidic devices, including polymer polydimethylsiloxane (PDMS),
polymethylmethacrylate (PMMA), polystyrene (PS), polycarbonate (PC), cyclic olefin
copolymer (COC)[66], silicon[67] and metal[68].Typically syringe pumps or
microfabricated

pumps

provide pressure-driven

flow

in

the

microchannels;

electrokinetic devices provide additional options for pumping liquids. Reagent
solutions are manipulated inside microfluidic devices. A T-junction is usually designed
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to generate droplets alternatively and fuse droplets in a tapered chamber[69]. Indeed, in
the Oldinski Laboratory, a microfluidic flow focusing device was developed, which is
consistently reproducible, readily characterized, and easy to test and use, to produce
homogeneous alginate microparticles[70]. Microfluidic devices allow researchers to
control the physical conditions and behavior of fluids in a micro/nano scaled domain to
fabricate polysaccharide biomaterials, offering versatile solutions for fabrication,
manufacturing and research in the field of cell biology, pharmacology and tissue
engineering.
1.4. Preclinical Applications
1.4.1. Tissue Engineering and Regeneration
Polysaccharides form hydrogels and micro/nanoparticles through various
reactions, and are able to encapsulate drug for therapeutic applications. Polysaccharide
based micro/nanoparticles also provide protection to encapsulated growth factors,
offering versatile release profiles in a controlled manner, while reducing the risk of
adverse events[71]. Tissue engineering is an emerging biomedical field aiming to assist
and enhance the regeneration of tissue as well as to substitute for the biological
functions of damaged organs. To promote tissue regeneration or wound healing, growth
factors are required to induce angiogenesis, which supplies oxygen and nutrients to
cells transplanted for organ substitution, to maintain their biological functions[72].
Some growth factors stimulate the proliferation and differentiation of stem cells via
certain cellular signaling pathway[73]. Various growth factors enhance the proliferation
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and survival of multipotential stromal cells, including transforming growth factor beta
(TGF-β), fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF),
platelet-derived growth factor (PDGF), epidermal growth factor (EGF), hepatocyte
growth factor (HGF) and Wnt[74]. Almubarak et al. summarized the role of common
growth factors in angiogenesis and osteogenesis, with the current status of preclinical
and clinical trials[75]. Table 1-1 lists a series of examples of different polysaccharides
for the delivery of bioactive agents for various applications.
Polysaccharide
type
Alginate

Bioactive
Application
Agents
Amidated pectin Wound healing
hosting
doxycycline
(Antibiotics)
human
Cartilage
fibroblast
defects
growth factor 1
(FGF-1)
human bone
morphogenetic
protein 4 (BMP4)

Role in Tissue
Engineering
Inhibit bacterialinfection-caused
necrosis in wound
healing process
Promote the in
vitro development
of mature
adipocytes

Reference

Alginate

human
fibroblast
growth factor 1
(FGF-2)

Peripheral
artery disease
and coronary
artery disease

[78]

Alginate

FGF-1

Hypoxia

Promote
neovascularization
and restore blood
flow and tissue
function of heart
muscle
Enhancement of
graft
neovascularization
in a retrievable
rat omentum
pouch

Alginate
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[76]

[77]

[79]

Alginate

Alginate

Hyaluronic acid

Hyaluronic acid
Chitosan
Hyaluronic acid
Chitosan

Poly(L-lactideco-glycolide)
(PLGA)-grafted
hyaluronic acid

Transforming
growth factorbeta (TGF-β)

Articular
cartilage
defects

Controlled
delivery of TGF-β
selectively to the
injury site and
improve the repair
of articular
cartilage defects
in rabbit model
Insulin-like
Nervous
Enhanced the
growth factor-1
system
proliferation of
(IGF-1)
disorders such
the encapsulated
as stroke
NSCs
None
atherosclerosis
Reach the
atherosclerotic
lesion after
systemic
administration
with high
potential as carrier
for diagnosis and
therapy of
atherosclerosis
VEGF
Wound healing
Promote
angiogenesis and
accelerate healing
VEGF
Development
Promote
PGDF-BB
of vascular
angiogenesis
network during
implantation
bone
Bone
Promote the
morphogenetic
regeneration
attachment,
protein-2 (BMPproliferation,
2) and IGF-1
spreading, and
alkaline
phosphatase
(ALP) activity of
human adiposederived stem cells
(hADSCs).
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[80]

[81]

[82]

[83]

[84]

[85]

Alginate
TGF-β3
Cartilage repair
microspheres
Parathyroid
within hormone related
hyaluronic acid protein (PTHrP)
hydrogels
Hyaluronic DNA encoding Cartilage tissue
acid/Chitosan
TGF-β1
engineering
nanoparticles
embedded in
porous chitosan
scaffold
Glycidyl
BMP-2
Wound
methacrylated
Healing
dextran
Acetalated
Hepatocyte
Myocardial
Dextran
growth factor
Infarction (MI)
fragment

Promote neo
cartilage
formation

[86]

Promotion of
chondrocyte
proliferation

[87]

Periodontium
Drug Delivery

[88]

Largest arterioles,
[89]
fewest apoptotic
cardiomyocytes
bordering the
infarct, and the
smallest infarcts
Methacrylated
Ischemia
Increase blood
[90]
VEGF
perfusion and
dextran
angiogenesis
Chitosan–
BMP-2 gene
Repair of bone
Affect cell
[91]
polyethylenimine
defect
differentiation
through a BMP-2
signal pathway
and promote new
bone formation at
the defect area
Table 1-1. A series of examples of different polysaccharides for the delivery of bioactive
agents for various applications.

1.4.2. Cancer Therapy
1.4.2.1. Therapeutic Aspect
Cancer remains one of the worlds’ major causes of death[92] and the
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improvement of effective therapies continues to challenge researchers. With optimal
size and surface properties, polysaccharide nanoparticles can be designed and
engineered to increase bloodstream circulation time. Due to the enhanced permeability
and retention effect, and ligand conjugation, nanoparticles can accumulate in the tumor
site while delivering anticancer therapeutics, providing a higher targeting efficacy
comparing to traditional drug delivery methods. Surface conjugation of cell targeting
moieties also facilitates precise delivery of chemotherapeutics, resulting in higher
treatment efficiency and fewer adverse events[93]. Table 1-2 list a serious of examples
of polysaccharide based drug delivery systems for cancer therapy.

Polysaccharide
Type

Anticancer
agents

Hyaluronic Acid None
(HA)

Imaging
Agents
Cy5.5

Cancer
Type
Xenograft
subcutaneous
dorsa
of
athymic nude
mice
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Result and
Application

Referen
ce

To visualize the [94]
biodistribution
of
HA
nanoparticles
accumulating
into the tumor
with
a
combination of
passible
and
active targeting
mechanism

Liposomeprotaminehyaluronic acid

TGF-β
siRNA

Melanoma

Induction
of [95]
antigen-specific
immune
response and
target
modification of
tumor
microenvironm
ent; powerful
tool
for
immunotherapy

Chitosan

siRNA for None
VEGRA,
VEGFR1
and
VEGFR2

Breast
Cancer

Suppressive
[96]
effect on VEGF
expression and
tumor volume

Chitosan/Alginat
e

Doxorubici
n

None

HepG2
hepatoma
cells
xenografts

Induce
the [97]
apoptosis
of
HepG2 tumor
cells both in
vitro and in
vivo

Alginate

Doxorubici
n

None

Liver tumor

Tumor
[98]
necrosis; heart
cells
and
healthy
liver
cells
surrounding the
tumor were not
affected

Glycyrrhetinic
acid-modified
alginate

Doxorubici
n

None

Hepatoma
Carcinoma

Tumor
[99]
inhabitation
rate
reach
79.3%

None
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Alginate-g- Poly Doxorubici
(Nn
isopropylacrylam
ide) (PNIPAAm)

FCR-675

Squamous
cell
carcinoma

DOX-loaded
[100]
alginate-gPNIPAAm
micelles
showed
excellent anticancer
therapeutic
efficacy in a
mouse model
without
any
significant side
effects

Alginate

Cisplatin

Cy5.5

Human
caucasian
ovary
adenocarcino
ma

Enhance
[101]
delivery
of
CDDP
into
ovarian tumor
tissues
and
improved the
antitumor
efficacy
of
CDDP, while
reducing
nephrotoxicity
and
body
weight loss in
mice

N-trimethyl
chitosan

Cisplatin–
alginate
complex

None

Human
Induce
ovarian and apoptosis
lung
Carcinoma

[102]

Hyaluronic acid

Cisplatin

None

Human
malignant
gliomas

Induce
apoptosis

[103]

Chitosan

Destrandoxorubici
n

None

Various
Cancer type

Induce
[104]
apoptosis and
shrink
tumor
size
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Hyaluronic acid

Cisplatin
siRNA that
downregula
te
antiapopotic
genes
overexpress
ed
in
cisplatin
resistant
tumor

Indocyani
ne green

Lung cancer

Overcome the [105]
Multidrug
resistance
effect of lung
cancer
in
xenograft
model
and
induce
apopotosis

Table 1-2. Examples of polysaccharide based drug delivery systems for controlled
delivery anticancer agents.

Zhang et al. used glycyrrhetinic acid (GA) modified alginate nanoparticles to
target the delivery of doxorubicin (DOX) to mice for treating liver cancer. After single
tail-vein injections of 7mg/kg body weight, the concentration of DOX in the liver
reached 67.8

4.9 µg/g, which was 2.8-fold and 4.7-fold higher compared to non-GA

modified alginate nanoparticles and free DOX HCl. Histological examination showed
tumor necrosis in both experimental groups. Most importantly, the heart cells and the
liver cells surrounding the tumor were not affected by administration of DOX/GA-ALG
NPs, whereas myocardial necrosis and apparent liver cell swelling were observed after
DOX·HCl administration[106].

1.4.2.2. Imaging/Monitoring Aspect
The rapid developing field of cancer treatment requires an appealing and
versatile strategy for selective drug delivery, diagnostic and therapy purpose. Molecular
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imaging technology has gained tremendous attention in cancer therapy, driven by
nanoparticle mediated theranostics[107-111]. The nanotheranostics-based imaging
platform holds great potential to provide invaluable insights into both cancer diagnosis
and therapeutic response monitoring. Polysaccharide particulates can encapsulate
multiple imaging contrasts into one single system for systematic administration. Chan
et al. reported of using gadolinium-chelating crosslinkers to crosslink self-assembled
pullulan nanogels to both impact magnetic properties and to stabilize the materials for
tumor magnetic response imaging (MRI). The polysaccharide coating provides high
signal enhancement lasting 7 days in long imaging time scales while causing no
damage or toxicity in major organs over three months’ monitoring, highlighting the
potential clinical application of this Gd-chelating pullulan nanogels as a tumor-imaging
MRI contrast agent, permitting tumor identification and assessment with a high signalto-background ratio[112].
Another application of polysaccharides in assisting cancer imaging is through
surface coating of nanoparticles, especially magnetic nanoparticles. The polysaccharide
coatings of magnetic particles increased their biocompatibility, stability and
concentration in the in vivo circulation[113, 114]. Thomas et al. reported

developing

hyaluronic acid (HA) coated superparamagnetic iron oxide nanoparticles (SPIONs)
primarily for use in a hyperthermia application with an MR diagnostic feature. As
stated in the previous session, HA is able to target CD44 over expressed cancer cells,
providing more functionality to the imaging contrast agent. HA-SPION-injected mice
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tumors showed nearly 40% MR T2 contrast compared to the 20% MR T2 contrast of
the HA-PEG10-SPION group over a 3 h time period[115].
The RNA interference (RNAi) technique has been a new route for cancer therapy
and several candidates are being tested clinically. In the development of RNAi-based
techniques, imaging methods provide a visible and quantitative solution to investigate
the therapeutic effect at anatomical, cellular and molecular level, able to noninvasively
trace the distribution and study the biological processes in preclinical and clinical
stages[116]. Nanocarrier-mediated delivery of RNAi therapeutics usually encounters
different biological barriers including reaching the circulation, crossing the vascular
barrier, cellular uptake, and endosomal escape. With the advancements in chemical
modification and nanotechnology, polysaccharide nanoparticles are diverse in size and
charge, being widely applied as platforms for simultaneous gene/drug delivery and
imaging[117]. Yoon et al. reported a novel type of biodegradable hyaluronic acid-graftpoly(dimethylaminoethyl methacrylate) (HPD) conjugate that can form complexes
with siRNA and be chemically crosslinked via the formation of the disulfide bonds
under facile conditions, exhibiting high stability in 5-% serum solution compere
to uncrosslinked ones.The in vivo study, which was performed using FPR675labeled
HPDwith siRNAcomplexes, showed the efficacy of selective accumulation of the
complexes at the tumor site after intravenous injection into tumor-bearing mice,
achieving successful gene silencing effect while being able to be monitored with whole
body NIRF imager[118].
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While the application of polysaccharide-coated particles show promising
results in research, there are limitations. One problem is to target sites located farther
from the magnetic source. Future research should focus on designing multimodality
imaging probes with polysaccharide coatings to upgrade the use of particle based
imaging based contrasts, offering versatile solutions for early cancer detection
and monitoring[113].

1.5. Clinical Translations
Despite the potential for polysaccharide-based nanoparticles, they

remain

elusive to the market and only a few products have continued to a clinical trial. As
natural biomaterials, polysaccharides have been applied in different industries,
including food and medical. Table 1-3 includes a list of ongoing and completed clinical
trials with polysaccharide-based drug delivery systems; many of the clinical trials
involving alginate focus on dietary supplements, such as iron[119]. DIABECELL is
one of the most promising products available, in Phase III clinical trial, for the
encapsulation of porcine islets for the treatment of type 1 diabetes[79]. In addition,
there are a wide variety of applications using polysaccharide coatings on other
nanoparticles to reduce cytotoxicity and immunogenicity[120, 121].
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Indications

Name

Delivery
Route
Dietary
Supplement
Dietary
Supplement

Bioactive
Components
ferrous
gluconate
Domperidon
e
Omeprazole
Alginic acid

Delivery
System
Alginate
beads
N/A

Iron deficiency
anemia
Gastroesophag
eal Reflux
Disease
Systemic
Sclerosis
Scleroderma
Type 1 diabetes

Alginate
beads
Alginic acid

DIABECEL
L
IK-5001

Xenotranspl
antation
Intracoronar
y slow bolus
injection

Porcine
islets
Calcium
Gluconate

Alginate

Cystic Fibrosis

OligoG CF5/20

Inhalation

N/A

Phase I

Breast Cancer

RadiaPlex
Aquaphor

Hyaluroni
c acid

Immune related
Disease

Chitin
MicroParticles
Immucist®

Injection to
the medial
half or the
lateral half
of the
irritated
breast.
Intranasal
dosing

OligoG CF5/20 Gblock
Oligosaccha
ride Derived
From
Alginate
Polysacchari
de
Radiation

N/A

Bacillus
CalmetteGuérin
29

Myocardial
Infarction

non-muscle
invasive
bladder cancer
·

Intravesical
administrati
on

Developmen Country
t Phase
Complete
United
Phase I trial Kingdom
Ongoing
Thailand
Phase III

N/A

New
Zealand
United
States,
Australia,
Belgium,
Canada,
France,
Germany
, Israel,
Poland,
Spain
Merthyr
Tydfil,
United
Kingdom

[122]

Phase III

United
States

[125]

Chitin

Phase I

Denmark

[126]

Hyaluroni
c acid

Phase I

Italy

[127]

Sodium
Alginate

Ongoing
Phase III
Phase I

Referenc
e
[119]

[123]

[124]

Table 1-3. Examples of clinical trials with polysaccharides.

1.6. Conclusions
The biocompatibility, accessibility, and versatile options for chemical modifications
make polysaccharides desired materials for applications in biomedical engineering. I
have selected alginate as the focus of my research to make different systems for tissue
engineering and drug delivery applications.
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CHAPTER 2: OSTEOGENIC DIFFERENTIATIO OF HUMAN
MESENCHYMAL STEM CELLS THROUGH ALGINATE-GRAFTPOLY(ETHYLENE GLYCOL) MICROSPHERE-MEDIATED
INTRACELLULAR GROWTH FACTOR DELIVERY
The intracellular delivery of growth factors increases opportunities for
controlling cell behavior and maintaining tissue homeostasis. Recently, VEGFA was
reported to enhance osteogenic differentiation of mesenchymal stem cells (MSCs)
through an intracrine mechanism, suggesting a new strategy to promote bone tissue
formation in osteoporotic patients. The goal of this study was to design and fabricate
ligand-conjugated alginate-graft-poly(ethylene glycol) microspheres for intracellular
delivery and release of VEGFA in primary human MSCs to enhance osteogenic
differentiation as a potential therapeutic. Three types of microspheres were synthesized
and characterized by scanning electron microscopy, in vitro drug release kinetics, MSC
uptake and internalization: alginate alone (Alg), alginate-graft-poly(ethylene glycol)
(Alg-g-PEG) and alginategraft-poly(ethylene glycol)-S-S-arginine-glycine-aspartic acid
(Alg-g-RGD). Each of the different microsphere formulations successfully transported
bioactive VEGFA into primary human MSCs within 48 h of culture, and significantly
enhanced osteogenic differentiation compared to control treatments with empty
microspheres (intracellular control) or non-encapsulated VEGFA (extracellular
control). Adipogenic differentiation was not affected by the presence of VEGFA
intracellularly or extracellularly. These results demonstrating the internalization of
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alginate-based microspheres and intracellular delivery of VEGFA support the efficacy
of using this drug delivery and intracrine mechanism to control the fate of human
MSCs and enhance osteogenic differentiation.

2.1. Introduction
Osteoporosis is defined by a reduction in the quantity and quality of bone that
results in skeletal fragility [1]. As people age, bone resorption rates become unbalanced
and bone resorption dominates over bone formation, which leads to reduced bone mass
and altered bone architecture. Human bone marrow progenitor cells known as
multipotent stromal cells or mesenchymal stem cells (MSCs) can differentiate into
osteoblasts, chondrocytes and adipocytes and show promise for clinical bone repair [2].
A notable recent study with murine MSCs showed that intracellular as opposed to
extracellular signaling of vascular endothelial growth factor A (VEGFA) had the ability
to distinctly regulate MSC lineage commitment toward osteoblasts or adipocytes [3].
Liu et al. (2012) demonstrated that murine bone marrow stromal cells were more likely
to differentiate into osteoblasts when MSC expressed VEGFA and possessed
intracellular VEGFA, compared with no change in osteoblastic differentiation
following exposure of MSCs to extracellular VEGFA. The investigators proposed that
VEGFA regulated differentiation through an intracrine mechanism unique to the
intracellular form of VEGFA and different from the typical mechanism for secreted,
extracellular VEGFA and signaling through cell surface receptors. For patients, the
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intracellular delivery of VEGFA into MSCs prior to cell therapy could be a potential
approach to speed the repair of large or complex bone fractures or perhaps even to treat
chronic skeletal diseases such as osteoporosis [4]. In this work, we developed and
functionally tested a specialized drug delivery system designed to accomplish the
controlled, intracellular delivery of VEGFA in MSCs.
Modern drug delivery systems are designed to maintain the structure and
bioactivity of biomolecules and to release therapeutics in a controlled and predictable
manner. Micro-encapsulation is one of the core technologies used in polymer drug
delivery systems [5]. Polymeric particles or microspheres for controlled drug delivery
applications are designed to provide uniform particle dimensions, shield the drug from
the extracellular environment, and be biocompatible [6]. Alginate microspheres have
attracted much attention for the development of controlled- and sustained-release drug
delivery systems for proteins [7], cytokines [8] and cells [9, 10]. Alginate is a naturally
occurring polysaccharide extracted from brown seaweed that is generally regarded as
non-toxic. The fabrication of alginate microspheres is favorable for drug delivery due
to the relatively mild yet rapid gelation process that omits the use of harsh chemicals to
ensure stability of encapsulated biomolecules [11-14]. However, the application of
alginate microspheres has been limited due to their relatively large diameters (10 – 100
μm) and rapid drug-release rates (< 24 h) [15]. In addition, the anionic nature of
alginate interferes with the encapsulation and release of charged molecules such as
polyelectrolytes. To overcome these limitations, alginate microspheres have been
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refined by varying molecular weight and concentration, stirring conditions, degree of
crosslinking, and chemical modification of the alginate polymer to achieve sustained
drug release [16, 17].
Poly(ethylene glycol) (PEG) is the most widely applied synthetic polymer in the
emerging field of biomaterials for drug delivery. Recently, alginate has been modified
with PEG for the fabrication of microcapsule coatings [18], mucoadhesive polymers
[19, 20], self-assembling nanospheres [21, 22] and hybrid microspheres [23, 24]. The
ability of PEG to influence the pharmacokinetic properties of drugs and drug carriers
has been used to modify many different pharmaceutical compounds and components
[25]. Biocompatibility and stealth behavior make PEG an ideal material to avoid
opsonization and subsequent elimination by the reticuloendothelial system [26]. In
addition, PEG-modified products are less immunogenic and antigenic; hemolysis and
aggregation of erythrocytes may also decrease, as can the risk of embolism. However,
the lack of a cell adhesion ligand limits its application in targeted drug delivery
systems. To address this issue, we developed novel PEG-modified alginate copolymer
microspheres with and without the surface conjugation of a bioactive cell adhesion
ligand.
Proteins containing tri-peptide arginine-glycine-aspartate (RGD) attachment
sites, along with the integrins serving as receptors for them, constitute a major
recognition system for cell adhesion to the extracellular matrix (ECM) [27].
Consequently, researchers continue to utilize RGD in order to mimic cell adhesion
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proteins and bind to integrins [28], inhibit apoptosis, angiogenesis, and tumor formation
[29], coat surfaces for use as biomaterials [30], and enhance drug delivery systems [31,
32], including microspheres [33]. In this study RGD was utilized as a model cellrecognition molecule to demonstrate the efficacy of immobilizing ligands onto
microsphere surfaces. Our results demonstrate that the incorporation of an adhesion
ligand onto the surface of alginate-graft-PEG (Alg-g-PEG) microspheres containing
VEGFA provides a promising strategy to regulate osteoprogenitor cell differentiation
and bone tissue homeostasis, in addition to providing efficacy for the use of surface
ligands for cell-targeted therapeutic applications in vivo.

2.2 Materials and Methods
2.2.1. Materials
Sodium alginate (MW = 65–75 kg/mol, 60-70% guluronic acid residues) was
generously donated by FMC BioPolymer. Cysteine-L-arginyl-glycyl-L-aspartic acid
(CRGD) was purchased from Genscript. Amine-poly(ethylene glycol)-thiol (NH2-PEGSH, MW = 1000 g/mol) and methyl-poly(ethylene glycol)-amine (mPEG-NH2, Mw =
500 g/mol) were purchased from Laysan Bio. N-ethyl-N’(3-dimethylaminopropyl)
carbodiimide hydrochloric acid (EDC), N-hydroxysuccinimide (NHS),

2,2’-

dithiodipyridine, methanol (MeOH, anhydrous, 99.8%), biology-grade mineral oil,
Span 80, Tween 80, ethylenediaminetetraacetic acid (EDTA), dexamethasone, ascorbic
acid, β-glycerol phosphate, hydrocortisone, isobutylmethylxanthine, indomethacin,

43
·

deuterium oxide (D2O), the In Vitro Toxicology Assay Kit (MTT-based), Hoechst
33342 and Alizarin red were purchased from Sigma-Aldrich. One molar hydrochloric
acid (HCl) and 1 M sodium hydroxide were purchased from BDH ARISTAR®PLUS.
Dichloromethane (DCM, 99.9%), sodium citrate, isopropanol, sodium chloride (NaCl),
sodium acetate (NaAc), alpha-modified eagle medium (α-MEM, Hyclone), DyLight
550 Microscale Antibody Labeling Kit, and 20X phosphate buffered saline (PBS) were
purchased from Fisher Scientific. Penicillin, streptomycin and Trypsin EDTA were
purchased from Corning Cellgro. AdipoRedTM was purchased from Lonza Inc. Human
VEGF DuoSet ELISA Kit was purchased from R&D Systems. Fetal bovine serum
(FBS) was purchased from Atlanta Biologics and screened for a lot that best supported
growth of human MSCs. Green fluorescent protein (GFP)-labeled human MSCs were
generated by lentiviral transduction for stable integration of the gene and enriched by
selecting for GFP-positive cells by fluorescence activated cell sorting (FACS).

2.2.2. Alg-g-PEG-S-S-Pyridine Copolymer Synthesis
First, NH2-PEG-SH (0.1 mg, 0.1 mM) was dissolved in 5 mL of de-gassed
acetate buffer (0.1 N sodium acetate adjusted to pH 4.6 with acetic acid, 0.3 M sodium
chloride, and 1 mM EDTA) into which a solution of 2,2’-dithiodipyridine (88.124 mg,
0.4 mM) dissolved in 10 mL of MeOH was added; the mixture was stirred at room
temperature under a flowing N2 atmosphere for 4 h. The MeOH was extracted three
times with DCM and the sample was prepared for 1H-NMR analysis [34].
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Alginate was modified with the newly formed NH2-PEG-S-S-pyridine using
EDC and NHS chemistry. The COOH:EDC:NHS molar ratio remained consistent at
1:8:3.2 during the carbodiimide reactions, where COOH refers to the moles of alginate
carboxyl groups. A 1% (w/v) alginate solution was adjusted to pH 5 with 1 N HCl.
EDC was then added followed by NHS and the solution was mixed at room
temperature for 30 min. NH2-PEG-S-S-pyridine and mPEG-NH2 (the control PEG graft
chain) were added to separate alginate solutions, respectively; the target degrees of
PEG modification of the alginate was 10 %. After 12 h of reacting at room temperature,
the various alginate and PEG polymer solutions were placed into dialysis cassettes
(MWCO 20 kDa, Pierce Biotechnology) and dialyzed against deionized (DI) water for
4 d; dialysis solution was changed every 12 h. The Alg-g-PEG-S-S-pyridine copolymer
product was lyophilized and the powder was stored in a desiccator until use. PEG
retention post-fabrication was verified using 13C-NMR (Bruker AVANCE III 500 MHz
high-field NMR spectrometer) in D2O [34]. As a control, Alg-g-PEG copolymers were
synthesized with this approach using mPEG-NH2. The polymer was dissolved in D2O
and the result was verified via 1H-NMR (Bruker AVANCE III 500 MHz high-field
NMR spectrometer).

2.2.3. Microsphere Fabrication
To fabricate microspheres containing VEGFA, Alg-g-PEG-S-S-pyridine was
dissolved in phosphate buffered saline (PBS) with pH pre-adjusted to 5.0 with 1 N HCl.
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Non-modified alginate (Alg) and Alg-g-PEG microspheres were fabricated using a 1%
(w/v) polymer solution. VEGFA was added to the copolymer solution at a ratio of 106:1
(copolymer:VEGFA). Microspheres without VEGFA were fabricated as blank controls.
One mL of polymer/VEGFA solution was slowly added to 6.72 mL of biological-grade
mineral oil containing 5% (v/v) Spam 80 while mixing at 1200 rpm for 5 min at room
temperature. Next, 400 µL of 30% (v/v) Tween 80 was added and the emulsion was
mixed for an additional 5 min. Then, 5 mL of 1 M calcium chloride (CaCl2) solution
was added slowly. After 30 min of mixing, 3 mL of isopropanol was added to the
emulsion and allowed to mix for 5 min, then was centrifuged at 400 rpm for 5 min to
precipitate microspheres. The microspheres were washed sequentially with isopropanol
(x2) and DI water (x2), respectively, and centrifuged after each wash. The Alg-g-PEGS-S-pyridine microspheres were formed in a similar fashion, however, the DI water
wash was replaced with a 1% (w/v) CRGD solution (x2); the corresponding
microspheres are here-after identified as Alg-g-RGD. Microspheres were flash frozen
in liquid N2.
After lyophilization Alg, Alg-g-PEG and Alg-g-RGD microspheres were
characterized by scanning electronic microscopy (SEM, JEOL 600; samples were
sputter coated with 45 nm of gold). SEM micrographs of various magnifications were
used to quantify microsphere diameters; images were analyzed using ImageJ (3 images
per group).
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2.2.4. Cytotoxicity Assay
Human MSCs were isolated from bone marrow aspirates with an IRB-approved
protocol. Human MSCs (passage 7) were seeded in 24 well tissue culture polystyrene
(TCPS) plates at a density of 20,000 cells/well in 500 µL/well of standard MSC growth
medium (α-MEM, 10% fetal bovine serum (FBS), 100 U/mL penicillin, 100 µg/mL
streptomycin) and allowed to adhere for 24 h. Cells were incubated in the presence of
Alg, Alg-g-PEG, and Alg-g-RGD microspheres encapsulating VEGFA (n = 3 per
group) at concentrations of 10, 50, 100, 500 µg/mL at 37°C and 5% CO2. After 24 h of
incubation, medium containing the microspheres was removed, and cells were rinsed
two times in sterile PBS then analyzed using a MTT-based In Vitro Toxicology Assay
Kit following the manufacturer’s protocol. The optical density was measured at 570 nm
using a BioTek plate reader. Background absorbance at 690 nm was subtracted from
the measured absorbance. Absorbance values for the experimental and control samples
were normalized to non-modified TCPS controls [35].

2.2.5. Dylight 550 Labeling of Human VEGFA
Recombinant human VEGFA was cloned, expressed in HEK 293 cells, and
purified in the Spees laboratory [36]. 1 mg/mL of purified VEGFA in PBS was used for
labeling. The DyLight Microscale Antibody Labeling Kit was used according to the
manufacturer’s instructions. Briefly, 100 μL of 1 mg/mL protein was mixed with a
commercial vial of DyLight 550 reagent and incubated for 60 min in the dark after
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gentle vortexing and a quick centrifugation step to mix the sample and dye. Spin
columns provided by the kit were then placed into microfuge collection tubes and used
for purification of protein from unbound dye. The labeling solution was mixed with
purification resin and centrifuged in the spin column to purify labeled protein. The dye:
protein ratio was determined based on methods described in the labeling kit.

2.2.6. VEGFA Encapsulation and Release
A known amount of lyophilized VEGFA-loaded Alg, Alg-g-PEG and Alg-gRGD microspheres was dissolved by immersion in 3% (w/v) sodium citrate solution to
dissolve the microspheres by displacing calcium ions [37]. The VEGFA concentration
was measured with a DuoSet ELISA Development Kit. Briefly, standard series and
sample solutions were added to a culture plate (100 µL/well) pre-coated with capture
antibody after washing in mild detergent (0.05% Tween 20 in PBS). After 2 h of
blocking and incubation at room temperature, the biotin-conjugated detection antibody
was added and incubated for another 2 h. Then 100 µL poly HRp conjugated
streptavidin substrate was incubated in each well for 20 min after washing the detection
antibody, followed by incubation with 100 µL substrate (ABTS, Thermo Scientific.) in
the dark at room temperature. The absorbance was measured at 450 nm with a BioRad
microplate reader. The VEGFA concentration was determined with a standard curve,
and the VEGFA encapsulation efficiency (mass of VEGFA encapsulated in the
microspheres / mass of VEGFA added when forming the microspheres) was calculated.
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A VEGFA release test was performed in a 48 well plate at 37°C. Six mg
lyophilized VEGFA-loaded Alg, Alg-g-PEG and Alg-g-RGD microspheres was
dissolved in 500 µL of PBS (pH 7.4). At each time point (1, 2, 4, 8, 12, and 24 h,
followed by collection each day for a total of 14 d) 100 µL of the PBS was removed
and another 100 µL was added to maintain the total volume. The released VEGFA
concentration was determined with the DuoSet ELISA Development Kit as above.

2.2.7. Human Mesenchymal Stem Cells Intracellular Delivery
DyLight 550-labeled VEGFA (red fluorescence) was incorporated within Alg,
Alg-g-PEG and Alg-g-RGD microspheres using the same above approach except the
ratio of polymer to VEGFA was increased from 106:1 to 105:1 to increase the intensity
of the visualized signal. Microspheres (500 μg/mL) were cultured with GFP-labeled
human MSCs (100,000 cells, passage 4, green fluorescence) for 24 h in glass bottom
culture dishes pre-coated with poly-d-lysine (MatTek Corporation). Confocal laser
scanning (CLS) microscopy (Zeiss LSM 510 META) was used to visualize the
microspheres by detecting directly through the plate. Z-stack images were formed with
the use of AimImage Software.

2.2.8. Human Mesenchymal Stem Cells Differentiation Assay
Human MSCs (passage 4) were seeded in 12 well TCPS plates at a seeding
density of 50,000 cells/well. Cells were cultured at 37°C and 5% CO2 in standard MSC
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growth medium containing 100 μg/mL of VEGFA-encapsulated microspheres (Alg,
Alg-g-PEG or Alg-g-RGD) or pure microspheres not containing VEGFA. The
experiments were done in triplicate. After 48 h, old medium was aspirated off and one
plate was given osteogenic differentiation medium (growth medium including
dexamethasone, ascorbic acid, β-glycerol phosphate) and the other plate received
adipogenic differentiation medium (growth medium including hydrocortisone,
isobutylmethylxanthine, indomethacine). Cells that served as controls were cultured
without the addition of microspheres (either with VEGFA or without VEGFA).
Differentiation medium was changed every 3 d. After 14 d of culture in differentiation
medium, cells were rinsed with sterile PBS and analyzed via an Alizarin Red
osteogenic differentiation assay [38, 39] or an AdipoRedTM adipogenesis assay
(Sigma). In addition, six different concentrations of VEGFA ranging from 0 to 20
ng/ml (0, 0.01, 0.025, 0.05, 0.5, 20 ng/ml) were incubated with human MSCs for the
control assay (extracellular VEGFA). The extracellular VEGFA differentiation
experiment was conducted in 24 well TCPS plates with a seeding density of 30,000
cells/well. After 48 h, medium containing VEGFA was aspirated off and the plates
were given either osteogenic or adipogenic differentiation medium. Differentiation
medium was changed every 3 d. After 7 d of culture in differentiation medium, cells
were rinsed with sterile PBS and analyzed via an Alizarin Red osteogenic
differentiation assay [38, 39] or an AdipoRedTM adipogenic differentiation assay
(Sigma).
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2.2.9. Statistical Methods
All experiments were performed in triplicate; results are reported as mean ±
standard deviation. Statistical analysis was performed using one-way ANOVA with
Tukey multiple comparisons (α = 0.05) via the SAS statistics program in the GLM
procedure as the post-test to compare all of the groups. A p < 0.05 is considered
significantly different.

2.3 Results
2.3.1. Synthesis of Alg-g-PEG and Alg-g-PEG-pyridine Copolymers
The copolymer reactions for the chemical modification of alginate are shown in
Figure 2-1. To synthesize Alg-g-PEG-pyridine, the oligomer NH2-PEG-S-S-pyridine
was synthesized first. 1H-NMR spectral analysis confirmed the presence of both PEG
and pyridine in the final product (7.1 ppm, 7.5 ppm, 7.7 ppm, 7.9 ppm corresponding to
the hydrogen on pyridine ring and 3.6 ppm corresponding to the hydrogen within the
repeat group in PEG) when compared to the alginate and PEG controls (Figure 2-7).
The large peak at 1.8 ppm corresponds to the excess acetate in the reaction system; this
by-product does not interfere with the carbodiimide chemistry and can be removed
through dialysis in the proceeding step of the copolymer reaction. Quantification of the
reaction yield by peak integration determined approximately 70% reaction efficiency.
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Figure 2-1. Chemical modification of alginate (Alg) with two different poly(ethylene
glycol) (PEG) oligomers with methyl and pyridine end groups, respectively. The
synthesis of Alg-g-PEG was conducted using carbodiimide chemistry at pH 5 and room
temperature. To synthesize Alg-g-PEG–S-S-Pyridine, NH2-PEG-SH was reacted with
2,2’-dithiodipyridine in degassed acetate buffer at pH 4 and room temperature under N2
flow. Next, the modified NH2-PEG-pyridine was conjugated to alginate using
carbodiimide chemistry.

The natural polysaccharide alginate was grafted with a short chain PEG
decorated with either pyridine or methyl end groups resulting in the copolymers Alg-g-
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PEG or Alg-g-PEG-pyridine. For the synthesis of Alg-g-PEG, 1H-NMR spectral
analysis confirmed the presence of both alginate and PEG functional groups in the final
purified graft copolymers through the appearance of new peaks and peak shifts in the
Alg-g-PEG spectrum (Figure 2-8); 3.36 ppm corresponds to the -CH3 moiety of the
PEG side chain and 4.31 ppm corresponds to the shift of hydrogen atoms due to the
grafting of the PEG side chain when compared to the alginate and PEG controls. As
stated in the methods, the theoretical degree of PEG modification was 10 molar % of
alginate backbone. Quantification of PEG conjugation by peak integration of the 1HNMR spectra was not successful due to extensive broadening and overlapping of peaks
corresponding to alginate in the Alg-g-PEG spectra. The synthesis of Alg-g-PEGpyridine was confirmed by

13

C-NMR (Figure 2-9); 132.31 ppm, 136.05 ppm, 141.37

ppm, 143.53 ppm, 149.24 ppm correspond to carbon on the pyridine ring, 69.76 ppm
corresponds to the carbon within the repeat unit of PEG, and 42.84 ppm corresponds to
the carbon on the alginate. Verification of NH2-PEG-S-S-pyridine by

13

C-NMR

confirmed that the reaction was successful.

2.3.2. Fabrication of Alg, Alg-g-PEG and Alg-g-RGD Microspheres
Complete microsphere fabrication strategies are shown in Fig. 2. Alg, Alg-gPEG and Alg-g-RGD microspheres were designed to encapsulate VEGFA without
interfering with the bioactivity and electrostatically-condensed structure of VEGFA.
The mild gelation method by the addition of CaCl2 during an emulsion was successful
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in creating microspheres encapsulating VEGFA. The surface functionalization of
microspheres through CRGD conjugation did not appear to affect the shape or yield of
the microspheres. SEM photomicrographs demonstrate that the microspheres (Alg,
Alg-g-PEG and Alg-g-RGD) were spherical in shape with an average diameters and
standard deviations of approximately 1.9 ± 1.0 µm, 0.5 ± 0.1 µm, and 1.1 ± 0.4 µm,
respectively (Figure 2-2).

Figure

2-2.

Schematic

representation

of

microsphere

fabrication

techniques.

Microspheres with or without VEGFA were prepared by premixing alginate or alginatebased copolymer solutions with VEGFA and creating a water/oil emulsion at room
temperature in the presence of 1M calcium chloride. An additional surface modification
step was performed on Alg-g-PEG-S-S-Pyridine microspheres to chemically conjugate
CRGD via disulfide bonds. For Alg-g-RGD microspheres, the conjugation of 2,2’dithiodipyridine was used to exchange the thiol group on the cysteine-RGD (CRGD) after
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microsphere fabrication.

Figure 2-3. The shape, average diameter, VEGFA encapsulation efficiency and
cytotoxicity of alginate-based microspheres were verified using scanning electron
microscopy (SEM), an ELISA assay (n = 3), and an MTT-based In Vitro Toxicology
assay. SEM micrographs representing (A, D) Alg, (B, E) Alg-g-PEG, and (C,F) Alg-gRGD microspheres were fabricated without the addition of VEGFA through a water/oil
emulsion; micrographs shown in A,B,C have a scale bar = 10 μm while micrographs in
D,E,F have a scale bar = 10 μm. In preparation for imaging, microspheres were frozen by
immersion in liquid N2 and subsequently lyophilized; samples were sputter-coated with
45 nm of Au-Pb. (G) Microsphere diameters were determined using ImageJ analysis on
SEM micrographs. (H) The effect of microsphere concentration (10, 50, 100, and 500
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μg/mL) on primary human MSC viability after 24 h culture in standard MSC growth
medium at 37°C and 5% CO2 was determined. Experimental groups were normalized to
non-modified confluent human MSCs cultured on tissue culture polystyrene.

2.3.3. Alg-g-PEG Microspheres Exhibit no Cytotoxic Effects
The viability of human MSCs in the presence of Alg, Alg-g-PEG and Alg-gRGD microspheres containing no VEGFA was determined at increasing concentrations
(10, 50, 100 and 500 µg/mL, Fig. 3H). These results demonstrated that Alg, Alg-g-PEG
and Alg-g-RGD microspheres were non-toxic (cell viability > 90%) at concentrations
up to 100 µg/mL. and cell viability > 75% at a concentration as high as 500 µg/mL.
RGD-modified and PEG-modified alginate microspheres showed increased viability in
higher concentrations compared to Alg microspheres.

2.3.4. VEGFA Encapsulation and Release Rates
VEGFA release rates from Alg, Alg-g-PEG and Alg-g-RGD microspheres are
shown in Fig. 4. VEGFA encapsulation efficiency values were 52, 22 and 35%
respectively for the different microsphere groups (see Fig. 3G). All of the microsphere
groups sustained VEGFA release for 14 d; almost 100% of the encapsulated VEGFA
was released within the 14 d sudy. Alg-g-RGD microspheres released more drug
overall when compared to the other microsphere groups (shown in Fig. 4A). More
importantly, within the first 72 h the VEGFA release profile demonstrated that the
microspheres released a substantial amount correlating to the 48 h incubation time used
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during for the differentiation assays. Alg and Alg-g-RGD microspheres released nearly
twice that of Alg-g-PEG microspheres (shown in Fig. 4B). When comparing the 72 h
release profile with the longer 14 d release profile, it is evident that a burst release
within the first 12 h was followed by a gradual sustained release until the termination of
the study.
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Figure 2-4. Quantitative release of VEGFA was calculated using the encapsulation
efficiencies of each sample group and the VEGFA concentration after each time point.
Sample aliquots were collected and VEGFA concentration was determined using an
ELISA assay (n = 3). (A) Cumulative VEGFA release (ng/mL) from alginate-based
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microspheres in phosphate buffered saline at pH 7.4 and 37°C over a sampling period of
14 days and (B) 72 hours was determined.

2.3.5. Microsphere Internalization
Internalized Alg, Alg-g-PEG and Alg-g-RGD microspheres encapsulated with
DyLight 550 (red fluorescent) labeled VEGFA was verified after examination of CLS
micrographs. GFP human MSCs (green) were successfully delivered DyLight-labeled
VEGFA (red) using the Alg, Alg-g-PEG and Alg-g-RGD microsphere delivery systems
(Figure 2-5). The red microspheres were spread throughout the cytoplasm and
appeared to surround the nucleus. The intensity of red is a qualitative visualization of
microsphere internalization rather than a quantitative measurement.
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Figure 2-5. Confocal light microscopy images of GFP-labeled human MSCs (green)
after 24 h of culture with DyLight 550 labeled-VEGFA-encapsulated alginate-based

60
·

microspheres (red) at a concentration of 500 µg/mL in standard MSC growth medium.
The Alg, Alg-g-PEG and Alg-g-RGD images all verify the internalization of
microspheres, especially compared to the non-modified empty Alg microsphere
control. The red intensity is a qualitative visualization of microspheres internalization
rather than a quantitative measurement.

2.3.6. Human MSC Differentiation
The UV absorbance of Alizarin red and fluorescent AdipoRed™ assays were
used to quantify the osteogenic and adipogenic differentiation of human MSCs,
respectively. The extent of differentiation was normalized to cell number by measuring
the fluorescence intensity of Hoechst nuclear staining. As shown in Figure 2-6,
incubation of human MSCs with microspheres containing VEGFA resulted in a
significant increase in osteogenic differentiation when compared with non-modified
TCPS controls. Statistical analysis of the data indicated a significant difference (p <
0.04) between the experimental groups (Alg, Alg-g-PEG and Alg-g-RGD) and the
control group (cells cultured without the addition of VEGFA-encapsulated
microspheres). The p-values for Alg, Alg-g-PEG and Alg-g-RGD microsphere groups
compared to the control group were 0.0001, 0.0005 and 0.0330, respectively. For the
adipogenesis differentiation assay, the Alg microsphere group showed a significant
enhancement compared to the control group (p = 0.02). For the other two groups (Algg-PEG and Alg-g-RGD), there were no significant differences for the adipogenesis
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assay with p-value of 0.28 and 0.57 respectively (Figure 2-6). The empty microspheres
and pure VEGFA experimental groups did not exhibit any trends or significant
differences for either adipogenic or osteogenic differentiation (p > 0.06) as shown in
Figure 2-6. The significant differences between the experimental and control groups
demonstrate that the VEGFA-encapsulated microspheres (Alg, Alg-g-PEG, Alg-gRGD) were internalized by hMSCs and that VEGFA was delivered intracellularly,
resulting in a functional output (osteogenic differentiation).
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Figure 2-6. In vitro osteogenic (gray) and adipogenic (black) differentiation assay
results of human MSCs after 14 days in culture with differentiation growth medium.
(A) and (B) represent the VEGFA-encapsulated microspheres, (C) and (D) represent
empty microspheres, and (E) and (F) represent extracellular delivery of pure VEGFA at
different concentrations ranging from 0 to 20 ng/ml. A turkey statistical test was
performed to compare the experimental groups to the control groups (n = 3). ** shows
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a significant p-value less than 0.0005 and * shows p-value less than 0.04. For the
control group, only standard MSC growth medium was added. The graphs illustrate a
significant difference between VEGFA encapsulated Alg, Alg-g-PEG and Alg-g-RGD
microsphere groups compared to the control group in the osteogenesis assay as well as
for the VEGFA encapsulated Alg microsphere group in the adipogenesis group. No
significant differences were seen (p ≤ 0.05) between control and experimental groups
for the osteogenesis and adipogenesis assays when empty microspheres were used or
VEGFA was delivered extracellularly.

2.4. Discussion
There is a growing demand for injectable acellular therapeutics for the enhanced
mineralization of osteoporotic bone. This study provides the first evidence that Alg,
Alg-g-PEG and Alg-g-RGD microspheres, fabricated from graft copolymers of alginate
and amine-terminated PEG or alginate and pyridine-conjugated PEG, may be used for
the controlled intracellular delivery of VEGFA into living human stem/progenitor cells
for enhanced osteogenic differentiation. Through the use of a biodegradable natural
polymer, mild gelation methods, chemical conjugation of PEG, and immobilization of
the adhesion ligand RGD, the applicability of controlled drug delivery by means of
microspheres increases. The Alg, Alg-g-PEG and Alg-g-RGD microspheres were
uniform in shape, of a moderate size to allow for internalization into human MSCs, and
proved adaptable to surface-modification [34, 35]. The fabrication was easy to perform
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and translate to engineering applications compared to other approaches which require
higher spinning speeds and double emulsion processes.
VEGFA release from alginate-based microspheres was sustained over a period
of 14 d, which is promising for targeted intracellular delivery. However, the main
interest of this paper was the intracellular delivery of VEGFA into human MSCs, which
took place over a shorter time-span of 48 h during culture. The non-selectivity of the
microspheres in culture with MSCs allowed uptake to occur quickly, and this is also
believed to be the case for the internalization of microspheres during the differentiation
assay; the microsphere concentration and duration of co-culture were consistent among
the internalization and differentiation studies. The short time frame allowed for delivery
also suggests that the VEGFA content of the internalized microspheres was high
enough to significantly affect human MSC differentiation. Indeed, alginate
modification with bulky side groups can hinder drug diffusion; an effect that has been
reported for Alg-g-PEG chains of moderate to high molecular weights [19].
Modification of alginate through PEG conjugation at the carboxyl groups decreases the
electrostatic repulsion within the hydrogel, thus decreasing the degree of swelling and
decreasing the rate of drug diffusion. The varying release kinetics with time suggest
that the microsphere structure may be optimized further for controlled release
applications [40].
Multiple uptake pathways have been targeted as a means of delivering material
intracellularly, namely endocytosis, in the case of cationic nanoparticles [41] or for

65
·

larger micron-scale particles [42]. Due to the mild and quick gelation used to fabricate
Alg, Alg-g-PEG and Alg-g-RGD microspheres, encapsulated drugs and proteins are
better protected. Chemical conjugation of RGD onto PEG utilized disulfide bonds,
which are covalent linkages arising from the oxidation of two sulfhydryl (SH) groups
of cysteine connected to RGD (CRGD) and the SH terminal group on PEG (SH-PEGNH2). Disulfide bonds exist commonly in eukaryotic cell proteins with the function of
fortifying the protein tertiary structure. Due to the reversibility and relative stability in
plasma, the disulfide bond linkage becomes attractive in designing drug delivery
systems. In addition, the physical properties and network structure of the calcium
crosslinked alginate-based microspheres are readily changed after alterations in pH
(such as in an endosome) or in the presence of calcium chelators. For the system
described herein, it is hypothesized that the microspheres rapidly released VEGFA into
the cytoplasm once inside the human MSCs [43, 44] due to the disassembly of the
microspheres.
RGD is widely utilized in tissue engineering studies and has been used in
studies with alginate [45, 46]. In the current study RGD was used a model ligand which
may be replaced with more relevant cell-recognition molecules for targeting MSCs in
vivo. However, RGD has been shown to increase uptake of surface modified DNA
complexes for intracellular delivery [47]. Although a limitation of the current study was
in the collection of qualitative internalization results, future work will investigate RGD
modified microspheres for enhanced MSC uptake and it may be combined with other
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cell-recognition motifs to control drug delivery for target cell populations. Results of
the differentiation assays did not exhibit significant enhancement of the RGD or PEG
modification between alginate

microsphere

groups in

promoting osteoblast

differentiation. Although Alg-g-PEG microspheres resulted in the highest Alizarin red
absorbance, several reasons may account for this. The cells in the current study were
only directed to differentiate for 14 d, meaning that the human MSCs cultured with
Alg-g-RGD microspheres might still result in enhanced osteogenesis but more time is
needed to demonstrate that result. Another possible explanation is RGD’s influence on
differentiation signaling. The research of Garcia et al. (2005) and Park et al. (2010)
indicate a promotion effect of RGD in stem cell differentiation [33, 48]. In addition, it
could also enhance chondrogenic differentiation [49]. However, other studies present
findings in disagreement with the aforementioned work [50, 51]. The potential for Alg,
Alg-g-PEG and Alg-g-RGD microspheres to deliver VEGFA intracellularly may be
applied to investigate a wide array of differentiation lineages for MSCs and perhaps
other progenitor cells.
Of special interest, our functional tests with VEGFA-bearing microspheres
support an intracrine mechanism for VEGFA in human MSCs and are consistent with
results reported by Liu et al. (2012) with retroviral expression of VEGFA in murine
MSCs. We found that intracellular delivery of VEGFA via alginate-based microspheres
resulted in up-regulated osteogenic differentiation by human MSCs, suggesting the
effectiveness of our drug delivery system to control the intracrine mechanism that
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balances osteoblast and adipocyte activity. Extracellular VEGFA did not alter
differentiation of human MSCs. To carefully evaluate the function of intracellular
VEGFA in regard to specificity for bone formation, we used adipogenesis as an
alternative differentiation out-put. MSCs from osteoporotic bones exhibit a higher
adipogenic capacity compared to healthy MSC donors, which is why adipogenic
differentiation was chosen as the alternative lineage [52]. Except for the Alg
microsphere group, in which adipogenesis by MSCs was enhanced, there was not a
significant difference in adipogenesis for MSCs incubated with the VEGFAencapsulated Alg-g-PEG and Alg-g-RGD microspheres. Based on the enhanced
adipogenesis we observed in the VEGFA-encapsulated Alg microspheres group, Alg-gPEG and Alg-g-RGD microspheres may be better suited for controlled intracellular
delivery to enhance osteogenesis in vivo. The investigation of various cell-recognition
molecules (i.e. ligands, antibodies, etc.) may provide a viable option for targeting a
specific cell population in vivo for enhanced mineralization of osteoporotic bone.

2.5. Conclusion
This study is the first to report the fabrication and surface-functionalization of
Alg, Alg-g-PEG and Alg-g-RGD microspheres for the encapsulation and intracellular
delivery of a bioactive growth factor, VEGFA. Alg, Alg-g-PEG and Alg-g-RGD
microspheres containing VEGFA promoted osteogenic differentiation of human MSCs
upon intracellular delivery after 48 h of incubation time. These results provide
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encouraging evidence for development of a systemic growth factor delivery system
with potential to treat many debilitating diseases. Future work will involve
manipulation of the surface ligand to enhance cell-targeted internalization of
microspheres for intracellular growth factor delivery.

2.6. Supplemental Materials
NH2-S-S-pyridine was verified via 1H-NMR spectra (500 MHz, D2O) as shown
in Figure 2-7. The peaks within the range of 7-8 ppm confirmed the success of the
chemistry. 1H-NMR analysis of Alg-g-PEG was performed to verify the retention of
PEG after the grafting reaction. Alg-g-PEG was synthesized using mPEG-NH2 and
sodium alginate via carbodiimide chemistry (Figure 2-8). 1H-NMR spectra (500 MHz,
D2O) are shown, comparing the graft copolymer Alg-g-PEG to the homopolymer
constituents: mPEG-NH2 and sodium alginate. The inset image is the chemical
structure of the Alg-g-PEG copolymer. The alginate conjugation onto NH2-S-Spyridine which forms the Alg-g-pyridine was confirmed by 13C-NMR (500 MHz, D2O)
(Figure 2-9).
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Figure 2-7. 1H-NMR spectra of NH2-PEG-S-S-pyridine copolymer. The fours peaks
between 7-8 ppm, which is amplified on the left, indicated the successful conjugation of
pyridine onto PEG. The H2O peak represents the solvent D2O and the large peaks near 2
ppm and 3.7 ppm represent residual CH3COOH in the reaction buffer.
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Figure 2-8. 1H-NMR result of Alg-g-PEG copolymer synthesis. The peak of 3.36 ppm
corresponds to the CH3 moiety of the PEG side chain and 4.31 ppm corresponds to the
shift of hydrogen atoms due to the grafting of the PEG side chain. Quantification of Algg-PEG conjugation by peak integration of the 1H-NMR was not successful due to
extensive broadening and overlapping of the peaks corresponding to the alginate in the
Alg-g-PEG.
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Figure 2-9. 13C-NMR result of Alg–g-PEG-S-S-pyridine synthesis. Peaks at 132.31 ppm,
136.05 ppm, 141.37 ppm, 143.53 ppm, 149.24 ppm correspond to carbon on the pyridine
ring, 69.76 ppm corresponds to carbon in the repeat unit of PEG, and 42.84 ppm
corresponds to carbon on the alginate repeat unit.
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CHAPTER 3: DUAL-CROSSLINKED METHARYLATED ALGINATE SUBMICROSPHERES FOR INTRACELLULAR CHEMOTHERAPEUTIC
DELIVERY

Intracellular delivery vehicles comprised of methacrylated alginate (Alg-MA)
were developed for the internalization and release of doxorubicin hydrochloride
(DOX). Alg-MA was synthesized via an anhydrous reaction, and a mixture of Alg-MA
and DOX was formed into sub-microspheres using a water/oil emulsion. Covalently
crosslinked sub-microspheres were formed via exposure to green light, in order to
investigate effects of crosslinking on drug release and cell internalization, compared to
traditional techniques such as ultra violet (UV) light. Crosslinking was performed using
light exposure alone, or in combination with ionic crosslinking using calcium chloride
(CaCl2). Alg-MA sub-microsphere diameters were between 88 – 617 nm, and zetapotentials were between -20 and -37 mV. Using human lung epithelial carcinoma cells
(A549s) as a model, cellular internalization was confirmed using flow cytometry;
different sub-microsphere formulations varied the efficiency of internalization, with
UV-crosslinked sub-microspheres achieving the highest internalization percentages.
While blank (non-loaded) Alg-MA sub-microspheres were non-cytotoxic to A549s,
DOX-loaded sub-microspheres significantly reduced mitochondrial activity after five
days of culture. Photo-crosslinked Alg-MA sub-microspheres may be a potential
chemotherapeutic delivery system for cancer treatment.
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3.1. Introduction
Lung cancer is one of the most widespread type of carcinoma, resulting in the
largest number of cancer-related deaths around the world.[1-3] Greater than 85% of
lung cancer cases are currently classified as non-small-cell lung cancer (NSCLC),
including adenocarcinoma, squamous-cell carcinoma and large-cell carcinoma. Despite
the recent advances in early detection and cancer treatment, NSCLC is often diagnosed
at an advanced stage and has a poor prognosis.[1] Chemotherapy is one of the current
recommended treatments to prevent or reduce tumor-induced symptoms, prolong
patient survival, and maintain patient quality of life.[4] Chemotherapy treatments can
last as long as 6 months at high parenteral dosages, and are frequently associated with
systemic toxicity.[5, 6]

Doxorubicin hydrochloride (DOX) is one of the most widely used
chemotherapeutic drugs, and is known as an anthracycline antibiotic.[7] The main anticancer mechanisms that have been suggested for DOX fall into the following
categories: 1) DOX intercalation into DNA, shutting down protein synthesis and DNA
replication; 2) DOX-induced production of reactive oxygen species (ROS), inducing
DNA damage and/or lipid membrane peroxidation; 3) DNA crosslinking, binding and
alkylation; 4) DOX interference with DNA unwinding, strand separation and helicase
activity; 5) damage to the bilayer structure of cell membranes; 6) DNA inhibition of
topoisomerase II, initiating DNA damage pathways. All the above activities require that
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DOX be presented inside the cytoplasm,[8-10] which requires intracellular delivery of
DOX to cancer cells. DOX treatment induces several side effects including nausea,
vomiting, and fever in patients.[11] A significant incidence of cardiovascular side
effects – hypotension, tachycardia, arrhythmias, and ultimately congestive heart failure
– are also reported.[8, 12] Therefore, there is a need for drug delivery systems which
efficiently encapsulate and deliver chemotherapeutics while reducing adverse events.
As a small molecule, concerns of low encapsulation efficiency, drug leakage, and
aggregation limit the therapeutic efficacy of DOX, and complications associated with
sterilization have not been resolved.[5]

Modern drug delivery systems are designed to maintain the structure and
bioactivity of biomolecules and to release therapeutics in a controlled and predictable
manner. Micro-encapsulation is one of the core technologies used in polymer drug
delivery systems.[13] However, the relatively large micron-size (> 10 µm) of the drug
delivery particles limits cellular internalization. Therefore, the association of DOX to
sub-micron carriers has drawn greater interest,[14] including liposomes,[15]
nanospheres and sub-microspheres,[16] and micelles.[17]

Alginate is an unbranched polysaccharide consisting of 1→4 linked β-Dmannuronic acid (M) and its C-5 epimer α-L-guluronic acid (G). Alginate is extracted
from brown seaweed, and has been investigated for biomedical and pharmaceutical
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applications due to its relatively low cost, low toxicity, biocompatibility, and
biodegradability.[18-21] Alginate particles have increasingly been shown to offer
controllable drug encapsulation efficiencies and release profiles, while maintaining the
bioactivity of various drugs, including proteins,[22] cytokines,[23] and small
molecules.[24] Through the formation of a water/oil emulsion and subsequent exposure
to calcium ions, alginate particles within the micrometer – nanometer size scale can be
generated, and are often referred to as ionically crosslinked alginate particles.[20, 22,
25]

The fabrication of alginate microspheres and sub-microspheres is favorable for
drug delivery due to the relatively mild ionic gelation process.[22, 26] However,
limitations associated with the relatively weak ionic bonds include low drug
encapsulation efficiency and rapid drug-release rates (< 24 h).[27] To overcome these
limitations, methacrylated alginate (Alg-MA) was synthesized [28] and submicrospheres were generated utilizing a water/oil emulsion [22] and subsequent
crosslinking.

Alg-MA

sub-microspheres

were

covalently

crosslinked

using

photoinitiators and visible (i.e., green) or UV light irradiation.[28] Dual-crosslinked
sub-microspheres were generated with the subsequent addition of calcium chloride.[22]
To evaluate the efficiency of internalization and the bioactivity of DOX-loaded AlgMA sub-microspheres, human lung epithelial carcinoma cells (A549s) were utilized as
a model system. We hypothesized the dual-crosslinking would result in a tighter
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hydrogel network for more efficient intracellular DOX delivery (Figure 1). DOX
encapsulation efficiency and in vitro release were quantified using an absorbance assay.
While blank (non-loaded) Alg-MA sub-microspheres were non-cytotoxic to A549s,
DOX-loaded sub-microspheres significantly reduced mitochondrial activity after five
days of in vitro culture.

3.2. Materials and Methods
3.2.1. Materials and Reagents
Sodium alginate (MW = 65–75 kg/mol, 60-70% guluronic acid residues) was
generously donated by FMC BioPolymer. Irgacure D2959 was generously donated by
Ciba Inc. Biology-grade mineral oil, Span 80, Tween 80, ethylenediaminetetriacetic
acid (EDTA), deuterium oxide (D2O), dimethyl sulfoxide (DMSO, 99% anhydrous),
dodecyltrimethylammonium bromide salt (DTAB), methacrylic anhydride (MA), 4(dimethylamino)pyridine (DMAP), doxorubicin hydrochloride (DOX), N-ethyl-N’(3dimethylaminopropyl) carbodiimide hydrochloric acid (EDC), N-hydroxysuccinimide
(NHS), and the in vitro toxicology assay kit (3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide (MTT)-based) were purchased from Sigma-Aldrich. One
molar hydrochloric acid (HCl) and 1 M sodium hydroxide (NaOH) were purchased
from BDH ARISTAR®PLUS. Dichloromethane (DCM, 99.9%), sodium citrate,
isopropanol, sodium chloride (NaCl), sodium citrate, DMEM/F-12 mammalian cell
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culture medium, Alexa Fluor® 647 cadaverine and 20X phosphate buffered saline
(PBS) were purchased from Fisher Scientific. Fetal bovine serum (FBS) was purchased
from Atlanta Biologics. Penicillin, streptomycin, and 0.25% trypsin EDTA were
purchased from Corning Cellgro. A549 (CCL-185™) human lung epithelial carcinoma
cells were purchased from ATCC®.

3.2.2. Synthesis and Characterization of Methacrylated Alginate (Alg-MA)
Alg-MA was synthesized utilizing an anhydrous reaction to control the degree
of methacrylation (DOM).[28, 29] Sodium alginate was rendered soluble in anhydrous
DMSO through an ion exchange with DTAB. Aqueous solutions of sodium alginate
(1%, w/v) and DTAB (2%, w/v) were prepared and slowly mixed while stirring at 1000
rotations per minute (rpm). The precipitate was washed in DI water and lyophilized. A
1% (w/v) alginate-DTA/DMSO solution was reacted with MA in the presence of a
catalyst, DMAP, for 24 hours at room temperature. The solution was hydrolyzed
through extensive dialysis in 0.2 M sodium phosphate dibasic salt solution followed by
further dialysis in DI water. Alginate methacrylation was confirmed using 1H-NMR
spectroscopy, (Bruker AVANCE III 500 MHz high-field NMR spectrometer) by the
presence of methacrylate (6.25, 5.75 ppm) and alginate methyl resonances (2.0 ppm). A
1% (w/v) polymer solution in D2O was analyzed at room temperature, spinning at 20
Hz for 16 scans.[28, 30] The DOM was quantified by peak integration and calculation
of the ratio between of the methyl protons at 2.0 ppm and the newly formed methylene
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protons of methacrylate at 5.75 ppm and 6.25 ppm.[30, 31]

3.2.3. Dual-crosslinked Alg-MA Sub-Microspheres Design and Fabrication
Aqueous Alg-MA solutions were mixed with photoinitiators for UV (0.05%,
w/v, Irgacure D2959) or visible green light activation [1 mM eosin Y (photosensitizer),
125 mM triethanolamine (initiator) and 20 mM 1-vinylpyrrolidone (catalyst)],
respectively. Two percent (w/v) Alg-MA solutions were mixed with 0.1% (w/v) DOX
and formed into sub-microspheres using a water/oil emulsion and subsequent
crosslinking (Figure 2). Alg-MA sub-microspheres without DOX were fabricated as
blank (i.e., non-loaded) controls.22 One milliliter of polymer/DOX solution was slowly
added to 6.72 mL of biological-grade mineral oil containing 5% (v/v) Span 80, while
mixing at 1200 rpm for 5 minutes at room temperature. Subsequently, 400 µL of 30%
(v/v) Tween 80 (in biological-grade mineral oil) was added and mixed for an additional
5 minutes. Crosslinking was performed four different ways: 1) green light exposure for
10 minutes (Green, using 525 nm wavelength, NFLS-G30 3-WHT, SuperBrightLEDs);
2) UV light exposure for 10 minutes (UV, using 320–390 nm wavelength, Uvitron
Intelliray 400); 3) green light plus 5 mL of 0.5 M CaCl2, mixing for 15 minutes
(Green+C); and 4) UV light plus 5 mL of 0.5 M CaCl2, mixing for 15 minutes
(UV+C).28 After crosslinking, 3 mL of isopropanol was added to the emulsion and
mixed for 5 minutes, then centrifuged at 400 rpm for 5 minutes to precipitate submicrospheres. Alg-MA sub-microspheres were washed sequentially with isopropanol
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(x2) and DI water (x2), respectively, and centrifuged after each wash.
The diameters and zeta-potentials (i.e., surface charge) for hydrated, blank and
DOX-loaded Alg-MA sub-microspheres were quantified using dynamic light scattering
(DLS, Zetasizer Nano ZSP, Malvern). Sub-microspheres were suspended in PBS, pH =
7.4, at room temperature. Hydrodynamic diameters were determined based on number
averages, and the size distribution was plotted for each sub-microsphere group. After
lyophilization, Alg-MA sub-microspheres were characterized by scanning electronic
microscopy (SEM, JEOL 600); samples were sputter coated with 45 nm of Au-Pb prior
to imaging. SEM micrographs of various magnifications were used to visualize or
attempt to visualize Alg-MA sub-microspheres.

3.2.4. Drug Loading and Mechanism of Release
Covalently and/or dual-crosslinked Alg-MA sub-microspheres were evaluated
for use as chemotherapeutic delivery vehicles. DOX was utilized as a model drug for its
intrinsic UV absorbance and ease of quantification, for drug encapsulation, drug release
and effectiveness assays. To determine whether or not UV or green light exposure
changed the chemical structure or bioactivity of DOX, aqueous DOX solutions were
exposed to UV and green light for 10 minutes, and then characterized by 1H-NMR,
using non-modified DOX as a control. DOX encapsulation efficiency, i.e., drug
retention during sub-microsphere fabrication, was calculated as a percentage of the
initial loading concentration. Covalent crosslinking of the sub-microspheres prevents
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dissolution; therefore, an extended diffusion process was utilized to quantify
encapsulated drug. Briefly, 1 mg of sub-microspheres was suspended in 1 mL of PBS,
incubated at 37°C and agitated for three weeks. The solution was centrifuged, and the
supernatant was analyzed on a microplate reader (Synergy HT microplate reader,
BioTek) at 485 nm absorbance, and compared to standard curve (EE = Actual Drug
Encapsulated ÷ Theoretical Drug Loaded). Detection of drug lost during washing
procedures was not possible due to presence of multiple phases of emulsion additives
and the absorbance detection limit of DOX on the equipment utilized.
To characterize in vitro release profiles, released DOX concentration was
quantified using the intrinsic absorbance at 485 nm in a 48-well tissue culture
polystyrene (TCPS) plate at 37°C (Synergy HT microplate reader, BioTek). One
milligram of lyophilized DOX-loaded Alg-MA sub-microspheres was dissolved in 500
µL of PBS, pH 7.4 (n = 3). At 1, 2, 4, 8, 12, and 24 hours, and daily up to 11 days, 100
µL of PBS was removed for analysis, and replaced with 100 µL of fresh PBS to
maintain the total volume. DOX concentration was determined using an absorbance
assay and generating a standard curve. Cumulative DOX (µg) released over time was
calculated by adding the mass of DOX released at each time point per mass of submicrospheres.
3.2.5. Cellular Uptake of Alg-MA Sub-Microspheres
Four different formulations of blank (i.e., non-loaded) Alg-MA submicrospheres were reacted with Alexa Fluor® 647 cadaverine dye to form fluorescent
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sub-microspheres (Alexa 647-Alg-MA); the surface reaction chemistry was performed
according to the manufacturers protocol through carbodiimide chemistry at room
temperature catalyzed by NHS/EDC. Alg-MA sub-microspheres without DOX were
used in order to avoid cell death during internalization and analysis. A549s were seeded
in 48-well TCPS plates at 25,000 cells/well in 500 µL/well of standard growth culture
medium (DMEM/F-12, 10% FBS, 100 U/mL penicillin, 100 µg/mL streptomycin), and
allowed to adhere for 24 hours at 37°C and 5% CO2. Cells were then incubated with
blank Alexa 647-Alg-MA sub-microspheres (n = 6 per group) at 100 µg/mL, 37°C and
5% CO2. After 12 hours, culture medium containing Alexa 647-Alg-MA submicrospheres was removed, and adherent cells were thoroughly rinsed with PBS three
times to remove non-internalized and cell-surface-bound sub-microspheres. Cells were
trypsinized and re-suspended in PBS at 1x106 cells/mL, and analyzed by flow
cytometry (BD LSRII Flow Cytometer) to quantify the percentage of A549s that
internalized the sub-microspheres. A549s cultured with no sub-microspheres, and cells
cultured with non-fluorescent sub-microspheres, were prepared and analyzed as
controls.[22]

3.2.6. Drug Bioactivity and Efficacy of Alg-MA Sub-Microsphere Delivery
Vehicles
3.2.6.1. Cytotoxicity of Blank and Drug-loaded Alg-MA Sub-Microspheres
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The cytotoxicity of blank (i.e., non-loaded) and DOX-loaded sub-microspheres
was evaluated using a toxicology, MTT-based assay. A549s were seeded in 48-well
TCPS plates at 25,000 cells/well in 500 µL/well of standard growth culture medium,
and allowed to adhere for 24 hours at 37°C and 5% CO2. Cells were then incubated in
the presence of blank Alg-MA sub-microspheres or DOX-loaded Alg-MA submicrospheres (n = 6 per group, per fabrication type) at sub-microsphere concentrations
of 10, 50, 100 µg/mL. After 24 hours, medium containing sub-microspheres (blank
groups and DOX-loaded groups) was removed, cells were rinsed two times in sterile
PBS, and then analyzed using a MTT-based assay according to the manufacturer’s
protocol. The optical density was measured at 570 nm; background absorbance at 690
nm was subtracted from the measured absorbance at 570 nm (Synergy HT microplate
reader, BioTek). Absorbance values for the experimental samples were normalized to
controls and reported as normalized mitochondrial activity.[22]

3.2.6.2. Effective of Intracellular VS. Extracellular Drug Delivery on Cell
Proliferation
The bioactivity of the DOX-loaded sub-microspheres was evaluated using a
similar method discussed in section 2.6.1. A549s were seeded in 48-well TCPS plates
at 10,000 cells/well in 500 µL/well of standard growth culture medium, and allowed to
adhere for 24 hours. Cells were incubated in the presence of DOX-loaded Alg-MA submicrospheres (n = 6 per fabrication type) at sub-microsphere concentrations of 10, 50,
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and 100 µg/mL. A549s and Alg-MA sub-microspheres were co-cultured for 5 days
with media exchanges. Free DOX (i.e., DOX contained within the cell culture medium)
was added to A549s at different concentrations (5, 4, 3, 2, 1, 0.5, 0.25, 0.125, 0.06,
0.03, 0.015 and 0 µg/mL) to compare the effect of intracellular versus extracellular
DOX delivery. After 1, 3 and 5 days of culture, a MTT-based assay was performed
according to the manufacturer’s protocol, to quantify the effects of DOX-loaded AlgMA sub-microspheres and free DOX on in vitro cancer cell proliferation. Absorbance
values for the experimental samples were normalized to controls and reported as
normalized mitochondrial activity.[22]

3.2.7. Data Analysis
The quantitative results for all experiments are reported as mean ± standard
deviation. Statistical analysis was performed on Alg-MA sub-microsphere co-cultured
cell assays, using one-way ANOVA with Tukey multiple comparisons (α = 0.05) via
the SAS statistics program in the GLM procedure, as the post-test to compare all of the
groups. A p < 0.05 was considered significantly different.

3.3. Results and Discussion
3.3.1. Synthesis and Characterization of Alg-MA
The chemical modification of alginate rendered it hydrophobic and soluble in
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organic solvents. An anhydrous methacrylation of alginate resulted in a functionalized
biomacromolecule with a controllable DOM.[28] 1H-NMR spectra for Alg-MA and
non-modified alginate are shown in Supplemental Figure S1. The DOM for the AlgMA used as the base material in the sub-microspheres was approximately 64%.[31-34]
Peaks between 3.0 and 3.5 ppm indicate methyl groups at the end of alginate chains
resulting from degradation during the methacrylation chemistry.

Figure 3-1. Schematic of the hydrogel network structure comprising photo-crosslinked
and dual-crosslinked Alg-MA sub-microspheres. (I) Photo-crosslinked sub-microspheres
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exhibit a porous hydrogel network with intermolecular covalent crosslinks, encapsulating
DOX. (II) Upon the addition of ionic crosslinking, the hydrogel network tightens,
resulting in reduced drug loss and slower diffusion-based drug release; this is the desired
product. (III) However, the introduction of aqueous-based calcium chloride (CaCl2)
solution may result in drug loss during the ionic crosslinking step. (IV) The non-ideal
dual-crosslinked product may exhibit lower drug loading capacity due to the additional
steps in the fabrication process.
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Figure 3-2. (A) Chemical structure of methacrylated alginate (Alg-MA). Alg-MA was
covalently crosslinked in the presence of photoinitiators under light activation, to form
photo-crosslinked Alg-MA hydrogel networks. Alg-MA hydrogels were ionically
crosslinked in the presence of calcium chloride (CaCl2) to form dual-crosslinked Alg-MA
hydrogel networks. (B) Schematic representation of microsphere fabrication techniques.
Microspheres with or without DOX were prepared by premixing Alg-MA solutions and
creating a water/oil emulsion at room temperature. Alg-MA sub-microspheres were
photo-crosslinked upon exposure to visible or UV light, respectively, and further dualcrosslinked in the presence of 1 M CaCl2.
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3.3.2. Fabrication and Characterization of Dual-crosslinked Alg-MA Hydrogel
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Sub-Microsphere
The formation of Alg-MA sub-microspheres was indicative of a crosslinked
hydrogel network, obtained through either covalent crosslinking[35] (e.g., via photocrosslinking) alone, or in combination with ionic crosslinking (e.g., by the addition of
CaCl2), as illustrated in Figure 2.[27, 35, 36] The DOM for the Alg-MA base material
was 64%, and this moderate-DOM sustained both covalent and ionic crosslinking.
Photo-crosslinking occurred upon UV or green light activation between adjacent
acrylate groups, while the subsequent presence of CaCl2 induced ionic crosslinking
between adjacent carboxyl groups. While methacrylation took place at available
hydroxyl groups, ionic crosslinks formed between adjacent carboxyl side-groups on
neighboring alginate chains, thus allowing Alg-MA to sustain dual-crosslinking.
DOX-loaded sub-microsphere hydrodynamic diameters were quantified using
DLS analysis (Table 1). The largest populations of DOX-loaded sub-microspheres were
sized between 243 – 391 nm: UV = 243 nm, Green = 391 nm, UV+C = 346 nm,
Green+C = 358 nm. The variability of the sub-microsphere diameters, plotted as size
distributions in Figure 3A+B, is an almost unavoidable result of the emulsion process,
and is indeed a limitation of the fabrication method; however, the linear size
distribution plots indicate the following: Alg-MA sub-microspheres exhibited size
populations within the same size scale, thus demonstrating consistency in fabrication
method. SEM images (see Supplemental Figure S2) also indicated that Alg-MA submicrospheres were spherical in shape, however heterogeneous in size. The zeta-
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potentials ranged between -20 mV and -37 mV, and none of the groups demonstrated
any significant outlying data.

3.3.3. Swelling and Diffusion-based Drug Release
The efficacy of Alg-MA sub-microspheres as chemotherapeutic delivery
vehicles was investigated. DOX was utilized as a model drug for its intrinsic UV
absorbance and ease of quantification for subsequent drug encapsulation, drug release
and effectiveness assays. Alg-MA sub-microspheres were designed to encapsulate
DOX without interfering with the detectability or bioactivity of DOX. Both photocrosslinking alone or dual-crosslinking were successful in fabricating DOX-loaded submicrospheres. The low level of UV or green light exposure required for submicrosphere fabrication did not change the chemical structure of DOX, verified by 1HNMR spectroscopy (see Supplemental Figure S3), and the toxic effects of DOX were
still active.37 The mild-gelation techniques used to form Alg-MA sub-microspheres
may retain the functionality and bioactivity of other therapeutics. Indeed, it was
hypothesized that secondary, ionic crosslinking may show no beneficial effect on DOX
encapsulation efficiency, however, the effect of ionic crosslinking may result in
sustained drug release due to a tighter hydrogel network structure.
The cumulative mass of DOX released over time was calculated from four
different types of Alg-MA sub-microspheres, and release profiles are shown in Figure
4. The DOX release profiles followed two different trends – a linear release profile was
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seen during the first 8 hours of release, consistent with hydrogel-swelling induced drug
release (see Figure 4A). Cumulative DOX release profiles through 11 days are shown
in Figure 4B. The release profiles for UV, Green, and Green+C groups followed a
logarithmic trend (trend line R2 ≥ 0.92), while the UV+C group followed a linear
release profile up to 11 days (trend line R2 = 0.98); however, these trends were not
analyzed further. The amount of DOX released did show a similar trend with
encapsulation efficiencies: dual-crosslinked sub-microspheres encapsulated less drug
and released less drug over an 11 day period.38-39 The introduction of aqueous-based
CaCl2 solution to the emulsion resulted in drug loss due to DOX solubility in aqueous
solutions.40 The varying release kinetics with time suggest that the sub-microsphere
structure may be optimized further for controlled release applications, by varying the
degree of crosslinking to extend or delay the drug release rate.35 It is hypothesized that
increasing the drug-loading concentration, increased efficacy over longer time periods
could be achieved. Decreasing the variability in the diameter of the sub-microspheres
and varying the Alg-MA DOM may also result in varied release rates due to changes in
the network microstructure. However, sub-microsphere size homogeneity and drug
release profile optimization were outside the scope of this study and may be addressed
through further investigations.
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Figure 3-4. Quantitative cumulative release of doxorubicin (DOX) from DOX-loaded
Alg-MA sub-microspheres for a period of 11 days (average ± standard deviation, n = 6
hydrogel samples per group). Sample aliquots were collected and the DOX concentration
was determined using a standard curve at an absorption wavelength of 485 nm. (A)
Cumulative DOX release profile during the first 8 hours; the release profiles for all of the
Alg-MA sub-microsphere groups followed a linear trend (trend line R2 ≥ 0.98). (B)
Cumulative DOX release profile during 11 days; the release profiles for the UV, Green,
and Green+C Alg-MA sub-microsphere groups followed a logarithmic trend (trend line
R2 ≥ 0.92), while the UV+C group continued to follow a linear release profile up to 11
days (trend line R2 = 0.98).
3.3.4. Cellular Uptake of Alg-MA Sub-Microsphere
Uptake of Alg-MA sub-microspheres into A549s was quantitatively determined
via flow cytometry to detect the fluorescent signal of Alexa-647-labeled submicrospheres. Non-treated A549s and cells cultured with non-fluorescently labeled submicrospheres were used as controls. Utilizing gate settings based on the fluorescent
95
·

intensity level of the probe, negative and positive populations were established, and it
was found that all four types of Alg-MA sub-microspheres were readily internalized by
A549s.[22] The positive population was > 80% in all four treatment groups (Figure 5AF). UV crosslinked Alg-MA sub-microspheres (single and dual-crosslinked) exhibited
higher internalization rates compared to green light crosslinked groups (Figure 5G),
which may be related to sub-microsphere diameter; however, statistics were not
performed on the internalization data.

Sub-Microsphere Group

Hydrodynamic Diameter by
Number (nm)

Zeta-Potential (mV)

Encapsulation
Efficiency (%)

Blank

DOX Loaded

Blank

DOX Loaded DOX Loaded

Green Light

334

391

-37

-27

28

UV Light

331

243

-21

-21

84

Green Light + Calcium

88

358

-29

-33

26

UV Light + Calcium

197

346

-27

-25

3

Table 3-1. Dynamic light scattering (DLS) quantitative analysis of hydrodynamic
diameters and zeta-potentials of blank (i.e., non-loaded) and DOX-loaded photocrosslinked and dual-crosslinked Alg-MA sub-microspheres. DOX encapsulation
efficiencies were determined using an absorbance assay after sub-microsphere
fabrication.
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Figure 3-5. Flow cytometry analysis of Alg-MA sub-microspheres after 12 hours of coculture with human lung epithelial carcinoma (A549) cells. (A) Non-treated cell control,
(B) cells cultured with non-labeled blank sub-microspheres, (C) cells cultured with green
photo-crosslinked sub-microspheres, (D) cells cultured with green photo-crosslinked and
calcium crosslinked sub-microspheres, (E) cells cultured with UV photo-crosslinked submicrospheres, and (F) cells cultured with UV photo-crosslinked and calcium crosslinked
sub-microspheres. (G) Flow cytometry histograms were presented to show the different
fluorescence intensity between control cells and different Alg-MA groups.

3.3.5. Cytotoxicity of Blank and Drug-Loaded Alg-MA Sub-Microspheres
To verify the non-toxicity and retention of DOX bioactivity after submicrosphere encapsulation, MTT assays were performed on blank Alg-MA submicrospheres and DOX-loaded Alg-MA sub-microspheres after 24 hours of culture
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with A549s to quantify mitochondrial activity. A549 viability was assessed in the
presence of Alg-MA sub-microspheres at increasing concentrations (10, 50, 100
µg/mL, Figure 6). Blank Alg-MA sub-microspheres (with no drug content) were
minimally cytotoxic to A549s (mitochondrial activity > 80%) at concentrations up to
100 µg/mL (Figure 6A). Increased mitochondrial activity may be attributed to low
molecular weight soluble alginate (i.e., sugar) in the culture media. Additionally, we
hypothesize the reduced cytotoxicity seen in the UV+C group may be due to enhanced
clearance of residual UV photoinitiator upon secondary crosslinking with an aqueous
calcium chloride solution.[37] DOX-encapsulated sub-microspheres delivered bioactive
drug, significantly reducing mitochondrial activity within 24 hours (Figure 6B).

Figure 3-6. Human lung epithelial carcinoma (A549) cells were cultured in the presence
of hydrogel sub-microspheres for 24 hours in standard growth medium at 37˚C and 5%
C02. Cell viability was determined using an absorbance-based quantitative assay to
measure mitochondrial activity (MTT); absorbance data for the groups treated with submicrospheres were normalized to the non-treated cell control (average ± standard
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deviation, n = 6 hydrogel samples per group). The cytotoxicity of Alg-MA submicrospheres was analyzed on (A) blank (non-loaded) sub-microspheres. The bioactivity
of doxorubicin (DOX) was verified using (B) DOX-loaded sub-microspheres. Various
groups (white diamonds = green photo-crosslinked, white circles = UV photocrosslinked, black diamonds = green + Ca2+ dual crosslinked, black circles = UV + Ca2+
dual crosslinked) and sub-microsphere concentrations (10, 50, 100 µg/mL) were
characterized.

3.3.6. Effect of Soluble Drug VS Sub-Microparticle Mediated Delivery on Cell
Proliferation
Four different types of DOX-loaded Alg-MA sub-microspheres were cultured
with A549s at concentrations of 10, 50 and 100 µg/mL. In addition, different
concentrations of free DOX was added to the culture media and served a control. A
short-term cell proliferation study (utilizing an MTT assay) was performed for 5 days.
On day 1, all of the Alg-MA sub-microsphere groups reduced A549 proliferation,
regardless of the crosslinking type or concentration (Figure 7A). On days 3 and 5, the
UV crosslinked Alg-MA sub-microspheres showed the greatest reduction in the A549
proliferation. For comparison, normalized mitochondrial activity was plotted versus
free DOX, Figure 7B, or DOX-loaded sub-microspheres calculated, Figure 7C.
Compared to the free DOX control, Alg-MA sub-microsphere-mediated delivery shows
a similar decreasing trend as drug concentration increases, though remains less
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released intracellularly. Another consideration is that due to the extended drug release
profile of DOX from sub-microspheres (Figure 4B), improved efficacy beyond 5 days
may be achieved. Indeed, photo-crosslinked microspheres alone are advantageous for
delivering a chemotherapeutic to cancer cells, at clinically-relevant dosages, and
decreased lung cancer cell mitochondrial activity.
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chemotherapeutic delivery vehicles was assessed using a MTT-based assay, to quantify
cell proliferation over a 5-day period. A549 activity was recorded as mitochondrial
activity and normalized to non-modified cell controls. Various formulations and
concentrations (10-100 µg/mL) of sub-microspheres were assessed: green photocrosslinked (Green), green + Ca2+ dual-crosslinked (Green+C), UV photo-crosslinked
(UV), UV + Ca2+ dual-crosslinked (UV+C). DOX was added exogenously (Free DOX) to
the cell culture medium at various concentrations to test the effect of intracellular versus
extracellular DOX delivery. (A) Effect of Alg-MA sub-microsphere concentration for
each crosslinking type on A549 mitochondrial activity; (B) Effect of ‘free dox’
concentration on A549 mitochondrial activity on days 1, 3, and 5; (C) Effect of DOX
concentration encapsulated within Alg-MA sub-microspheres on A549 mitochondrial
activity on days 1, 3, and 5.
3.4. Conclusions
The study reported here-in focused on the efficacy of utilizing crosslinked AlgMA sub-microspheres to intracellularly deliver a chemotherapeutic. Photo-crosslinked
and dual-crosslinked Alg-MA sub-microspheres successfully encapsulated DOX, were
internalized by A549s, and delivered DOX to A549s, reducing mitochondrial activity
compared to non-modified cell controls. The outcome of this study suggests that photocrosslinking alone, and in particular green light activation, is an effective means of
producing drug delivery vehicles, and perhaps additional crosslinking steps or
procedures are not beneficial, perhaps even detrimental, to drug encapsulation
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efficiencies. Based on drug encapsulation predictions and calculations, effective
clinical drug dosages were achieved, as compared to free DOX delivery, and were
controllable. While the efficacy for using photo-crosslinking Alg-MA submicrospheres was shown during a short time frame (5 days) in vitro, future in vivo work
may show enhanced drug efficacy using microsphere-mediated delivery compared to
exogenous intravenous chemotherapy over extended periods of time.

3.5. Supplemental Materials

Figure 3-8. The 1H-NMR spectra of Alg-MA and alginate are shown here. The peaks at
5.75 and 6.25 ppm indicated that hydrogens on the methylene of the methacrylate groups
were present on the alginate backbone after modification.
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CHAPTER4: NANOPARTICLE-MEDIATED INTRACELLULAR FGF-2
DELIVERY AS A CELL-SELECTIVE, INTRACRINE CANCER THERAPEUTIC
Systemic toxicity and adverse events (AEs) are often unavoidable drawbacks of
conventional chemotherapy. Therefore, it is highly desirable to develop more specific
treatments to target cancer cells that avoid use of broad-spectrum toxins. Previous
reports have shown that cytosolic fibroblast growth factor 2 (FGF-2) promotes
chromatin compaction and death of cancer cells through intracrine-mediated activation
of Extracellular signal Regulated Kinase (ERK1/2) and engagement of mitochondria.
The goal of our study was to provide controlled, intracellular delivery of FGF-2 using
alginate-graft-poly(ethylene glycol) nanoparticles (ABN) to activate the FGF-2
intracrine signaling mechanism(s) and reduce cancer cell proliferation. We observed
that both adenocarcinomic human alveolar basal epithelial cells (A549 cells) and
healthy bronchial epithelial cells (HBE) readily internalized ABN by means of nonselective endocytosis, and displayed intracellular trafficking within 24 hours.
Compared with extracellular exposure to FGF-2, intracellular delivery of FGF-2 via
ABN significantly reduced mitochondrial activity and significantly increased the
nuclear content of activated-ERK1/2 in A549 cells. In contrast, HBE were not affected
by ABN-mediated intracellular FGF-2 treatment. Our results demonstrate that FGF-2loaded ABN hold promise as an effective cancer therapeutic that selectively targets
cancer cells through the intracrine FGF-2 signaling pathway.
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4.1. Introduction

Lung cancer is one of the most prevalent types of carcinoma, resulting in the
largest number of cancer-related deaths worldwide.[1-3] Greater than 85% of lung
cancer cases are classified as non-small-cell lung cancer (NSCLC), including
adenocarcinoma, squamous-cell carcinoma, and large-cell carcinoma. Despite recent
advances in early detection and cancer treatment, NSCLC is often diagnosed at a late
stage in the disease and bears a poor prognosis.[1] Standard of Care treatment for
NSCLC includes surgical resection of pulmonary lesions, combined with
radiotherapy[4] or chemotherapy to prevent or reduce tumor-induced symptoms,
prolong patient survival, and maintain quality of life.[5] Chemotherapy can last up to 6
months at high parenteral dosages, and is frequently associated with systemic
toxicity[6, 7] and long-term adverse effects (AEs) for patients that include hearing loss,
cardiomyopathy, sterility, and hypomagnesaemia.[8] Accordingly, cancer treatments
that are selectively-cytotoxic and that prevent recurrence are highly sought after by
clinicians and the biomedical research community.
Among the family of receptor tyrosine kinases (RTKs), fibroblast growth factor
receptors (FGFRs) transmit signals from the extracellular space to the cytoplasm, and
are commonly altered in cancer. FGFs are secreted glycoproteins that are readily
sequestered by the extracellular matrix and cell surface. FGF-FGFR binding leads to
receptor dimerization and trans-phosphorylation of tyrosine kinase domains,[9, 10]
extracellular signal-regulated kinase 1 and 2 (ERK1/2) activation and nuclear transport;
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these signals commonly result in cell proliferation, drug resistance, and
neoangiogenesis.[11] FGFR signaling also plays significant roles in the invasion and
survival of several types of tumor cells.[12-14] Notably, the ERK pathway is reported
as a master regulator of cell proliferation, survival, transformation, and programmed
death.[15-18]
Low and high molecular weight FGF-2 (lo-FGF-2 and hi-FGF-2) isoforms can
have similar, as well as isoform-specific, effects on cell proliferation, differentiation,
migration, and survival, and accumulate in varying proportions in different cell
types.[19] Lo-FGF-2 is associated with paracrine/autocrine signaling – it is smaller and
can be secreted from cells.[20] In contrast, hi-FGF-2 is a larger protein that is generally
not secreted by cells.[21] The hi-FGF-2 isoform, specifically, has activity independent
of cell surface FGFR activation and that instead involves an intracrine signaling
pathway which activates ERK1/2. This, in turn, can activate a Death Associated Protein
Kinase (DAPK) that promotes nuclear transport of ERK1/2, chromatin compaction and
cell death.[22] Notably, several reports suggest the FGF-2 isoform can negatively
impact cell division,[23-25] and endocytosis of FGF-2 bound latex microspheres by
cultured avian cochleovestibular ganglion cells was shown to deplete cell surface
FGFR.[26] Furthermore, hi-FGF-2 was shown to reduce glioma cell proliferation in
vivo by inhibiting cell-cycle progression and protein translation.[27] Thus, intracellular
delivery of FGF-2 has exciting potential to target proliferating cancer cells and may led
to novel intracrine-based therapeutics for cancer patients.
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Particle encapsulation is a core technology used in drug delivery systems,[28]
and provides the following benefits: (a) uniform particle size and shape; (b) protective
barrier from the extracellular environment; and (c) controlled temporal and drug
release.[29] Nanoparticles encompass an assortment of colloidal nano-systems (<1
µm), capable of passing through biological barriers (i.e., passive targeting), and
encapsulating drugs at relatively high densities. Compared with systemic or exogenous
drug delivery methods, nanoparticles that deliver chemotherapeutics through
intracellular means exhibit enhanced drug efficacy.[30]
Alginate, a naturally occurring biopolymer, has been formed into microspheres
and used to deliver proteins, cytokines, cells, and small molecules.[31-33] However,
the relatively large diameter, rapid drug-release,[34] and anionic properties of alginate
particles impede efficient cellular uptake and drug encapsulation, limiting its clinical
application. To overcome these limitations, we conjugated poly(ethylene glycol) onto
alginate to form a slightly-neutralized alginate-graft-poly(ethylene glycol) (Alg-gPEG), which was then used to form nanoparticles.[35] The Alg-g-PEG-based
nanoparticles (ABN) improved cellular uptake compared with that of non-modified
alginate nanoparticles.
Using an engineered ABN, here we investigate the direct, controlled
intracellular delivery of FGF-2 as a potential intracrine-mediated cancer treatment.
Unlike typical FGF-2 signaling, which requires cell surface FGF-2/FGFR dimerization,
we delivered FGF-2 by non-FGFR-mediated endocytosis, via ABN, to determine
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whether we could effectively activate an FGF-2-mediated intracrine signaling pathway.
We hypothesized that non-FGFR-mediated internalization of FGF-2-loaded ABN
would generate intracrine signals that are: 1) Selectively-toxic to proliferating cancer
cells and 2) Relatively non-toxic for normal, healthy, non-cycling primary cells.
Herein, for both diseased (transformed) and healthy (non-transformed) primary cells
treated with FGF-2-loaded ABN, we report the routes of cellular uptake,
internalization, and intracellular trafficking for FGF-2-loaded ABN. Furthermore, we
demonstrate dramatic, specific effects of internalized, FGF-2-loaded ABN on the
cytosolic and nuclear protein pools that correlate to decreased proliferation of cancer
cells, but not of healthy primary cells.
4.2. Materials and Methods
4.2.1. Materials
Sodium alginate (Mw=65–75 kg/mol, 60–70% guluronic acid residues) was
generously donated by FMC BioPolymer. Amine-poly(ethylene glycol)-thiol (NH2PEG-SH,

Mw=1000 g/mol)

NH2, Mw=500 g/mol)

were

and

methyl-poly(ethylene

purchased

from

glycol)-amine

Laysan

Bio.

(mPEG-

N-ethyl-N′(3-

dimethylaminopropyl) carbodiimide hydrochloric acid (EDC), N-hydroxysuccinimide
(NHS), 2,2′-dithiodipyridine, methanol (MeOH, anhydrous, 99.8%), biology-grade
mineral oil, Span 80, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT)-based In Vitro Toxicology Assay Kit, cholera toxin, bovine serum albumin
(BSA) and dexamethasone were purchased from Sigma-Aldrich. One molar
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hydrochloric acid (HCl) and 1 M sodium hydroxide were purchased from BDH
ARISTAR®PLUS. Sodium citrate, isopropanol, calcium chloride (CaCl2), sodium
chloride (NaCl), magnesium chloride (MgCl2), Alexa Fluor® 647 Cadaverine, 20x
phosphate buffered saline (PBS), 4% paraformaldehyde (PFA) in PBS, Triton® X-100,
4-(2-hydroxyethyl)-1-piperazineethanesulfonic

acid

(HEPES),

glycerol,

phenylmethylsulfonyl fluoride (PMSF), sodium orthovanadate (Na3VO4 ), aprotinin,
leupeptin, a bicinchoninic acid assay (BCA) kit, a subcellular protein fractionation kit
for cultured cells, and BupH™ MES Buffered Saline Packs were purchased from Fisher
Scientific. Fetal bovine serum (FBS) was purchased from Atlanta Biologics. Dulbecco's
Modification of Eagle's Medium (DMEM, glutaGRO™)/F-12 media, penicillin,
streptomycin and trypsin EDTA were purchased from Corning Cellgro. A human FGF
ELISA Kit was purchased from BioLegend. Human anti-FGF-2 antibody and
immunoglobulin G (IgG) (rabbit) were purchased from Abcam. Human epidermal
growth factor (EGF), insulin, transferrin, and bovine pituitary extract (BPE) were
purchased from Lonza. A549 (CCL-185™) adenocarcinomic human alveolar basal
epithelial cells (A549 cells) and healthy bronchial epithelial cells (HBEs), were isolated
and cultured in Dr. Van der Vliet’s laboratory.[36]

4.2.2. Alginate-g-PEG Sub-microsphere (ABN) Fabrication
FGF-2-loaded ABN Fabrication
ABN fabrication was based on our previous work, including Alg-g-PEG
synthesis.[35] FGF-2 was added to a 1% (w/v) Alg-g-PEG solution at a weight ratio of
110
·

1:105 (FGF-2:polymer). ABNs without FGF-2 were fabricated as blank controls. At
room temperature, 1 mL of Alg-g-PEG/FGF-2 solution was added to 6.72 mL of 5%
(v/v) Span 80 in mineral oil and mixed at 1200 rpm for 5 minutes. Next, 400 µL of
30% (v/v) Tween 80 in mineral oil was added followed by the slow addition of 5 mL of
2 M calcium chloride (CaCl2) solution. The emulsion was mixed for 30 minutes, 3 mL
of isopropanol was added, and then the emulsion was centrifuged at 4000 rpm for 5
minutes. ABNs were washed sequentially with isopropanol (x2) and DI water (x2). The
size and zeta-potential of ABNs were determined using dynamic light scattering (DLS,
Zetasizer Nano ZSP, Malvern) in PBS at pH = 7.4, room temperature. ABNs were flash
frozen in liquid N2, lyophilized, and characterized by scanning electronic microscopy
(SEM, JEOL 600); samples were sputter coated with 45 nm of gold/palladium (Au/Pd).

FGF-2 Encapsulation and In Vitro FGF-2 Release Assay
Lyophilized FGF-2-loaded ABNs were dissolved in 3% (w/v) sodium citrate
solution.[37] The FGF-2 concentration was measured using a BioLegend ELISA
Development Kit as per manufacturer’s instructions.

4.2.3. Cellular uptake of ABNs
Cellular Uptake
A549 cells and HBEs were seeded in 6 well plates at 3x105 per well and
cultured until they reached 80% confluence.6,38 A549 cell culture medium contained
DMEM/F12, 10% FBS, and 1% penicillin/streptomycin. HBE culture medium
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contained DMEM/F12, cholera toxin (10 ng/mL), epidermal growth factor (10 ng/mL),
transferrin (5 μg/mL), BPE (15 μg/mL) and BSA (0.5 mg/mL). ABN were labeled with
AlexaFluor 647 via carbodiimide chemistry and added to cells at 100 µg/mL (n=3).
After 24 hours of co-culture, medium was removed and the adherent cells were
thoroughly rinsed with PBS. Cells were trypsinized and centrifuged at 200 x g for 10
minutes, and then re-suspended and fixed in 1 mL of 4% PFA in PBS for 10 minutes.
After fixation, cells were centrifuged to remove excess PFA, and thoroughly rinsed
with 1 x PBS. Cells were re-suspended in sterile PBS and transferred to 5 mL
polystyrene round-bottom tubes for flow cytometry to determine the percentage of the
cell population that internalized ABN (BD LSRII Flow Cytometer). Alexa 647-positive
cell population percentages were gated with non-treated cells and those treated with
non-labeled ABN.
Route of Internalization and Intracellular Transportation
Blank ABN were labeled with AlexaFluor 647 via carbodiimide chemistry, and
suspended in medium with various blockers of endocytosis– 1) chlorpromazine
hydrochloride (CH) to inhibit clathrin-mediated endocytosis[38] (10 mg/mL); 2)
nyastin (NY) to inhibit caveolar-mediated endocytosis[39] (25 µg/mL); 3) colchicine
(CO) to inhibit macropinocytosis[40] (40 µg/mL); and 4) dynasore (DY) to inhibit
dynamin[41, 42] (80 µM).[43] A549 cells were seeded in 6-well plates at 3x105 per
well and cultured until they reached 80% confluence. Cells were incubated in the
presence of blank AlexaFluor 647-labeled ABN (n=3) at 100 µg/mL, 37°C and 5%
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CO2. After 30 minutes, culture medium was removed and adherent cells were
thoroughly rinsed with sterile PBS to remove non-internalized ABN. Cell samples were
prepared for flow cytometry (vida supra). A Tukey test was performed to compare the
difference of the percentage of cells with ABN between non-blocked groups and
blocked groups. To verify that fluorescent signals were coming from internalized ABN,
and not membrane-bound ABN, the same cell samples were imaged using confocal
laser scanning microscopy (CLSM, Zeiss LSM 510 META). Z-stack images were
obtained with AimImage Software.
To track ABN internalization, A549 cells were incubated with AlexaFluor 647labeled ABN (100 µg/mL) and rhodamine-labeled dextran (12.5 mg/mL) for 10 and 30
minutes, and 3 and 24 hours.[44, 45] Cells with non-labeled dextran, and without any
treatments, were prepared as controls. At different time points, medium was removed
and adherent cells were thoroughly-rinsed with PBS. Cells were prepared for CLSM
(vida supra) and z-stack images were obtained.
A549 cells were seeded on sterile Nunc™ Thermanox™ Coverslips in 6-well
plates overnight in preparation for transmission electron microscopy (TEM). ABN (100
µg/mL) were added to the medium and co-cultured for 10 and 30 minutes, and 1, 4, 8,
12, 24 and 48 hours. At each time point, medium was removed and cells were
thoroughly-rinsed with PBS. Cells were fixed for 30 minutes in Karnovsky’s fixative
(2.5% glutaraldehyde, 1% PFA in 0.1 M PBS) at 4°C, rinsed with Millonig’s phosphate
buffer, and post-fixed in 1% osmium tetroxide (OsO4) in 0.1 M cacodylate buffer at
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4°C for 30 minutes. Samples were dehydrated in a graded series of ethanol, through
propylene oxide, and infiltrated and embedded in Spurr's resin. Ultra-thin sections were
cut with a diamond knife, placed onto 200 mesh nickel thin-bar grids, and contrasted
with alcoholic uranyl acetate and lead citrate. Grids were viewed with a TEM (JEOL
1400 USA, Inc.) operating at 60 or 80 kV, and digital images were acquired with an
AMT-XR611 11 megapixel ccd camera.[46, 47] A customized Matlab code was written
to measure particle diameters using TEM images, providing an image-based average
size of internalized ABNs.[48, 49]

4.2.4. Bioactivity of Cells after 24 treatment of FGF-2 Intracellularly
Mitochondrial Activity Assay
A549 cells and HBE cells were seeded in 24 well plates at 5*104 per well and
cultured until reaching 80% confluent. ABNs with or without FGF were added to cell
seeded plates at concentration of 100 µg/ml were added to each well and co-culturing
for 24h with n=3 replicates. Extracellular FGF-2 (20 ng/ml) and ABNs with BSE (100
μg/ml) were also added to cells serving as controls. After 24h co-culturing, medium
with ABNs were removed and fresh full medium without ABNs was added to culture
for another 24h. Finally, fresh medium was washed with PBS for three times. then
analyzed using a MTT-based In Vitro Toxicology Assay Kit following the
manufacturer's protocol. The optical density was measured at 570 nm using a BioTek
plate reader. Background absorbance at 690 nm was subtracted from the measured
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absorbance. Absorbance values for the experimental and control samples were
normalized to non-modified TCPS controls[50].

Western Blot
The production of ERK1/2 proteins in A549 cells and HBEs, after treatment
with ABN, was determined by immunoblotting.[23] Six control and experimental
groups were prepared – 1) cells without any treatment; 2) cells with FGF-2-loaded
ABNs; 3) cells with extracellular FGF-2 (20 ng/ml); 4) cells with blank ABNs; 5) cells
treated with 2 μg/mL anti-FGF for 30 minutes, and FGF-2-loaded ABNs; and 6) cells
treated with 2 μg/mL IgG for 30 minutes, and with FGF-2-loaded ABNs. Cells were
plated and cultured until 80% confluence, and the different treatments were added to
the cultures for 24 hours. For whole cell protein analysis, cells were lysed using 200 μL
of 1x western solubilization lysis buffer (1% Triton X-100, 50 mM HEPES, 250 mM
NaCl, 10% glycerol, 1.5 mM MgCl, 1 mM PMSF, 1 mM EGTA, 2 mM Na3VO4, 10
μg/mL aprotinin, 10 μg/mL leupeptin), pH 7.4, per well. For cellular fraction protein
analysis, protein samples from membrane/cytosol and nuclei fractions were obtained
using a subcellular protein fractionation kit based on the manufacturer’s protocols.
Equal amounts of protein (20-25 μg; determined using BCA protein assay) were
separated on Novex 10% Tris-Glycine gels, transferred to nitrocellulose membranes,
and blotted using antibodies against pERK-1/2 (#4370; 1:1000; Cell Signaling) and
Erk1/2 (#4695; 1:1000; Cell Signaling).[43, 51]
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4.3. Results
4.3.1. ABN Fabrication and Characterization
Blank and FGF-2-loaded ABNs were fabricated using a water/oil emulsion
based on our previous reports.[52] SEM images of lyophilized ABNs depicted a
textured surface and spherical morphology (Fig.4-1A,B). To quantify ABN properties,
we used dynamic light scattering (DLS) on suspended ABNs at physiological
conditions. Indeed, the greatest population of particles were <100 nm and the average
hydrodynamic diameter of FGF-2-loaded ABN was 84 nm (Fig.4-1C). ABN were
slightly negative and the average surface charge of ABN was -8 mV (Fig.4-1D). This
was expected, since alginate is an anionic molecule.[33] Furthermore, with only 10%
PEGylation, ABN should retain some electronegativity.[35] The encapsulation
efficiency (i.e. amount of drug retained) of FGF-2 after loading and ABN fabrication
was 60%, an appreciably high value; however, in the future, it may be possible to
optimize the ABN fabrication to improve upon this value. Using the encapsulation
efficiency, FGF-2 release in buffered saline at 37˚C was quantified over the course of 2
weeks. FGF-2 diffusion occurred for 14 days, although the rate of release leveled -off
after 8 days, and a FGF-2 concentration around 10 ng/mL was maintained (Fig.4-1E).
While the data demonstrate that FGF-2 was loaded and subsequently released from the
ABNs, it is critical that FGF-2 remain within ABN until cellular uptake occurs.
Although only ~30% of the drug was released within the first day, our data suggest that
further optimization could help to limit the extracellular release of FGF-2 from ABNs.

116
·

Figure 4-1. Scanning electron micrographs depicting spherical ABNs with (A) scale bar
= 1 µm and (B) scale bar = 500 nm. (C) Hydrodynamic diameter distribution of FGF-2loaded ABNs, measured in PBS, pH 7.4, 37˚C, and reported as number-average mean (84
nm). (D) Hydrodynamic zeta-potential distribution was measured in PBS, pH 7.4, and
reported as number-average mean (-8 mV). (E) Cumulative FGF-2 release from 5 mg
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ABNs over 14 days; FGF-2 concentration (ng/mL) was measured with an ELISA; FGF-2
encapsulation efficiency was 60%.
4.3.2. ABN Internalization
Logarithmic plots of non-treated cells (Fig.4-2A,E), and cells treated with nonlabeled ABNs (Fig.4-2B,F), were prepared as controls (with positive cell populations
<1.3%) and used to establish gates for AlexaFluor 647-labeled ABN experimental
groups. Further flow cytometry analysis demonstrated that >40% of A549 cells (Fig.42C) and >15% of HBEs (Fig.4-2G) internalized AlexaFluor 647-labeled ABNs after 24
hours of culture. Histograms (Fig.4-2D,H) demonstrate clear shifts in fluorescent
intensities between control and experimental groups for each cell type, demonstrating
successful internalization and more efficient uptake of ABNs cultured with cancer cells
compared to healthy cells. The median fluorescence intensity (MFI) for non-treated
A549 cells and for A549 cells treated with non-labeled ABN were 355 and 375,
respectively, whereas the MFI for AlexaFluor 647-labeled ABNs notably increased to
1155 (Fig.4-2D). The MFI for non-treated HBEs and HBEs treated with non-labeled
ABN were only 361 and 328, respectively, whereas the MFI for AlexaFluor 647labeled ABNs increased to 838 (Fig.4-2H).
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Figure 4-2. Flow cytometry and quantification of the cell population (%) that internalized
ABN after 12 hours of co-culture at concentration of 100 µg/ml: A549 cells (top panel)
and HBEs (bottom panel). (A,E) Non-treated cell controls; (B,F) cells treated with nonlabeled ABNs; (C,G) cells with treated with AlexaFluor 647-labeled ABNs; and (D,H)
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cell count curves plotted on a log scale showing representative mean fluorescent
intensities (MFI) for each control and experimental group.

Endocytosis Assay
We explored the endocytic pathways used by A549 cells to internalize ABN in
order to further understand the cellular mechanism mediating the process. The
inhibition of clathrin-mediated endocytosis significantly reduced the ABN-positive cell
population more than other blockers and decreased ABN uptake by 41% (Fig.4-3A),
suggesting that endocytosis played a key role in transport of ABN across the cell
membrane. The inhibition of macropinocytosis had the least effect on ABN uptake,
reducing internalization by 24%. Indeed, compared with the control group (without any
blockers), all four blockers significantly decreased ABN uptake, suggesting that a
combination of multiple pathways may be involved.[53, 54] In addition, viability of
A549 cells was not significantly affected by the inhibition of endocytosis during the 30
minutes of culture (Fig.4-3B). To verify that ABN were indeed inside cells, CLSM was
performed following flow cytometry. Z-stack merged images confirmed AlexaFluor
647-labeled ABN (red) were located inside the cytoplasm rather than adhered to the
cell surface (Fig.4-3C, D, E, F).
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Figure 4-3 Endocytosis-dependent ABN uptake by A549s. Results are presented as a
percentage of the ABN-positive A549 cell population after treatment with various
blockers and normalized to the control. (ANOVA, *p < 0.01 versus ABN control, n=3).
Clathrin-inhibitors demonstrated the greatest reduction in ABN-positive cell populations.
(B) The effect of ABN exposure and inhibition of endocytosis on mitochondrial activity
in A549 cells after 30 minutes of culture was not significant. (C) CLSM merged images
of A549 cells verified ABN internalization (red).

4.3.3. Intracellular Trafficking of ABNs
Internalization by A549 cells and vesicle-mediated intracellular transport of
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AlexaFluor 647-labeled ABN (red) was confirmed by culturing with rhodamine-labeled
dextran (green), which is enclosed in membrane-bound vesicles during intracellular
transport (e.g., endosomes and lysosomes). After culturing for 10 minutes, fluorescent
signals for both ABN (red) and dextran (green) were visible, and merged images
verified co-localization (yellow) of ABN within dextran-labeled vesicles (Fig.4-4A).
Thus, the CLSM data complemented our previous flow cytometry data, demonstrating
that ABN are internalized in membrane-bound vesicles. Next, we examined cultures
after 24 hours to determine if ABN were escaping endo/lysosomes. Indeed, there
appeared to be less overlay between dextran-labeled lysosomes and ABN, indicating
that ABN were escaping lysosomes (Fig.4-4B). We hypothesize that the mechanism is
via ABN swelling , or the proton sponge effect in the relatively low-pH lysosomes,
thereby causing vesicles to burst and release their contents within the cytoplasm.[55]
Notably, however, this concept will need to be investigated further.

122
·

Figure 4-4. CLSM images of A549 cells cultured with AlexaFluor 647-labeled ABN
(red) and rhodamine-labeled dextran (green) after (A) 10 minutes and (B) 24 hours of
incubation. PC = phase contrast.
CLSM was followed by transmission electron microscopy (TEM). Compared to
images of non-treated (control) cells, in images of treated cells, the ABN were clearly
distinguishable from intracellular compartments and organelles due to their dark
contrast and spherical shape (Fig.4-5A). In TEM images of A549 cells exposed to ABN,
extension of the cell membrane and endocytosis were seen within 30 minutes’ postincubation (Fig.4-5B). At 4 hours’ post-incubation, higher concentrations of ABNs
were seen within the cell, close to the cell membrane (Fig.4-5C). ABN located at the
edge of the cell membrane were still detectable at later time points, and we
hypothesized that cellular endocytosis and exocytosis were occurring continuously. At
8 hours’ post-incubation, the density of ABN decreased in the cytoplasm, however, the
ABN that remained in the cell localized closer to the nucleus (Fig.4-5D). At later time
points, ABN located at the edge of the cell membrane were still detectable, indicating
that cellular endocytosis and exocytosis had continued. At 24 and 48 hours postincubation, ABNs localized to the nucleus and appeared to interact with the nuclear
membrane (Fig.4-5E,F). Using a custom-written MATLAB code, we performed a
numerical analysis of the internalized ABN in the TEM micrographs, and determined
the average size of ABN internalized by the cells was 297 nm (diameter). This value
differed from that detected by DLS since it could only measure ABN inside cells. Both
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the CLS and TEM photos confirmed the destination/fate of endocytosed nanoparticles,
namely that they surrounded cell nuclei while releasing bioactive ABN contents. Of
interest, our analysis indicated that intracellular trafficking of nanoparticles should
likely be considered as important as particulate design and characterized whenever new
particulate types are being developed.

Figure 4-5. TEM images of A549 cells without exposure to ABN (A) or with exposed to
ABN for (B) 30 minutes, (C) 4 hours, (D) 8 hours, (E) 24 hours, and (F) 48 hours. Two
images at different magnifications are shown for each time point, scale bar = 2 µM.
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Yellow arrows indicate the location of ABN.
4.3.4. Bioactivity of FGF-2 Intracellular Delivery
ABN (e.g. blank and FGF-2-loaded) cytotoxicity and the effects on healthy and
diseased cell ERK1/2 activation were used to determine the bioactivity of FGF-2 and
the effectiveness of our delivery system. After 24 hours of exposure, our results
indicated that FGF-2-loaded ABN significantly decreased MTT activity in A549 cells,
while the exogenous (i.e. free) FGF-2 significantly increased MTT activity (Fig.4-6A).
Notably, no significant effect was seen in HBEs after exposure to FGF-2 loaded ABN
indicating these effects may be selective for cancer cells; however, mitochondrial
activity slightly increased due to exposure to exogenous FGF-2 (Fig.4-6B). As
expected, blank ABN had no significant effect on either cell type.
To determine further whether or not the cytotoxic effects correlated with
changes in ERK1/2 activation, we first examined whole cellular protein lysates and
observed no significant difference between treatment groups, in either cell type
(Supplemental Information). Therefore, we quantified ERK1/2 activation in different
cellular fractions (membrane/cytosol and nucleus). Immunoblotted protein bands for
phosphorylated ERK (pERK1/2) and total ERK (tERK1/2) are shown in Fig.4-6C,D.
Nuclear ERK1/2 activation in A549 cells treated with FGF-2-loaded ABN was the
highest compared with that of control or other treatment groups (Fig.4-6E). The second
highest amount of activated nuclear ERK1/2 was associated with exogenous FGF-2,
however, values were approximately 50% that of the FGF-2-loaded ABN treatment
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group. Most notably, compared with levels in control cells and those for the other
treatment groups, the level of nuclear ERK1/2 activation in HBEs decreased (Fig.46F). Thus, we found that the distribution of ERK1/2 was governed by the stimulus
concentration, the route of stimulation (paracrine vs. intracrine), and the duration of
stimulation.
Reports in the literature suggest that upregulation of nuclear ERK1/2 may lead
to apoptosis and cell death,[56] which supports the cumulative bioactivity data for
FGF-2-loaded ABNs

(summarized in Fig.4-7). Nuclear activation of ERK1/2

upregulates p53 expression, which is a pro-apoptotic protein known to induce
chromatin compaction and cell death.[57, 58] Conversely, cytosolic ERK1/2 activation
can inhibit nuclear ERK1/2 activation, inducing cell proliferation.[57] In addition, the
ERK/p53 signal transduction pathway is also involved in various chemotherapeuticinduced cell apoptotic events.[56, 57, 59] In agreement with our observations, Ma et al.
suggested that mitochondrial engagement plays an important role in inducing chromatin
compaction and cell death.[22]
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Figure 4-6. In vitro MTT test result of different treatments (non-treated control group,
empty ASNs, extracellular FGF-2, and FGF-2 loaded ABNs) with HBE cells and A549
cells. (C, F) western blot photos of both membrane cytosol ERK1/2 activation and
nuclear ERk1/2 activation for HBE cells and A549 cells. (B, E) OD reading ratio of
pERK/ERK of western blot bands in both membrane/cytosol fraction and nuclear fraction
for HBE cells and A549 cells.
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Figure 4-7. Schematic representation of proposed internalization and intracellular
activity of FGF-2-loaded ABNs.
4.4 Conclusions
This study is the first to report on the toxic effects of ABN-mediated FGF-2
delivery on cancer cells. We demonstrated successful cellular uptake using flow
cytometry and electron microscopy, and our data suggest ABN are internalized through
non-specific endocytosis. Healthy cells did not respond significantly when dosed with
FGF-2 loaded ABNs. However, when delivered to cancer cells, intracellular delivery of
FGF-2 via ABN produced significantly higher cytotoxic effects that correlated to
significantly higher activated-ERK1/2 nuclear content. Notably, the growth-inhibitory
effects of intracellular FGF-2 may be broadly applicable to various cancers of the lung
transformed epithelial cells in general, and perhaps those of other tissues/organs.
Moving forward, we are excited to now determine the efficacy of FGF-2 loaded ABNs
to treat animal models of tumorigenesis and metastasis.
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4.5 Supplemental Materials
DLS Result for ABNs
Size distribution by number

Size distribution by intensity

Size distribution by Volume
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Zeta potential by number

Total Protein ERK1/2 western blot

130
·

Reference
[1] Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong K-K. Non-small-cell lung cancers: a
heterogeneous set of diseases. Nat Rev Cancer 2014;14:535-46.
[2] Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J
Clin 2011;61:69-90.
[3] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA: A Cancer Journal for Clinicians
2015;65:5-29.
[4] Marina N, Gebhardt M, Teot L, Gorlick R. Biology and therapeutic advances for pediatric
osteosarcoma. The oncologist 2004;9:422-41.
[5] Manegold C. Chemotherapy for advanced non-small cell lung cancer: standards. Lung cancer
(Amsterdam, Netherlands) 2001;34 Suppl 2:S165-70.
[6] Lee WL, Guo WM, Ho VHB, Saha A, Chong HC, Tan NS, et al. Delivery of doxorubicin and
paclitaxel from double-layered microparticles: The effects of layer thickness and dual-drug vs.
single-drug loading. Acta Biomaterialia 2015;27:53-65.
[7] Wong HL, Bendayan R, Rauth AM, Li Y, Wu XY. Chemotherapy with anticancer drugs
encapsulated in solid lipid nanoparticles. Advanced Drug Delivery Reviews 2007;59:491-504.
[8] Wagner ER, Luther G, Zhu G, Luo Q, Shi Q, Kim SH, et al. Defective osteogenic differentiation
in the development of osteosarcoma. Sarcoma 2011;2011.
[9] Dieci MV, Arnedos M, Andre F, Soria JC. Fibroblast Growth Factor Receptor Inhibitors as a
Cancer Treatment: From a Biologic Rationale to Medical Perspectives. Cancer Discov
2013;3:264-79.
[10] Korc M, Friesel RE. The role of fibroblast growth factors in tumor growth. Curr Cancer Drug
Targets 2009;9:639-51.
[11] Touat M, Ileana E, Postel-Vinay S, Andre F, Soria JC. Targeting FGFR Signaling in Cancer. Clin
Cancer Res 2015;21:2684-94.
[12] Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev
Cancer 2010;10:116-29.
[13] Brooks AN, Kilgour E, Smith PD. Molecular pathways: fibroblast growth factor signaling: a
new therapeutic opportunity in cancer. Clin Cancer Res 2012;18:1855-62.
[14] Dienstmann R, Rodon J, Prat A, Perez-Garcia J, Adamo B, Felip E, et al. Genomic aberrations
in the FGFR pathway: opportunities for targeted therapies in solid tumors. Ann Oncol
2014;25:552-63.
[15] Shindo Y, Iwamoto K, Mouri K, Hibino K, Tomita M, Kosako H, et al. Conversion of graded
phosphorylation into switch-like nuclear translocation via autoregulatory mechanisms in ERK
signalling. Nat Commun 2016;7:10485.
[16] Yoon S, Seger R. The extracellular signal-regulated kinase: Multiple substrates regulate
diverse cellular functions. Growth Factors 2006;24:21-44.
[17] Kamata T, Hattori Y, Hamada H, Kizaki M, Terada M, Ikeda Y. Keratinocyte growth factor
regulates proliferation and differentiation of hematopoietic cells expressing the receptor gene
K-sam. Exp Hematol 2002;30:297-305.
[18] Caunt CJ, McArdle CA. ERK phosphorylation and nuclear accumulation: insights from singlecell imaging. Biochem Soc Trans 2012;40:224-9.
[19] Delrieu I. The high molecular weight isoforms of basic fibroblast growth factor (FGF-2): an
insight into an intracrine mechanism. FEBS Letters 2000;468:6-10.

131
·

[20] Liao S, Bodmer J, Pietras D, Azhar M, Doetschman T, Schultz JEJ. Biological Functions of the
Low and High Molecular Weight Protein Isoforms of Fibroblast Growth Factor-2 in
Cardiovascular Development and Disease. Developmental dynamics : an official publication of
the American Association of Anatomists 2009;238:249-64.
[21] Chlebova K, Bryja V, Dvorak P, Kozubik A, Wilcox WR, Krejci P. High molecular weight FGF2:
the biology of a nuclear growth factor. Cellular and molecular life sciences : CMLS 2009;66:22535.
[22] Ma X, Dang X, Claus P, Hirst C, Fandrich RR, Jin Y, et al. Chromatin compaction and cell
death by high molecular weight FGF-2 depend on its nuclear localization, intracrine ERK
activation, and engagement of mitochondria. J Cell Physiol 2007;213:690-8.
[23] Gaubert F, Escaffit F, Bertrand C, Korc M, Pradayrol L, Clemente F, et al. Expression of the
high molecular weight fibroblast growth factor-2 isoform of 210 amino acids is associated with
modulation of protein kinases C delta and epsilon and ERK activation. J Biol Chem
2001;276:1545-54.
[24] Stachowiak EK, Maher PA, Tucholski J, Mordechai E, Joy A, Moffett J, et al. Nuclear
accumulation of fibroblast growth factor receptors in human glial cells--association with cell
proliferation. Oncogene 1997;14:2201-11.
[25] Moffett J, Kratz E, Myers J, Stachowiak EK, Florkiewicz RZ, Stachowiak MK. Transcriptional
regulation of fibroblast growth factor-2 expression in human astrocytes: implications for cell
plasticity. Mol Biol Cell 1998;9:2269-85.
[26] Bilak MM, Hossain WA, Morest DK. Intracellular fibroblast growth factor produces effects
different from those of extracellular application on development of avian cochleovestibular
ganglion cells in vitro. J Neurosci Res 2003;71:629-47.
[27] Lemiere S, Azar R, Belloc F, Gursel D, Pyronnet S, Bikfalvi A, et al. Overexpression of high
molecular weight FGF-2 forms inhibits glioma growth by acting on cell-cycle progression and
protein translation. Exp Cell Res 2008;314:3701-11.
[28] Sinha VR, Trehan A. Biodegradable microspheres for protein delivery. Journal of Controlled
Release 2003;90:261-80.
[29] Wu YQ, MacKay JA, McDaniel JR, Chilkoti A, Clark RL. Fabrication of Elastin-Like polypeptide
Nanoparticles for Drug Delivery by Electrospraying. Biomacromolecules 2009;10:19-24.
[30] Cheng J, Pun SH. Polymeric biomaterials for cancer nanotechnology. Biomater Sci
2015;3:891-3.
[31] Lemoine D, Wauters F, Bouchend'homme S, Preat V. Preparation and characterization of
alginate microspheres containing a model antigen. Int J Pharmaceut 1998;176:9-19.
[32] Pawar SN, Edgar KJ. Alginate derivatization: A review of chemistry, properties and
applications. Biomaterials 2012;33:3279-305.
[33] Lee KY, Mooney DJ. Alginate: properties and biomedical applications. Progress in polymer
science 2012;37:106-26.
[34] Tonnesen HH, Karlsen J. Alginate in drug delivery systems. Drug Development and Industrial
Pharmacy 2002;28:621-30.
[35] Miao T, Rao KS, Spees JL, Oldinski RA. Osteogenic differentiation of human mesenchymal
stem cells through alginate-graft-poly(ethylene glycol) microsphere-mediated intracellular
growth factor delivery. Journal of Controlled Release 2014;192:57-66.
[36] Hristova M, Habibovic A, Veith C, Janssen-Heininger YMW, Dixon AE, Geiszt M, et al. Airway
epithelial dual oxidase 1 mediates allergen-induced IL-33 secretion and activation of type 2

132
·

immune responses. Journal of Allergy and Clinical Immunology.
[37] Gåserød O, Sannes A, Skjåk-Bræk G. Microcapsules of alginate–chitosan. II. A study of
capsule stability and permeability. Biomaterials 1999;20:773-83.
[38] Shimoda A, Sawada Si, Akiyoshi K. Cell Specific Peptide‐Conjugated Polysaccharide
Nanogels for Protein Delivery. Macromolecular bioscience 2011;11:882-8.
[39] Lee RJ, Wang S, Low PS. Measurement of endosome pH following folate receptor-mediated
endocytosis. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1996;1312:237-42.
[40] Huang R, Ke W, Han L, Liu Y, Shao K, Ye L, et al. Brain-targeting mechanisms of lactoferrinmodified DNA-loaded nanoparticles. Journal of Cerebral Blood Flow & Metabolism
2009;29:1914-23.
[41] Preta G, Cronin JG, Sheldon IM. Dynasore - not just a dynamin inhibitor. Cell
Communication and Signaling : CCS 2015;13:24.
[42] Kirchhausen T, Macia E, Pelish HE. Use of dynasore, the small molecule inhibitor of dynamin,
in the regulation of endocytosis. Methods Enzymol 2008;438:77-93.
[43] Yin S, Huai J, Chen X, Yang Y, Zhang X, Gan Y, et al. Intracellular delivery and antitumor
effects of a redox-responsive polymeric paclitaxel conjugate based on hyaluronic acid. Acta
Biomater 2015;26:274-85.
[44] Baravalle G, Schober D, Huber M, Bayer N, Murphy RF, Fuchs R. Transferrin recycling and
dextran transport to lysosomes is differentially affected by bafilomycin, nocodazole, and low
temperature. Cell and tissue research 2005;320:99-113.
[45] Mundy DI, Li WP, Luby-Phelps K, Anderson RGW. Caveolin targeting to late
endosome/lysosomal membranes is induced by perturbations of lysosomal pH and cholesterol
content. Molecular Biology of the Cell 2012;23:864-80.
[46] Hou X, Lewis KT, Wu Q, Wang S, Chen X, Flack A, et al. Proteome of the porosome complex
in human airway epithelia: Interaction with the cystic fibrosis transmembrane conductance
regulator (CFTR). Journal of Proteomics 2014;96:82-91.
[47] Wang S, Lee JS, Bishop N, Jeremic A, Cho WJ, Chen X, et al. 3D organization and function of
the cell: Golgi budding and vesicle biogenesis to docking at the porosome complex.
Histochemistry and cell biology 2012;137:703-18.
[48] Zhang Y, Xu DQ. Improved Watershed Algorithm for Cell Image Segmentation. Advanced
Materials Research 2012;546:464-8.
[49] Zhang Y, Duanquan X. Improvement on watershed algorithm of OpenCV and its application
in cell image segmentation. Journal of Computer Applications 2012;32:134-6.
[50] Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to
proliferation and cytotoxicity assays. Journal of Immunological Methods 1983;65:55-63.
[51] Sham D, Wesley UV, Hristova M, van der Vliet A. ATP-mediated transactivation of the
epidermal growth factor receptor in airway epithelial cells involves DUOX1-dependent oxidation
of Src and ADAM17. PloS one 2013;8:e54391.
[52] Miao T, Rao KS, Spees JL, Oldinski RA. Osteogenic differentiation of human mesenchymal
stem cells through alginate-graft-poly(ethylene glycol) microsphere-mediated intracellular
growth factor delivery. J Control Release 2014;192:57-66.
[53] Nam HY, Kwon SM, Chung H, Lee S-Y, Kwon S-H, Jeon H, et al. Cellular uptake mechanism
and intracellular fate of hydrophobically modified glycol chitosan nanoparticles. Journal of
Controlled Release 2009;135:259-67.
[54] Kou L, Sun J, Zhai Y, He Z. The endocytosis and intracellular fate of nanomedicines:

133
·

Implication for rational design. Asian Journal of Pharmaceutical Sciences 2013;8:1-10.
[55] Boussif O, Lezoualc'h F, Zanta MA, Mergny MD, Scherman D, Demeneix B, et al. A versatile
vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine.
Proc Natl Acad Sci U S A 1995;92:7297-301.
[56] Cagnol S, Chambard JC. ERK and cell death: mechanisms of ERK-induced cell death-apoptosis, autophagy and senescence. FEBS J 2010;277:2-21.
[57] Catalgol B, Batirel S, Taga Y, Ozer NK. Resveratrol: French Paradox Revisited. Frontiers in
Pharmacology 2012;3.
[58] Lee JH, Kim KT. Regulation of cyclin-dependent kinase 5 and p53 by ERK1/2 pathway in the
DNA damage-induced neuronal death. J Cell Physiol 2007;210:784-97.
[59] Liu J, Mao W, Ding B, Liang CS. ERKs/p53 signal transduction pathway is involved in
doxorubicin-induced apoptosis in H9c2 cells and cardiomyocytes. American journal of physiology
Heart and circulatory physiology 2008;295:H1956-65.

134
·

CHAPTER 5: TARGETED IMMUNOTHERAPY VIA ALGINATE AVIDIN
NANOPARTICLES
The goal of this study was to design and fabricate an alginate-graft-avidin
nanoparticles, which are able to conjugate with any biotinylated antibody of cell
surface marker (i.e. anti-CD 11b or anti-CD8) to target interacts with desire cell types.

5.1. Introduction
Targeted drug delivery is an innovative method of delivering medications to
patients in a manner that increases the concentration of the medication in desired
disease locations relative to other body parts. Recent research focused on three fronts:
finding the proper target for a particular disease state; finding a drug that effectively
treats this disease; and finding a means of carrying the drug in a stable form to specific
sites while avoiding the immunogenic and nonspecific interactions that efficiently clear
foreign material from the body[1]. Nanoparticles encompass a variety of submicron (<1
µm) colloidal nanosystems, able to pass through certain biological barriers and
encapsulate high density of therapeutic agents. With a large variety of chemical and
preparation methods, nanoparticles can be engineered to yield different properties and
release characteristics for the entrapped agent with different surface functionalities,
such as targeting ligands for interaction with specific cells or tissue[1], which is
required in p38 inhibitor delivery for MS treatment. Targeting moieties are classified as
proteins (antibodies and fragments), peptides, nucleic acids (aptamers), small
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molecules, or others molecules (vitamins or carbohydrates)[2]. Monoclonal antibodies
are clinically and commercially-established therapeutics[3-5]. The full sequence of an
antibody provides an accurate and efficient targeting effect compared to other types of
moieties.
Alginate, a naturally occurring non-toxic biopolymer, has been used as a matrix
for the entrapment and/or delivery of a variety of biological agents [18-20]. Alginate
sub-microspheres have attracted much attention for the development of controlled and
sustained-release drug delivery for proteins[6], cytokines[7, 8], and cells[9]. Our group
has previously reported on utilizing alginate sub-microspheres for promoting
osteogenic differentiation of human mesenchymal stem cells. However, the reported
targeting moieties was only a tri-peptide arginine-glycine-aspartic acid (RGD). To
increase the targeting efficiency, we herein report on utilizing the streptavidin
(SA)/biotin interaction to conjugate biotinylated antibodies, specific to macrophages
(anti-CD11b) or CD 8+ T cells, onto the SA surface modified alginate nanoparticles.
The high affinity of the noncovalent interaction between biotin and avidin has been
widely applied in research, which relies on the formation of an irreversible and specific
linkage between biological macromolecules[10]. The capture of the small molecule
biotin (vitamin H/vitamin B7) by the bacterial protein SA is both a powerful tool in
biology and a model system for the study of high-affinity protein–ligand
interactions[11]. Therefore, our SA surface modified alginate sub-microparticles will
serve as a general drug delivery platform for targeting drug delivery.
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5.2. Materials and Methods
5.2.1. Materials
Sodium alginate (MW = 65–75 kg/mol, 60–70% guluronic acid residues) was
generously donated by FMC BioPolymer. N-ethyl-N′(3-dimethylaminopropyl)
carbodiimide

hydrochloric

acid

(EDC),

N-hydroxysuccinimide

(NHS),

2,2′-

dithiodipyridine, methanol (MeOH, anhydrous, 99.8%), biology-grade mineral oil,
Span 80, bovine serum albumin (BSA) were purchased from Sigma-Aldrich. Sodium
citrate, isopropanol, calcium chloride (CaCl2), Alexa Fluor® 647 Cadaverine, 4%
Formaldehyde (PFA) Solution in PBS, BupH™ MES Buffered Saline Packs and 20 ×
phosphate buffered saline (PBS), Alexa 647 Cadaverine, FTIC avidin, alexa 647 avidin
were purchased from Fisher Scientific. Fetal bovine serum (FBS) was purchased from
Atlanta Biologics and screened for a lot that best supported growth of human cells.
Dulbecco's Modification of Eagle's Medium/Ham's F-12 Mix and 1X DMEM medium,
penicillin, streptomycin and Trypsin EDTA were purchased from Corning Cellgro. Rat
anti-CD11b antibody and anti-CD8+ were purchased from BioLegend.

5.2.2. Alginate Sub-Microsphere (ASM) Fabrication
ASMs were fabricated using a 1% (w/v) polymer solution. One milliliter of
alginate-graft-poly(ethylene glycol) solution was slowly added to 6.72 mL of
biological-grade mineral oil containing 5% (v/v) Spam 80 while mixing at 1200 rpm
for 5 min at room temperature. Next, 400 µL of 30% (v/v) Tween 80 was added and the
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emulsion will be mixed for an additional 5 min. Then, 5 mL of 2 M calcium chloride
(CaCl2) solution was added slowly. After 30 min of mixing, 3 mL of isopropanol was
added to the emulsion and allowed to mix for 5 min, then was centrifuged at 400 rpm
for 5 min to precipitate ASMs. ASMs were washed sequentially with isopropanol (x2)
and DI water (x2), respectively, and centrifuged after each wash. Microspheres were
flash frozen in liquid N2 and lyophilized into powder for long term storage. The size
and zeta-potential of the sub-microspheres were determined using dynamic light
scattering (DLS, Zetasizer Nano ZSP, Malvern) in PBS at pH = 7.4 at room
temperature.

5.5.3. ASM Surface Coating
The surface modification of ASMs with FTIC/Alexa 647 labeled avidin was
achieved via carbodiimide chemistry catalyzed with EDC and NHS. Twenty milligrams
of lyophilized ASMs were added to 3 mL of 0.1M MES buffer at pH 5 with the
addition of EDC and NHS, and stirred at room temperature to activate the carboxyl
groups on alginate. The COOH:EDC:NHS molar remained consistent at 1:8:3.2 during
the reaction, where COOH refers to the moles of alginate carboxyl groups. After 1 h of
vigorous stirring, 200 µg FTIC or Alexa 647 labeled avidin or Alexa 647®Cadaverine
(labeling control group) in 200 µL DI water were added to the reaction system and
reacted for 48 h at room temperature protected from light. The reaction suspensions
were centrifuged for 3 min at 4000 rpm to precipitate ASMs. ASMs were washed
sequentially with DI water (X2) respectively, and centrifuged after each wash. ASMs
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were flash-frozen in liquid N2 and lyophilized for long term storage. The size and zetapotential of ASMs were determined using dynamic light scattering (DLS, Zetasizer
Nano ZSP, Malvern) in PBS at pH = 7.4 at room temperature.

5.2.4. ASM Antibody Conjugation
Two milligrams of ASMs were mixed with 50 µg anti-CD11b, anti-CD8 or
isotype control IgG (BioLegend Cat# 101204, 100704 and 400604 respectively) in a
total volume of 100 µL PBS with 10% FBS and allowed to conjugate for 60 min at
room temperature. A separate reaction with no antibody served as an additional control.
After the reaction, ASMs were centrifuged for 5 min at maximum speed to pellet
antibody-coated ASMs. ASMs were washed sequentially with PBS (X2) respectively,
and re-suspended in 100 µL PBS.

5.2.5. Animals
C57BL/6J mice were purchased from The Jackson Laboratory and were
maintained in the animal facility at the University of Vermont. The experimental
procedures used in this study were approved by the Animal Care and Use Committee of
the University of Vermont.

5.2.6. Mixed Mice Spleen Culture
Single-cell suspensions of splenocytes were prepared and the red blood cells
were lysed with ammonium chloride. Total numbers of cells were counted using the
Trypan blue live dead staining. These cultures typically consist of a mixture B cells
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(CD19+), T cells (CD3+), macrophages (CD11b+, CD3-, CD19-), and other cells
(negative for all 4 markers). The cells were incubated overnight with 100, 10, 1, 0.1 and
0.01 µg/mL of ASM particles labeled with FITC or A647 and conjugated with CD11b,
CD8 or IgG isotype control. Labeled beads with no antibody conjugation served as an
additional control. For flow cytometric analysis, the cells were washed twice and
incubated for 30 min on ice with the desired fluorochrome-conjugated mAbs or isotype
control immunoglobulin at 0.5 µg/106 cells. The antibodies being used in the
experimental design includes anti-CD19 for B cells, anti-TCR for T cells, anti-CD4 and
anti-CD8 for individual T cell populations, anti-CD11b and anti F4/80 for
macrophages. All antibodies were purchased from BioLegend. As a parallel approach,
we will conjugate specific antibodies to ABNs that will direct them to our cells of
interest. There are many commercially available antibodies that will bind to surface
markers of macrophages (CD11b) and conventional DCs (CD11c).

5.3. Results and Discussion
5.3.1. Alexa 647 Labeled ASMs Uptake by Mixed Culture Splenocytes

Figure 5-1. Flow Cytometry result of Alexa 647 labeled ASMs
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The surface coating of avidin-Alexa 647 was verified through flow cytometry.
ASMs were coated with Avidin-Alexa 647 and then conjugated with anti-CD11b
(target to macrophages) and anti-CD8. IgG was also conjugated to ASMs avidin-Alexa
647 as control group. ASMs without avidin coating were labeled with Alexa Fluor
®647 cadaverine to obtain fluorescent labeled ASMs in order to be detected through
flow cytometry. ASMs without avidin or antibody coating were not internalized until
concentrations reached 10 µg/mL. At higher doses (100 µg/mL), >70% of the B cells
and >40% of the macrophages contained ASMs whereas <10% of CD8+ T cells and
CD4+ T cells internalized the ASMs. Similar results were also evident in isotype
controls (IgG), where 40% of B cells and 10% of macrophages were ASM positive and
all other type of cells were less than 5% positive at 100 µg/mL. Both non-avidin coated
groups and IgG coated groups presented nearly no uptake at concentrations less than 1
µg/mL; however, non-specific uptake occurred at concentrations equal to 100 µg/mL.
Using both groups as standard gates, we hereby analyzed antiCD11b groups, which
were hypothesized to target macrophages. The results indicated a nearly 100% of
uptake of macrophages at 10 µg/mL, whereas other types of cells’ uptake activity were
almost zero, indicating the successful targeting effect to macrophages. To back up our
targeting efficacy, we also coated anti-CD8 to ASMs. In our control experiments, T
Cells did not internalize ASMs at a concentration of 10 µg/mL. With the anti-CD8
coating, 80% of CD8+ cells were ASM positive at 1 µg/mL, while other cells did not
internalize ASMs.
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The above in vitro mixed culture proved the efficacy of using antibody-coated
avidin-ASMs for targeting specific cell populations. Avidin-Alexa647 ASMs are an
efficient drug delivery platform with multiple advantages: 1) they can be stored at -20
ºC long term after lyophilization; 2) they are traceable with Alexa 647 dye and can be
used to semi-quantitatively track cell specific uptake in vitro; 3) the targeting efficiency
was significantly effective at concentrations as low as 1 µg/mL[12].
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Figure 5-2 Alexa 647 labeled ASMs uptake by mixed culture plenocytes.

5.4. Conclusion
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100

SA surface modified ASMs will serve as a general drug delivery platform for
targeting drug delivery with different antibodies.
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CHAPTER 6: SELF-HEALING AND THERMO-RESPONSIVE DUAL
CROSSLINKED ALGINATE HYDROGELS BASED ON SUPRAMOLECULAR
INCLUSION COMPLEXES
β-cyclodextrin (β-CD), with a lipophilic inner cavity and hydrophilic outer
surface, interacts with a large variety of non-polar guest molecules to form noncovalent inclusion complexes. Conjugation of β-CD onto biomacromolecules can form
stiff, physically-crosslinked hydrogel networks upon mixing with a guest molecule.
Herein describes the development and characterization of self-healing, thermoresponsive hydrogels, based on host-guest inclusion complexes between alginate-graftβ-CD and Pluronic® F108 (poly(ethylene glycol)-b-poly(propylene glycol)-bpoly(ethylene glycol)). The mechanics, flow characteristics, and thermal response were
contingent on the polymer concentration, and the host-guest molar ratio. Transient and
reversible physical crosslinking between host and guest polymers governed selfassembly, allowing flow under shear stress, and facilitating complete recovery of the
material properties within a few seconds of unloading. The mechanical properties of the
dual-crosslinked, multi-stimuli responsive hydrogels were tuned as high as 30 kPa at
body temperature, which make it a potential candidate for biomedical applications such
as drug delivery and cell transplantation.
6.1. Introduction
Polymeric hydrogels are porous, 3-D networks of crosslinked macromolecules,
able to retain large amounts of water.[1] Injectable polymeric hydrogels, which are
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crosslinked and solidify in situ,[2] are advantageous for drug and cell delivery, and
tissue engineering applications.[2-4] Many existing injectable hydrogel systems
polymerize to form covalent crosslinks, through the use of photo-initiated systems,
autonomous redox reactions, or Michael Addition chemistries,[5] which can affect
cytocompatibility[6] and protein bioactivity.[7] Furthermore, covalently crosslinked
hydrogels are unable to undergo reversible solid-liquid transitions.[8] In contrast, the
dynamic and reversible nature of non-covalent interactions, such as physical crosslinks,
demonstrate variable mechanical properties and stimuli responses which lead to unique
and programmable modifications in the network structure.[9]
Indeed, physically-crosslinked hydrogels avoid the limitations associated with
permanently crosslinked hydrogel networks.[10] Gelation conditions are relatively
mild, and reversible physical crosslinks allow hydrogels to re-assemble, or self-heal,
after deformation or a disruption in the network.[11-13] In addition, physicallycrosslinked hydrogels offer a new route toward innocuous, stable materials and
components in vivo.[14] Recently, the utilization of supramolecular polymer chemistry,
specifically host-guest chemistry, has enabled the design of more sophisticated multifunctional materials.[15-18],[5, 10, 19, 20] Such hydrogels, which mimic strain and
stress-responsive tissues, are now being considered for biomedical applications.[21]
Several macrocyclic host-guest inclusion complexes are reported in the
literature, including crown ethers, cyclophanes, ctananes, and cavitands (such as
cyclodextrins, calix[n]arenes and cucurbit[n]urils).[1] Of particular interest is β-
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cyclodextrin (β-CD), which is easily grafted onto polymer chains, exhibits negligible
cytotoxic effects, and is an important attribute in the pharmaceutical and food
industries.[22] The covalent conjugation of β-CD onto large biomacromolecules, such
as alginate, increases the functionality of the large polymer.[23-25] Alginate is a plantderived polysaccharide, and alginate hydrogels have served as scaffolds for tissue
engineering, drug delivery vehicles, and models of extracellular matrices for biological
studies.[26-29] Alginate hydrogel properties, including stiffness, swelling, degradation,
cell attachment, and binding or release of bioactive molecules, can be optimized
through the chemical or physical modification of the polysaccharide itself or the
inclusion of alginate into a hydrogel network.[30, 31]
β-CD, with a lipophilic inner cavity and hydrophilic outer surface, interacts with
a large variety of non-polar guest molecules to form physical inclusion complexes.[22,
32] The hydrophobic guest molecule is held within the cavity of β-CD and the main
driving force of complex formation is the release of enthalpy-rich water molecules from
the cavity.[22, 32] The binding activities between host and guest molecules are not
fixed, but rather self-assemble in a dynamic manner.[22] Several guest molecules are
reported for β-CD, including adamantine,[5, 33, 34] cholesterol,[35] and other customdesigned

molecular

recognition

compounds.[36]

Macromolecules

such

as

poly(propylene glycol), PPG, have also been investigated as guest molecules for βCD.[15, 37-40] Difunctional block copolymers, such as PEG-b-PPG-b-PEG (i.e.,
Pluronic® F108), are utilized in drug delivery systems and cell culture due to low
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cytotoxicity and innate thermo-responsive propoerties.[41-48] The inclusion of
hydrophobic PPG chain segments into the inner cavity of β-CD affords a high binding
affinity to form a hydrogel network, while mobile PEG end-blocks entrap water
molecules and provide an innocuous environment for cells.[49-52] In addition, the
thermo-responsive property of Pluronic® F108 is advantageous for in vivo applications
due to the presence of PPG in the block copolymer - PPG is water-soluble at low
temperatures and reverts into an insoluble form at higher temperatures.[45, 53, 54] This
behavior is similar to poly(N-isopropyl acrylamide) (PNIPAAm), a commonly
synthesized thermo-responsive polymer.[16, 53, 55] However, the non-biodegradability
and relatively weak mechanical properties limit the wide application of PNIPAAm.[56]
The goal of this study was to create a host biomacromolecule, alginate-graft-βCD, and incorporate a difunctional guest molecule, Pluronic® F108, to create
physically-crosslinked, moderately stiff hydrogels. We hypothesized that the supra The
hydrophobic guest molecule is held within the cavity of β-CD and the main driving
force of complex formation is the release of enthalpy-rich water molecules from the
cavity.[22, 32] molecular inclusion complex formation between alginate-graft-β-CD
and Pluronic® F108 would generate non-cytotoxic, dual-crosslinked, multi-stimuli
responsive hydrogels with physiologically relevant mechanical properties for
biomedical applications.[56]

6.2. Experimental Section
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Materials: Sodium alginate (PROTANAL® LF200 FTS, Mv 67-142 kg/mol was
generously donated by FMC BioPolymer. Beta-cyclodextrin (β-CD), ρ-toluenesulfonyl
chloride (TosCl), acetonitrile, acetone, 1,6-hexanediamine (HDA), diethyl ether,
dimethylformamide (DMF), (benzotriazol-1-yloxy)tris-(dimethylamino) phophonium
hexafluorophosphate (BOP), dimethyl sulfoxide (DMSO), ethylenediamine (EDA),
and deuterium oxide (D2O) were purchased from Acros Organics. Sodium hydroxide,
ammonium chloride, hydrogen chloride (HCl), ethanol, tetrabuylammonium fluoride
(TBAF), phosphate buffered saline (PBS), 2-morpholinoethanesulfonic acid (MES)
buffer, alpha-modified eagle medium (α-MEM, Hyclone), and bovine serum albumin
(BSA) were purchased from Thermo Fisher Scientific. Human mesenchymal stem cellscreened fetal bovine serum (FBS) was purchased from Atlanta Biologics. Penicillin,
streptomycin, and trypsin ethylenediaminetetraacetic acid (EDTA) were purchased
from Corning Cellgro. Tetrabutylammonium hydroxide (TBAOH), N-ethyl-N’(3dimethylaminopropyl) carbodiimide hydrochloric acid (EDC), N-hydroxysuccinimide
(NHS), Pluronic® F108 (Mn ≈ 14,600 g/mol), and an In Vitro Toxicology Assay Kit (3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, i.e., MTT-based) were
purchased from Sigma Aldrich. BCA® Protein Assay Kit was purchased from Life
Technologies Inc.
Alginate-Tetrabutylammonium (Alg-TBA) Synthesis: Sodium alginate (Na-Alg,
2 g) was added to a mixture of HCl (0.6 N, 30 mL) and ethanol (30 mL) and stirred
overnight at 4 ºC. After filtering under vacuum with filter paper and washing with
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ethanol and acetone, pure alginic acid was obtained and dried overnight. The dried
powder was dispersed in DI water (100 mL). Aqueous TBAOH was added slowly
under continuous stirring and the pH was adjusted to between 7.0 and 10.0. The
solution was dialyzed and lyophilized to yield white Alg-TBA powder.[57-61]
β-CD-TosCl Synthesis: β-CD (20 g, 17.62 mM, 1 molar equivalent) was
suspended in 125 mL ice DI water, and TosCl (4.2 g) was dissolved in minimum
acetonitrile (~10 mL) and added drop wise to the aqueous phase. The reaction was
stirred vigorously for 2 h at room temperature. Sodium hydroxide (2.18 g) was
dissolved in DI water (~10 mL) and added drop wise. After 30 min of stirring at room
temperature, solid ammonium chloride was added to adjust the pH to 8.5 and the
solution was cooled on ice to collect precipitants. The product was washed with cold DI
water and acetone 3 times respectively and dried under vacuum; 6-ο-monotosyl-6deoxy-β-CD was obtained (~25%).[5, 62, 63]
β-CD-HDA Synthesis: β-CD-TosCl (5 g) was dissolved in DMF (25 mL) with
1,6-hexanediamine (20 g) and stirred under nitrogen at 80 ºC for 24 h using a
condenser. The product was precipitated out of solution using cold acetone (5 x 500
mL), washed with cold diethyl ether (2 x 100 mL), and dried under vacuum to afford
the final product mono-6-deoxy-6-aminohexaneamino-β-CD).[5, 64]
β-CD-EDA Synthesis: 6-(6-aminohyxyl)amino-6-deoxy-β-cyclodextrin (1.5 g)
was added to EDA (5 mL). The reaction was performed at 60 ºC for 24 h and cooled to
room temperature. The precipitant was collected from a large amount of ethanol and
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dried under vacuum to afford the final product (mono-6-deoxy-6-aminoethylamino-βCD).[65]
Alginate-graft-C6-Cyclodextrin (Alg-C6) Synthesis: TBAF (10 g) was dissolved
in DMSO (100 mL) to afford a 10% (w/v) solution. Alg-TBA (2 g, 1 molar equivalent)
and β-CD-HDA (2.96 g, 0.5 molar equivalent) were added to the mixture and stirred at
room temperature under nitrogen flow until a clear solution was obtained.[58] BOP
(1.06 g, 0.5 molar equivalent) was dissolved in minimal DMSO (5 mL) and added via
syringe. The reaction was carried out at room temperature under vigorous mixing for 24
h and then dialyzed against DI water (x 3), followed by 0.05 M sodium phosphate
dibasic solution until fully dissolved in water, and finally DI water (x 2). The final
product was frozen and lyophilized. The theoretical modification was 50%.[5]
Alginate-graft-C2-Cyclodextrin (Alg-C2) Synthesis: Sodium alginate (2.73 g)
was dissolved in 0.1 M MES buffer (pH 5.6, 150 mL) to which EDC (2 g) and NHS
(1.2 g) were added. After mixing for 30 min at room temperature, β-CD-EDA (4.5 g)
was added under vigorous mixing at room temperature for 1 day. The alginate solution
was dialyzed against DI water for 3 days, frozen, and lyophilized to afford dry
polymer.[65]
1

H-NMR Spectroscopy: To qualitatively verify the successful synthesis of Alg-

C6 and Alg-C2, lyophilized polymer was dissolved in D2O and the result was
confirmed via

1

H-NMR (Bruker AVANCE III 500 MHz high-field NMR

spectrometer). In addition to standard 1H-NMR, solvent (water) suppression 1H-NMR,
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as well as diffusion edited 1H-NMR at 95% strength (programmed in Bruker NMR
spectrometer), were also performed for alginate, Alg-C2, and Alg-C6, to confirm the
covalent conjugation of β-CD onto alginate. The detailed 1H-NMR spectra are provided
in the supplemental data.
Alginate Hydrogel Formation and Erosion: Alg-C2 and Alg-C6 hydrogels were
prepared from solutions of the individual polymers in PBS at desired concentrations. 4
and 6% (w/v) Alg-C2 and Alg-C6 solutions were prepared in 10 mL syringes.
Pluronic® F108 crystals were dissolved in DI water (10% w/v), frozen at -80 ºC, and
lyophilized to obtain a white powder, which was added to the Alg-g-CD solutions at
Pluronic® F108:β-CD ratios of 1:4 and 1:2, respectively. Hydrogels and single host and
guest polymer solutions were injected into glass vials; the glass vials were stored at
either 25 or 37 ˚C. Optical images were taken at each time point after the injection to
analyze hydrogel stability. To qualitatively analyze hydrolytic erosion of the hydrogels,
images were taken of the hydrogels after adding a known amount of PBS on top of each
hydrogel to qualitatively visualize hydrogel surface erosion over a period of 14 days at
37 ˚C under gentle agitation in a shaking incubator (see additional Supplemental
Materials). Samples were sealed with parafilm to eliminate water evaporation.
Rheological Characterization: All experiments were performed using an
AR2000 stress-controlled rheometer (TA Instruments) fitted with a 40 mm diameter
1°59’47’’ steel cone geometry and 27 µm gap at 37 °C, however, the temperature
sweep study included a temperature range. Oscillatory time sweeps for single polymer
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constituents (e.g., 4% (w/v) Alg-g-CD, 10% Pluronic® F108) and hydrogels were
deformed at 1% strain and 10 Hz over 250 s. Oscillatory frequency sweeps were
performed at 0.5% strain with increasing frequency from 0.1 to 100 Hz. Continuous
flow experiments used a shear rate linearly ramped from 0 to 1 s-1. Oscillatory strain
sweeps were performed at 10 Hz with increasing radial strain from 0.01 to 500%.
Dynamic shear strain tests were performed at high (250%) and low (0.5%) strains at 1
Hz and 37 °C for certain lengths of time and the cycles were repeated three times to test
the self-healing and recovery properties of the hydrogels. Temperature sweeps were
performed at 1 Hz and 1% strain, with a heating rate of 0.5 °C*min-1 from 25 to 37 °C.
In Vitro Cytotoxicity Assay: Materials for the in vitro cell study were lyophilized
and exposed to UV light overnight. The hydrogels and polymer solutions were prepared
with sterile PBS using similar protocols stated above. Primary human mesenchymal
stem cells (MSCs) were purchased from Rooster Bio. MSCs (passage 4) were seeded in
48-well tissue culture polystyrene (TCPS) plates at a density of 20,000 cells/well in
500 μL/well of standard MSC growth medium (α-MEM, 10% FBS, 100 U mL-1
penicillin, 100 μg mL-1 streptomycin) and allowed to adhere for 24 h. Cells were
incubated in the presence of Alg-C6 hydrogels with ratios of 1:4 and 1:2 and Alg-C2
hydrogels with ratios of 1:4 and 1:2. In addition, cells were incubated without
hydrogels under the same culture conditions as control group. After 24 h of incubation,
media containing the hydrogel and polymer solutions was removed, and cells were
rinsed two times in sterile PBS then analyzed using a MTT-based In Vitro Toxicology

153
·

Assay Kit following the manufacturer's protocol. The optical density was measured at
570 nm using a BioTek plate reader. Background absorbance at 690 nm was subtracted
from the measured absorbance. Absorbance values for the experimental and control
samples were normalized to non-modified TCPS controls.[66]
In Vitro BSA Release: BSA (10 mg) was added to 1 mL of different hydrogel
solutions (prepared as stated above) and injected into 24-well plates. The plates were
incubated at 37 ºC overnight to ensure gelation complete. One mL of PBS was added to
each well and the plate was gently agitated at 37 ºC in a shaker incubator. At each time
point, 100 µL sample aliquots were removed and replaced with 100 µL fresh PBS. The
protein concentration was determined using a BCA Protein Assay Kit according to the
manufacture’s protocol. The optical density was measured at 562 nm using a BioTek
plate reader. Background absorbance of non-modified TCPS controls was subtracted
from the measured absorbance; absorbance values for the experimental, blank (i.e.,
containing no BSA), and control samples were reported.
Statistical Methods: All experiments were performed in triplicate; results are
reported as mean ± standard deviation. Statistical analysis was performed on the
storage moduli for 25 and 37 °C between each of the treatment groups and in vitro
cytotoxicity data respectively, using one-way ANOVA with Tukey multiple
comparisons (α = 0.05) via the SAS statistics program in the GLM procedure as the
post-test to compare all of the groups. P < 0.05 was considered significantly different.
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6.3. Results and Discussion
6.3.1. Dual Strategies for Synthesizing Alginate-graft Cyclodextrin (Alg-g-CD)
Two

strategies

were

employed

to

synthesize

Alg-g-CD

(i.e.,

host

macromolecules) using a short-chain methylene group to conjugate β-CD onto the
alginate backbone, providing mobility and thus crosslinking efficiency. While one
reaction was performed in an organic solvent with six methylene groups (-CH2-)
connecting the alginate backbone to β-CD (Alg-C6),[12] the other reaction was
performed in aqueous solution with two methylene groups (-CH2-) connecting the
alginate backbone to β-CD (Alg-C2).[65] The detailed chemical synthesis for both
reactions are presented in Figure 6-1 A. Briefly, β-CD was first reacted with TosCl to
obtain β-CD-TosCl. In one reaction scheme, β-CD-TosCl was reacted with HDA in
DMF at 80 °C for 18 h. Amine groups reacted with carboxyl groups (pre-neutralized
with TBA salt) on alginate in DMSO in the presence of BOP. Alternatively, in the
aqueous solution method, β-CD-TosCl was reacted with EDA at 60 °C for 12 h to
obtain β-CD-EDA. The standard 1H-NMR spectra for the final products, Alg-C6 and
Alg-C2, are provided in 6.7 supplemental materials (chapter 6.5).
In addition to standard 1H-NMR, solvent suppression (water) 1H-NMR as well
as diffusion edited 1H-NMR at 95% strength for alginate, Alg-C2 and Alg-C6, were
performed to confirm the covalent conjugation of β-CD onto alginate. The detailed 1HNMR spectra are provided in the supplemental data. The spectra indicated that β-CD
was covalently conjugated onto alginate in both Alg-C2 and Alg-C6. By comparing
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alginate, Alg-C2 and Alg-C6 spectra, peaks between 1 – 3 ppm were only presented in
the final product of Alg-C2 and Alg-C6 rather than alginate, suggesting the covalent
conjugation of methylene groups, as linker between β-CD and alginate. The degree of
β-CD modification, i.e., β-CD density, may generate an effect on the hydrogel physical
and mechanical properties.[12] The theoretical reaction ratio of β-CD to alginate repeat
units (C6H7NaO6)n was 50%. However, by calculating the ratio of hydrogen integration
of sugar units (both on alginate backbone repeat units and on β-CD repeat units), and
hydrogen integration of the methylene groups on the linker between the backbone and
β-CD,[65] the actual β-CD modification for both reaction methods was 28% and 30%,
respectively for Alg-C2 and Alg-C6, indicating no significant differences in alginate
modification for the different Alg-g-CD reaction schemes. There are limitations with
using 1H-NMR to calculate the β-CD degree of modification due to the high molecular
weight and polydispersity of the alginate (Mv 67-142 kg/mol) starting material;
however, using either standard 1H-NMR or diffusion edited 1H-NMR is common in this
type of polymer chemistry characterization.[5, 12, 48]
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Figure 6-1 A) Schematic of Alg-g-CD synthesis using organic solvents or aqueous-based
solutions. Alg-C6 was the product of the organic synthesis (top), and Alg-C2 was the
product of the aqueous synthesis (bottom). B) Schematic of physical crosslinking
between Alg-g-CD macromolecules and Pluronic® F108, and the effect of Pluronic®
F108 on the thermo-response of hydrogel network; Pluronic® F108 forms micelles and
self-crosslinks at body temperature due to the triblock structure of PEG-b-PPG-b-PEG. βCD conjugated onto the alginate backbone served as the host (Alg-g-CD), which formed
a physically-crosslinked supramolecular inclusion complex with the guest, the PPG
component (green) of Pluronic® F108.
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6.3.2. Hydrogel Formation and Rheological Analysis
A self-assembled hydrogel network formed almost immediately upon mixing
Alg-g-CD and Pluronic® F108 solutions (quantity based on constituent molar ratios).
The formation of a pseudo-plastic hydrogel occurred through the complexation of hostguest moieties, i.e., β-CD conjugated alginate (Alg-g-CD) and PPG, as part of the
Pluronic® F108 structure. In addition to the supramolecular inclusion complex
formation between Alg-g-CD and Pluronic® F108, a dual-crosslinked hydrogel was
created via the innate thermo-response of Pluronic® F108. Such dual-crosslinking
capabilities significantly increased the storage moduli compared to a single physical
crosslinking technique based on host-guest chemistry alone (Figure 6-1 B).
The formation and physical integrity of the supramolecular inclusion complex
hydrogels were quantified using rheometry. Hydrogels and their pre-curser solutions
were exposed to varying shear forces to examine steady-state shear moduli with time,
the effect of frequency on shear moduli, and the effect of shear rate on the shear stress
and viscosity of hydrogel pre-curser solutions. To examine the hydrogels in their least
compliant states, experiments were performed at 37 °C. In Figure 6-2 A, the shear rate
was linearly ramped from 0 to 1 s-1 to investigate the effect of shear rate on viscosity
and resultant shear stress; the Alg-C2 group generated an increase in shear stress from
approximately 40 Pa to 400 Pa while shear rates increased from 0 to 0.3 s-1 and then
plateaued until 1 s-1. The viscosity decreased from near 3500 to 300 Pa*s while shear
rates increased from 0 to 0.7 s-1. For the Alg-C6 hydrogels (Figure 6-2 B), the shear
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stress increased from approximately 5 to 50 Pa for 4% (w/v) Alg-C6 hydrogels and
from 100 to 400 Pa for 6% and 8% Alg-C6 hydrogels. While maintaining the same
molar ratio between Alg-g-CD and Pluronic® F108, a more distinct concentrationdependent behavior was seen in the Alg-C6 groups compared to the Alg-C2 groups.
This may be due to the self-crosslinking of the Alg-C2 polymers, as the material
properties were less dependent on polymer concentration, as the β-CD conjugation for
both materials was ~30%.[65]
Shear storage and loss moduli were measured to both verify and quantify the
formation of the supramolecular inclusion complex hydrogel from independent
measurements of pre-curser solutions. Oscillatory rheology confirmed that the
individual Pluronic® F108 and Alg-g-CD pre-cursers were solutions at high frequencies
and that an increase in moduli of several orders of magnitude occurred immediately
upon mixing of the two components. While the individual polymer solutions (i.e.,
hydrogel constituents) displayed viscous behaviors associated with intermolecular
entanglement in solution, the formed supramolecular inclusion complex hydrogel was
stable during a qualitative inversion test. Pluronic® F108 remained unstable and free
flowing at room temperature and formed small micelles (size ~20nm) at body
temperature.[67, 68] The micelles were inter-connected with each other and therefore,
higher concentrations of Pluronic® F108 formed a soft network in solution, also shown
by the slight increase in viscosity. For the Alg-C2, the G′ increased from 300 Pa to 12
kPa (Figure 2C). The multi-arm structure of EDA on β-CD may also react with various
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carboxyl groups on neighboring alginate molecules, to create an intramolecularcrosslinked network beyond the host-guest interaction. Previous literature has shown
the concept that such crosslinking will increase the stiffness of the hydrogel, although
only slightly.[32] For Alg-C6, the G′ increased from 300 Pa for the polymer solution, to
near 10 kPa for the Pluronic® F108:Alg-g-CD hydrogel (1:2), and G″ increased from 50
Pa for the polymer solution to 10 kPa for the Pluronic® F108:Alg-g-CD hydrogel. The
large increase in shear moduli that occurred after mixing the two polymer constituents
verified that an interaction took place to form a more permanent network, compared to
polymer solutions alone; the formation of the supramolecular inclusion complex
resulted in the 100-fold increase in shear moduli (Figure 6-2 C,D). Thus, the bulk
material response indicated that the chemical modification of alginate was successful,
through the formation of a stiff hydrogel network upon mixing with Pluronic® F108.
Shear storage and loss moduli were also measured to determine effect of
frequency during dynamic shear application. Oscillatory frequency sweeps were
performed on 4% Alg-C6 and Alg-C2 hydrogels with a ratio Pluronic® F108:Alg-g-CD
1:4 at 0.5% radial strain and 37 °C. The hydrogel exhibited steady-state behavior up to
10 Hz, after which the moduli increased in response to the increasing shear rate. The
effect followed an exponential trend for frequencies greater than 10 Hz for the Alg-C2
hydrogels (Figure 6-2 E). In addition, the hydrogels were considered to be stable at
lower frequencies and not responsive to frequency as an input parameter. The Alg-C6
hydrogels displayed noisy data, which suggested a less stable network, especially at
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increasing frequencies (Figure 2F).

Figure 6-2. Rheological experiments were performed at 37 °C to verify formation and
physical integrity of the supramolecular alginate network. (A, B) Continuous, increasing
shear rates allowed for the determination of viscosity and shear stress of formed
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hydrogels; A) Alg-C2 and B) Alg-C6. The shear stress increased with an increase in
shear rate from 0 to 1 s-1, demonstrating viscoelastic behavior. (C, D) Oscillatory time
sweep experiments for hydrogel pre-curser solutions, Alg-g-CD and Pluronic® F108, and
formed hydrogels at 1% strain, 10 Hz, 37 °C; C) Alg-C2 and D) Alg-C6. The storage
moduli increased from 100 Pa for single polymer constituents to 10 kPa for 4% (w/v)
Pluronic® F108:Alg-g-CD hydrogels. (E, F) Oscillatory frequency sweeps were
performed at 0.5% radial strain; E) Alg-C2 and F) Alg-C6.

6.3.3. Strain Responsive Properties and Self-Healing
Multi-chain entanglements of macromolecular guest polymers create a unique
structure upon crosslinking which affords a high modulus hydrogel with shear-thinning
behaviors. Reversible, dynamic physical crosslinks allow supramolecular inclusion
complex hydrogels to exhibit flow and recovery characteristics under mechanical radial
strain. To validate and optimize the shear-shinning properties of the injectable delivery
systems, hydrogels were tested using oscillatory strain sweeps from 0.01% to 500%
radial strain at a frequency of 10 Hz. Both Alg-C2 and Alg-C6 (Figure 6-3 A,B)
groups were more elastic at low strains, with storage moduli (G') greater than the loss
moduli (G"). At 1% strain, the G' and G" curves for Alg-C2 began to cross over,
indicating a transition from an elastic solid material to a compliant, viscous liquid. The
crossover of G' and G" for Alg-C6 hydrogels occurred near 10% strain, suggesting that
the inter-molecular crosslinking density for Alg-C6 was higher compared to Alg-C2;
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this may be attributed to a longer amine chain, which may have provided more mobility
to allow Pluronic® F108 to enter the β-CD cavity. The shear-thinning characteristics
were also dependent on the de-association of host-guest polymers. Alg-C2 hydrogel
networks were more easily strained to failure compared to Alg-C6 hydrogels, and the
Alg-C2 hydrogels exhibited a lower transition strain (%) compared to Alg-C6
hydrogels.
The reversibility and repeatability of the self-healing properties of the hydrogels
were independent of host:guest ratios or polymer concentration. To assess material
recovery, hydrogels were subjected to cycles of high amplitude oscillatory strain
(250%) followed by low amplitude oscillatory strain (0.5%) at 1 Hz. Storage moduli
(G') decreased 1/100 fold with a change from low to high amplitude strain (i.e., each
time step with strain variation). A decline in moduli was concurrent with the presence
of solid-liquid transitions during the application of high strain. During transitions from
high to low strains, the initial mechanical properties were recovered in a short time
period of 10 s. These results indicate that the novel hydrogels exhibit shear-shinning
behavior, recovering mechanical properties immediately upon un-loading. Various
hydrogel formulations demonstrated a variety of strain-induced shear moduli values: D)
Alg-C6 (1:2) (Figure 6-3 D) and Alg-C2 (1:4) (Figure 6-3 E) hydrogels exhibited a
change in G' over 3 orders of magnitude, whereas the Alg-C2 (1:2) (Figure 6-3 C) and
Alg-C6 (1:4) (Figure 6-3 F) exhibited a change in G' by 2 orders of magnitude. Despite
that the crossover transient points for both Alg-C2 and Alg-C6 upon strain changes in
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strain were relatively low, the mechanical properties were as high as 10 kPa, indicating
a dynamic material with a range of achievable moduli.

Figure 6-3 (A, B) Oscillatory strain sweeps were performed at 10 Hz and 37 °C using a
40 mm 1°59'47" steel cone geometry on F108:Alg-g-CD hydrogels: A) Alg-C2 and B)
Alg-C6 hydrogels. The storage moduli (G') and loss moduli (G") of the hydrogels crossed
at higher strains, demonstrating a solid-liquid transition. (C – F) Dynamic shear strain
testing of hydrogels was performed to demonstrate a self-healing, physically crosslinked
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network. Dashed gray lines represent the radial strain (%) input parameters and the solid
black lines represent shear storage moduli (G') results. All of the groups tested
demonstrated a repeatable ability to deform and re-assemble upon loading and unloading, resulting in radial shear deformations. Hydrogels consisting of 4% (w/v) Alg-gCD were analyzed at various ratios of Pluronic® F108:Alg-g-CD; C) Alg-C2 (1:2), D)
Alg-C6 (1:2), E) Alg-C2 (1:4), F) Alg-C6 (1:4). The hydrogels exhibited higher storage
moduli values at 0.5% strain while exhibiting lower G' values at 250% strain. Compared
to alginate supramolecular inclusion complexes formed with β-CD, the novel Pluronic®
F108:Alg-g-CD hydrogels presented here are shear-thinning, and amendable to injectable
biomaterials applications[25].

6.3.4. Thermo-Responsive Properties
The alginate-based supramolecular inclusion complex hydrogels are thermoresponsive and exhibit secondary crosslinking effects with increasing temperature, due
to the incorporation of Pluronic® F108. To demonstrate the thermo-responsive
properties of the Alg-g-CD and Pluronic® F108 hydrogels, temperature sweeps were
performed from 25 to 37 °C at a heating rate of 0.5 °C min-1 (1% strain; 1 Hz). The
significant transition temperatures occurred near 30 °C. For all hydrogel groups tested,
the storage moduli (G') increased with increasing temperature (Figure 6-4). The shear
moduli for all hydrogel samples were statistically different between 25 and 37 °C for
all samples within the same group (Figure 6-4), with G' values significantly higher at
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body temperature compared to room temperature. Independent of polymer
concentration, hydrogels fabricated using Pluronic® F108:Alg-g-CD ratios of 1:2 were
significantly stiffer compared to ratios of 1:4 at both 25 and 37 °C. The differences in
G' within the same group at the different temperatures were elevated due to the addition
of Pluronic® F108 in the hydrogel system, indicating that Pluronic® F108 played a
significant role in the thermo-response of the host-guest hydrogels. Furthermore,
considering only hydrogels with a Pluronic® F108:Alg-g-CD ratio of 1:4, 6% (w/v)
Alg-g-CD hydrogels were significant higher compared to 4% hydrogels, for both AlgC2 and Alg-C6 formulations. Alg-C6 (1:2) hydrogels exhibited G' values of near 30
kPa at 37 °C, which corresponded to a ~3% increase in stiffness compared to hydrogels
at 25 °C (< 10 kPa). The thermo-transition from room temperature to body temperature
was markedly higher compared to existing literature,[69] suggesting potential in vivo
applications of the thermal-responsive hydrogel in

drug delivery and tissue

engineering. The novel Pluronic® F108:Alg-g-CD hydrogels were strain-responsive,
i.e., shear-thinning, in addition to exhibiting thermo-responsive behavior, exhibiting
mechanical and temperature responsive properties. Strain-responsive alginate-based
supramolecular inclusion complexes presented in the literature do not exhibit thermoresponsive behavior.[70] Likewise, thermo-responsive alginate hydrogels do not exhibit
shear-thinning and self-healing behavior.[71-73]
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Figure 6-4 (A, B) Oscillatory temperature sweeps were performed at 1 Hz and 1% radial
strain on Alg-g-CD hydrogels: A) Alg-C2 and B) Alg-C6. (C, D) Shear storage moduli
(G') for Alg-g-CD hydrogels at 25 °C (white bars) and 37 °C (black bars) (n = 3, average
± standard deviation), specifically C) Alg-C2 and D) Alg-C6. The ratio of Alg-g-CD to
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Pluronic® F108 was critical to the magnitude of the thermo-responsive properties. The
greater the ratio of Pluronic® F108, the stiffer the hydrogel and more responsive the
thermal behavior. Significant differences, of the same hydrogel sample between 25 and
37 °C, were observed in both Alg-g-CD hydrogel formulations. E) Images of Alg-g-CD
and Pluronic® F108 solutions, and Alg-g-CD hydrogels formed after mixing the two precursers and waiting 10 min, 1 day, and 5 days. Images were taken of hydrogels incubated
at room temperature (RT) and 37 °C, respectively.

6.3.5. Hydrogel Stability
The physical integrity of the hydrogel network (i.e., supramolecular inclusion
complex) was visually analyzed by examining hydrogel stability over 5 days at both
room temperature and 37 °C. The 4% (w/v) Alg-g-CD hydrogels, with Pluronic®
F108:Alg-g-CD ratios of 1:4 and 1:2, solidified (i.e., physically crosslinked) quicker
when exposed to 37 °C compared to those hydrogels exposed to room temperature. For
4% Alg-C2 (1:4 and 1:2) and 4% Alg-when C6 (1:4) formulations, a solid hydrogel
was only formed at 37 °C rather than at room temperature, indicating the significant
impact of the secondary physical crosslinking arising from the micelle formation of
Pluronic® F108. This effect was evident for hydrogels formed from lower concentration
solutions (supplemental materials 6.5). For higher concentration solutions, the
hydrogel formed upon mixing of the pre-curser solutions at room temperature (Figure
6-4). In summary, hydrogels remained stable for up to 5 days after initial formation of
the supramolecular inclusion complex, in a non-disturbed, static state. Further
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observation was performed of Alg-C2 and Alg-C6 hydrogels (see supplemental
material) at room temperature for over 6 months (sealed with parafilm to eliminate
water evaporation); optical photographs are shown in supplemental information 9 under
“day 0”. They remained solid and crosslinked, demonstrating the stability of the
hydrogels in air. However, in order to assess the stability of the hydrogels under
physiological conditions, a degradation or erosion experiment must also be performed.

6.3.6. Hydrogel Erosion
To visualize hydrolytic erosion of Alg-C2 and Alg-C6 supramolecular inclusion
complex hydrogels, a qualitative surface erosion was performed. Freshly prepared
hydrogels were injected into glass vials, flowed to take the shape of the container
before completion of crosslinked, and solidified at 37 ˚C. PBS was added to the vials,
and the vials were inverted each day 1 – 7, followed by static incubation for an
additional 7 days. After day 3, the Alg-C2 hydrogels appeared to reach a swollen
equilibrium state and remained at the bottom of the vial until day 14 (supplemental
information 9 under newly injected from day 0 with PBS to day 14). The surface
erosion of 4% and 6% Alg-C6 (1:4) hydrogels was observed as the height of the
solidified hydrogels getting shorter until day 14, which was different compared to the
response of the Alg-C2 hydrogels. The 4% (w/v) Alg-C2 hydrogels exhibited decreased
stability and less resistance to flow after 3 days of culture in PBS during physical
inversion; however, when the vials were returned to a static state, the hydrogels
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solidified. Over time hydrogels appeared to continue to crosslink, indicative of selfhealing characteristics, quantified above. Interestingly, the 6% Alg-C6 (1:2) hydrogel
network swelled and incorporated the PBS into the network, and solidified the solution.
This was likely due to surface erosion releasing Alg-C6 and Pluronic® F108 polymers
into the PBS. In addition, the Alg-C6 hydrogels may inherently enabled more flexibility
to the CD functional group compared to the Alg-C2 due to the longer methylene group.
This recovery and stability of the Alg-C6 hydrogels was more evident compared to the
Alg-C2 over the 14-day period.

6.3.7. In Vitro BSA Release
The inner cavity of β-CD undergoes hydrophobic interactions, not only with
PPG but with other organic molecules, and such interactions have been extensively
employed as drug carriers. Specifically, drug release profiles for supramolecular
inclusion network hydrogels utilizing β-CD as a physical crosslinker are of recent
interest.[5] For this study, BSA, a moderately sized biomolecule (66.5 kDa) with a
globular structure, was encapsulated and released from Alg-g-CD hydrogels. BSA
release was quantified for up to 14 days for both 4% (w/v) and 6% Alg-C6 and Alg-C2
hydrogels with ratios of 1:2 and 1:4. For each sample, BSA exhibited a sustained
release over 14 days to afford a release amount of 40% of the encapsulated drug
(Figure 6-5). A lower amount of BSA was released from hydrogels formulated with a
Pluronic® F108:Alg-g-CD ratio of 1:4, suggesting that the reduction in Pluronic® F108
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content created a moderately crosslinked hydrogel, resulting in a greater release of
BSA. Alg-C2 hydrogels (Figure 6-A) released less BSA compared to Alg-C6
hydrogels (Figure 6-5) over a period of 14 days, due to a swollen host-guest
intermolecular network observed in the qualitative surface erosion study (supplemental
information). As stated above, Alg-C2 hydrogels swelled after the addition of PBS.
Thus, the hydrogel structure was weakened and compromised, resulting an enhanced
released compared to Alg-C6 gels, who was degraded gradually from the top surface to
the bottom of glass vials.

6.3.8. In Vitro Cytotoxicity
The safety and efficacy of the alginate-based hydrogels for biomedical
applications was tested using a 24 h mitochondrial activity (i.e., MTT content) based
assay. 4% (w/v) and 6% Alg-g-CD hydrogels, with Pluronic® F108:Alg-g-CD ratios
1:2 and 1:4, were co-cultured with primary human MSCs for 24 h. An in vitro
cytotoxicity assay showed no toxic effects related to the presence of the hydrogels. AlgC2 hydrogels were slightly less cytotoxic compared to Alg-C6 hydrogels; however,
there were no significant differences between experimental groups (Figure 6-5) and the
control group (non-modified TCPS).
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Figure 6-5. (A,B) In vitro BSA release from Pluronic® F108:Alg-g-CD hydrogels.
Experiments were performed at 37 °C under mild agitation in PBS, pH 7.4, investigating
A) Alg-C2 and B) Alg-C6 hydrogels. Black circles represent 6% (w/v) Alg-g-CD
solutions, open circles represent 4% Alg-g-CD solutions. Solid lines represent Pluronic®
F108:Alg-g-CD hydrogels with ratios of 1:2; dashed lines represent hydrogels with ratios
of 1:4. C) In vitro MTT-based assay results of hydrogels cultured with primary human
MSCs indicated no toxic effect for the various hydrogels analyzed along with the nonmaterial treated control group. There were no significant differences between each group.

6.4. Conclusions
In summary, we have developed the first dual-crosslinked, self-healing, and
strain and thermo-responsive alginate-based hydrogels with moderate mechanical
properties, based on the supramolecular inclusion complex formation between
Pluronic® F108 and Alg-g-CD. The intermolecular entanglement of guest polymers
(e.g., PPG) creates a unique structure upon crosslinking which affords shear-thinning
behavior. Furthermore, Pluronic® F108 affords a thermo-responsive behavior of the
injectable hydrogel, generating a dual-crosslinked hydrogel upon increase to body
temperature. Upon mixing host and guest polymers, the shear storage moduli of the
hydrogel reached as high as 30 kPa at body temperature, exhibiting biologicallyrelevant mechanical properties for biomedical applications.
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6.5. Supplemental Materials
1. 1H-NMR spectrum of β-CD-TsCl
1
H-NMR (DMSO-d6) δ = 2.42 (s, 3H), , 4.12−4.40 (m, 6H), 4.77 (s, 2H), 4.83 (s, 5H),
5.60−6.05 (br s, 14H), 7.43 (d, 2H), 7.75 (d, 2H).

Figure 6-6. 1H-NMR spectrum of β-CD-TsCl in DMSO-d6. The peaks corresponding to δ
= 7.43 ppm (2H) and δ = 7.75 ppm (2H) identify the hydrogens on the benzene ring of
the toluenesulfonyl group. The remaining peaks between δ = 7 and 8 ppm refer to nonpurified p-tuluenesulfonyl chloride. The peak corresponding to δ = 2.42 ppm (3H) refers
to the hydrogens of the methylene group of the toluenesulfonyl group. Peaks between δ =
4.0 and 5.0 ppm refer to the hydrogens on the β-CD ring.[5] [12]
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2. 1H-NMR spectrum of β-CD-HAD
H NMR (DMSO-d6) δ = 1.14−1.61 (m, 12H), 3.48−3.78 (m, 28H), 4.28−4.56 (br s, 6H),
4.83 (s, 7H), 5.59−5.88 (br s, 14H).

Figure 6-7. 1H-NMR spectrum of β-CD-HDA. The disappearance of peaks between δ =
7 and 8 ppm indicates that the toluenesulfonyl group was replaced with hexanediamine.
The peaks corresponding to δ = 1.14-1.16 ppm (12H) refer to hydrogens on the
hexanediamine group. Peaks between δ = 3 and 5 ppm represent hydrogens on the β-CD
ring. Peaks between δ = 1.00 and 1.10 ppm (2H) represent hydrogens on the amine group.
[5, 12]
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3. 1H-NMR spectrum of β-CD-EDA
1
H NMR (300 MHz, D2O, DSS)  = 2.61 (2H, -NHCH2-), 2.73 (3H, -CH2CH2NH2, CH2(H-6’)-N), 2.92 (d, 1H, -CH2(H-6’)-), 3.33 (t, 1H, -CH(H-4’)-), 3.36-3.51 (m, 14H, CH(H-2,H-2’)-, -CH(H-5’)-, -CH(H-4)-), 3.73-3.84 (m, 25H, -CH(H-3,H-3’)-, -CH(H-5), -CH2(H-6)-), 4.92 (d, 7H, -CH(H-1, H-1’)-) ppm.

Figure 6-8. 1H-NMR spectrum of β-CD-EDA. The disappearance of peaks between δ = 7
and 8 ppm indicate that the toluenesulfonyl group was replaced with ethylenediamine.
The peak at δ = 2.61 ppm (2H) refers to hydrogens on the amine group. The peak at δ =
2.73 ppm (3H) refers to hydrogens on the methylene chain. Peaks between δ = 3.73 and
3.84 ppm represent hydrogens on the β-CD ring.[65]
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4.

Figure 6-9. 1H-NMR spectrum of Alg-C6 with integration
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Figure 6-10. 1H-NMR spectra of Alg-C6 with standard procedure (brown), water
suppression procedure (green), and diffusion edit procedure at 95% strength (blue).
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5.

Figure 6-11. 1H-NMR spectrum of Alg-C2 with integration.
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Figure 6-12. 1H-NMR spectra of Alg-C6 with standard procedure (brown), water
suppression procedure (green), and diffusion edit procedure at 95% strength (blue).
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6.

Figure 6-13. 1H-NMR spectra of alginate with standard procedure (brown), water
suppression procedure (green), and diffusion edit procedure at 95% strength (blue).
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7. Stacked 1H-NMR spectra of alginate (brown), Alg-C2 (green and Alg-C6 (brown).

Figure 6-14. 1H-NMR spectra of non-modified alginate (top) compared to Alg-g-CD
(middle, bottom). Peaks between δ = 7 and 8 ppm represent the hydrogens on the amine
group. Peaks between δ = 1 and 2 ppm refer to hydrogens on the methylene chain.
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8.

Figure 6-15. Optical photographs of hydrogel surface erosion in PBS at 37 ˚C over 14
days. Day 0 images demonstrate that the hydrogels crosslinked in the bottles, taking the
shape of the container; hydrogels were not exposed to PBS. Day 0 with PBS images
demonstrate how the hydrogels behaved after the addition of PBS. Day 3, 7 and 14 are
series photos taken of the same sample at a specific time point. During the 14 day study,
hydrogels were incubated at 37 ˚C under gentle agitation.
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The Alg-C2 hydrogel can be conjugate with cell instructive peptide such as RGD. The
hydrogel containing A549 cells were injected out and cultured for 24h before staining
with live/dead stain and imaged under CLS.
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CHAPTER 7 CONCLUSIONS AND FUTURE DIRECTIONS
The present dissertation has attempted to design and fabricate alginate based
biomaterials for biomedical applications. Starting with commercially available
polysaccharide material alginate, I have designed four generations of alginate based
nanoparticles with different types of polymer chemistry reactions. The first generation
is basic alginate nanoparticles fabricated through benchtop water/oil emulsion. With the
addition of poly (ethylene glycol) onto alginate, I was able to create particles with a
more neutral surface charge, which are favorable for cell uptake compared to cationic
alginates. This is the second generation of alginate-based nanoparticles. The third
generation of nanoparticles was created through disulfide bond chemistry, where I
conjugated short cell signal peptides for targeting delivery. However, the targeting
efficacy was not as specific compared to full antibody. Therefore, in the latest (forth)
generation of nanoparticle, I designed the streptavidin coated alginate nanoparticles,
which can conjugate to commercially available biotinylated antibodies to target cell
types.
All four generations of alginate nanoparticles can be readily internalized by
human mesenchymal stem cells, human cancer cells (A549), human epithelial cells
(HBE), mice macrophages, T cells and B cells. The application of alginate
nanoparticles ranges from tissue engineering to promote bone regeneration for treating
osteoporosis to cancer therapy for deliver chemotherapeutics to lung cancers. With the
powerful delivery alginate particles, I have been able to elucidate the intracrine
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mechanism underlying human mesenchymal stem cells and cancer cells, and modulate
the cell behavior based on the need for different therapies for different diseases.
However, particulate based drug delivery was just the first goal of this thesis. A
novel multi-stimuli hydrogel based drug delivery system was also design based on the
supramolecular interactions between β-cyclodextrin and pluronic®F108. β-cyclodextrin
(β-CD), with a lipophilic inner cavity and hydrophilic outer surface, interacts with a
large variety of non-polar guest molecules to form non-covalent inclusion complexes.
Conjugation of β-CD onto alginates can form physically-crosslinked hydrogel networks
upon mixing with a guest molecule. I have developed and characterized self-healing,
thermo-responsive hydrogels based on host-guest inclusion complexes between
alginate-graft-β-CD and Pluronic® F108 (poly(ethylene glycol)-b-poly(propylene
glycol)-b-poly(ethylene glycol)). The mechanics, flow characteristics, and thermal
response were contingent on the polymer concentration and the host-guest molar ratio.
Transient and reversible physical crosslinking between host and guest polymers
governed self-assembly, allowing flow under shear stress, and facilitating complete
recovery of the material properties within a few seconds of unloading. The mechanical
properties of the dual-crosslinked, multi-stimuli responsive hydrogels were tuned as
high as 30 kPa at body temperature, which make them potential candidates for
biomedical applications such as drug delivery and cell transplantation.
In additional to the alginate-based materials discussed in this thesis, I also
developed theta-gel networks for promoting chondrogenic differentiation. Theta-gels
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are hydrogels that form during the solidification and phase separation of two dislike
polymers, in which a low molecular weight polymer behaves as a porogen and is
removed through dialysis. Interpenetrating polymer network (IPN) hydrogels were
formed between polyvinyl alcohol (PVA) and gelatin using theta-gel fabrication
techniques, i.e., in the presence of a porogen. The addition of gelatin to a PVA thetagel, formed with a porogen, polyethylene glycol (PEG), created macro-porous
hydrogels, and increased shear storage moduli and elastic moduli, compared to PVA–
gelatin scaffold controls. A reduction in PVA crystallinity was verified by Fourier
transform infrared (FTIR) spectroscopy in hydrogels fabricated using a porogen, i.e.,
PVA–PEG–gelatin, compared to PVA, PVA–PEG, or PVA–gelatin hydrogels alone.
Van Geison staining confirmed the retention of gelatin after dialysis. A range of
hydrogel moduli was achieved by optimizing PVA concentration, molecular weight,
and gelatin concentration. PVA–gelatin hydrogels maintained primary human
mesenchymal stem cell (MSC) viability. Soft (∼10 kPa) and stiff (∼100 kPa) PVA–
gelatin hydrogels containing type II collagen significantly increased glycosaminoglycan
(GAG) production compared to controls. PVA–gelatin hydrogels, formed using thetagel techniques, warrant further investigation as articular cartilage tissue engineering
scaffolds.
Alginates have become an important polymer of polysaccharides because of
their utility in preparing hydrogels at mild pH and temperature conditions, suitable for
sensitive biomolecules like proteins and nucleic acids, and even for living cells such as
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islets of Langerhans[1]. These polysaccharides-based biomaterials have been designed
and modified to meet the different needs of drug delivery and form particulates and
scaffolds, which may have great potential for various biomedical application.
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APPENDIX: PHYSICALLY CROSSLINKED POLYVINYL ALCOHOL AND
GELATIN INTERPENETRATING POLYMER NETWORK THETA-GELS FOR
CARTILAGE REGENERATION
Theta-gels are hydrogels that form during the solidification and phase
separation of two dislike polymers, in which a low molecular weight polymer behaves
as a porogen and is removed through dialysis. For this study, interpenetrating polymer
network (IPN) hydrogels were formed between polyvinyl alcohol (PVA) and gelatin
using theta-gel fabrication techniques, i.e., in the presence of a porogen. The addition of
gelatin to a PVA theta-gel, formed with a porogen, polyethylene glycol (PEG), created
macro-porous hydrogels, and increased shear storage moduli and elastic moduli,
compared to PVA-gelatin scaffold controls. A reduction in PVA crystallinity was
verified by Fourier transform infrared (FTIR) spectroscopy in hydrogels fabricated
using a porogen, i.e., PVA-PEG-gelatin, compared to PVA, PVA-PEG, or PVA-gelatin
hydrogels alone. Van Geison staining confirmed the retention of gelatin after dialysis.
A range of hydrogel moduli was achieved by optimizing PVA concentration, molecular
weight, and gelatin concentration. PVA-gelatin hydrogels maintained primary human
mesenchymal stem cell (MSC) viability. Soft (~10 kPa) and stiff (~ 100 kPa) PVAgelatin hydrogels containing type II collagen significantly increased glycosaminoglycan
(GAG) production compared to controls. PVA-gelatin hydrogels, formed using thetagel techniques, warrant further investigation as articular cartilage tissue engineering
scaffolds.
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1. Introduction
Osteoarthritis is a degenerative inflammatory disease that results in irreversible
degradation of osteochondral tissue, which consists of surface articular cartilage and
underlying subchondral bone.[1] Recent tissue engineering approaches show promise;
however, innovative strategies are needed to recapitulate the mechanotransduction
pathways found in osteochondral tissue for tissue regeneration, and to maintain tissue
homeostasis.[2] The mechanisms by which cells receive signals from their environment
can be examined through the manipulation of the structure (e.g., topography and
porosity), level of bioactivity (e.g., cell adhesion, stem cell differentiation), and the
dynamic mechanical properties (e.g., stiffness, elasticity, toughness, etc.) of the
material systems.[3-5] Therefore, it is critical to define each parameter – structure,
bioactivity, and mechanical properties – independently and collectively to define the
critical parameters required to regenerate tissue, or treat a disease.[6-9]
Tissue engineering relies on synthetic or natural-based material systems to
interact with cells in order to enhance tissue regeneration. Material stiffness,[10]
porosity,[11] and bioactivity parameters influence the cellular response, in particular,
cell transcription and stem cell differentiation.[5] Thus, various mechanotransduction
pathways can be activated to direct stem cell differentiation for specific
applications.[12-18] Indeed, mesenchymal stem cells (MSCs) cultured on stiff
substrates favor an osteogenic differentiation pathway,[19, 20] while MSCs cultured on
soft substrates favor a chondrogenic differentiation pathway.[4] In addition to
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mechanical cues, MSCs are responsive to biological signals from their physical
environment. Collagen is an amino acid based protein that is found in the fibrous
tissues of the human body, including bone and cartilage.[21] Collagen increases cell
adhesion, migration, and proliferation.[22] Specifically, type II collagen, a component
of articular cartilage extracellular matrix (ECM), is known to significantly influence
chondrogenic differentiation and the maintenance of chondrocyte phenotype in vitro
and in vivo.[23]
Polyvinyl alcohol (PVA) is a synthetic, biocompatible polymer utilized for soft
tissue replacements and tissue regeneration.[24-26] PVA hydrogels are formed by the
crystallization of polymer chains through non-covalent linkages, i.e., physical
crosslinks.[27],[28, 29] Specifically, the formation of theta-gels incorporates the use of
a small molecular weight hydrophilic polymer, such as polyethylene glycol (PEG) as a
porogen during cooling, or solidification of a PVA solution.[30, 31] During a thermal
transition, PEG porogens phase separate from PVA, increasing the density of PVA-rich
regions, thus inducing crystallization. The PVA hydrogel network forms during a large
thermal transition and the creation of intermolecular hydrogen bonds.[32, 33] PEG is
removed through dialysis after the thermal transition, which results in large pores in a
rigid hydrogel network.
PVA hydrogels lack cell adhesion functionalities, and investigators have
incorporated biomolecules into the hydrogel network to enhance hydrogel mechanical
properties and bioactivity.[34] To enhance bioactivity of PVA hydrogels,
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polysaccharides and proteins have been added during hydrogel crosslinking. Gelatin, a
non-specific derivative of the protein collagen, contains cell adhesion ligands, which
provide cell adhesion sites to PVA hydrogels when blended together. While cryo-gels
of PVA and gelatin blends have been studied, the effect of adding gelatin to PVA thetagels, in the presence of PEG, has not been investigated.

The aim of this study was to develop and characterize PVA-gelatin hydrogels with
improved mechanical properties, through the incorporation of PEG porogens. We
hypothesized that the addition of a porogen would increase the density and interactions of
PVA and gelation, compared to the solidification of PVA and gelatin alone, to result in
macro-porous hydrogels with increased shear and compressive moduli. We evaluated the
potential of PVA-gelatin hydrogels to support chondrogenic MSC differentiation, and
varied hydrogel stiffness and the addition of type II collagen.

2. Experimental Section
2.1. Fabrication of PVA-Gelatin Theta-Gels
PVA-gelatin theta-gels, i.e., hydrogels, were prepared using different molecular
weights and concentrations of PVA, PEG, and gelatin. PVA (Mw = 145 kg/mol (H) and
95 kg/mol (L), Sigma Aldrich) was combined with 20% (w/v) PEG (Mw = 400 g/mol,
Sigma Aldrich) in DI water. PVA concentrations, for both molecular weights, were 18
and 36% (w/v). Experimental groups contained gelatin (Sigma Aldrich) at 1, 5, and
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18% (w/v). The control and experimental polymer blend solutions were autoclaved for
1 hour and the warm, homogenous solutions were transferred to curing molds
consisting of glass slides and 3.2 mm thick Teflon spacers, preheated to 90 °C. The
molds containing the polymer solutions were cooled to room temperature and cured for
24 hours. The hydrogel sheets were removed from the molds and dialyzed in DI water
for 5 days to remove PEG porogens; dialysis water was changed every 12 hours.
2.2. Fourier-Transform Infrared (FTIR) Spectroscopy
All sample hydrogels were prepared prior to performing spectroscopy: 18%
(w/v) PVA, high molecular weight, and 1% (w/v) gelatin solutions were prepared and
used as controls, 20% (w/v) PEG was used for all theta-gels. The hydrogels were
dialyzed for 5 days, to ensure removal of the porogen and air-dried after dialysis and
cut into small pieces. Then they were tested using Thermo-Nicolet IR200 FTIR
spectrometer with an attenuated total reflectance (ATR) head for 32 scans.

2.3. Rheological Characterization
All experiments were performed using an AR2000 stress-controlled rheometer
(TA Instruments) fitted with a 20 mm diameter steel cone geometry at 25 °C, however,
the temperature sweep study included a temperature range. All sample solutions were
prepared prior to performing the temperature sweep: 18% (w/v) PVA, high molecular
weight, and 1% (w/v) gelatin solutions were prepared and used as controls, 20% (w/v)
PEG was used for all theta-gels. Temperature sweeps were performed at 1 Hz and 1%
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strain, with a cooling rate of -5 °C*min-1 from 60 to 20 °C. Oscillatory time sweeps for
experimental (PVA-PEG-1Gel) and control hydrogels (gelatin, PVA, PVA-1Gel) were
tested directly after hydrolysis, and were deformed at 1% radial strain and 10 Hz over
100 s. Oscillatory frequency sweeps were performed at 0.5% radialstrain with
increasing frequency from 0.1 to 100 Hz.

2.4. Scanning Electron Microscopy
Hydrogel samples, containing PVA and PEG, with and without gelatin, were
flash frozen in liquid nitrogen after dialysis in DI water, cryo-fractured, lyophilized,
and characterized by scanning electronic microscopy (SEM, JEOL 600). Samples were
sputter coated with 10 nm of Au-Pd prior to imaging. SEM was used to quantify pore
diameters and characterize the inner structure of PVA-PEG-Gel hydrogel cross-sections
compared to PVA-PEG controls。

2.5. Van Geison Staining
To characterize the retention of gelation, hydrated hydrogels were placed in Van
Geison staining solution (ThermoFisher) for 2 minutes and rinsed in DI water several
times until the water remained clear. PVA-PEG-Gel hydrogels consisting of 18 and
36% (w/v) PVA, using low (L, 95 kDa) or high (H, 145 kDa) molecular weight PVA,
and 18% (w/v) PEG, were fabricated. Hydrogels also varied in gelatin content: 1, 5, and
18% (w/v). Control groups included PVA-PEG hydrogels with no gelatin content.
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Samples were dried at room temperature, and color images were taken using a digital
camera.

2.6. Equilibrium Water Content and Weight Loss
Cylindrical hydrogel specimens (6 mm x 3 mm) were lyophilized to ensure all
moisture was alleviated in preparation for equilibrium water content measurements and
weight loss values. The dehydrated specimens were weighed, then placed in 5 mL PBS,
pH 7.4, to rehydrate the scaffolds for 48 hours at 37 °C. Each specimen was weighed,
and the wet weight was recorded. Equilibrium water content was calculated as the
percentage of wet weight divided by initial dry weight. After each specimen’s wet
weight was recorded, each specimen was again froze to prepare for lyophilization. Each
specimen was then lyophilized for 24 hours. A second dry weight was then recorded to
test for how much weight was lost through the dehydration process. The weight loss
was calculated as final mass subtracted from the initial mass, divided by the initial
mass. Dry scaffolds were weight to determine the initial amount of polymer. To
determine the amount of non-crosslinked polymer, scaffolds were hydrated for 24 hours
in order to dissociate non-crosslinked PVA and gelatin. Scaffolds were then lyophilized
and massed. To determine the polymer loss due to hydration and diffusion of noncrosslinked molecules, the mass of a dry sample after the crosslinking process was
performed was measured.
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2.7. Unconfined Compression Testing
The unconfined compressive moduli of various hydrogel groups were
determined directly after dialysis. Cylindrical hydrogel specimens (6 mm x 3 mm) were
tested at 25 ˚C using an AR2000 rheometer (TA Instruments) equipped with a Peltier
plate and normal force transducer. Specimens were placed on the rheometer and the
geometry was lowered until a force of 0.01 N was measured, and the force was
normalized. The gap height was recorded as the original gage length for the modulus
calculation. A 20% uni-axial compressive strain was applied at a rate of 10 µm/s. Force
(N) and changes in gap height (μm) were obtained using analytical software (TA
Universal Analysis) and were subsequently used to calculate elastic strain (ε, %) and
stress (σ, kPa). The elastic modulus (E) was calculated as the slope of a linear fit
between 5 and 15% compressive strain within the linear-elastic region. A minimum of
four replicates from each group were tested.

2.8. Cytotoxicity Assay
The cytotoxicity of PVA-gelatin hydrogels to primary bone-marrow derived
human MSCs was assessed as a function of mitochondrial activity in living cells. MSCs
were seeded in treated 48-well tissue culture polystyrene (TCPS) plates at a density of
20,000 cells/well in 100 µL/well of standard MSC growth media (alpha minimum
essential medium (MEM), 10% fetal bovine serum (FBS), 100 U/mL penicillin, 100
µg/mL streptomycin) and allowed to adhere for 24 hours. MSCs were incubated in the

203
·

presence of various PVA-gelatin hydrogels (n = 4) at 37 °C and 5% CO2. Spherical
hydrogel specimens were 4 mm wide and 2 mm tall. After 24 hours of incubation,
media was removed and cells were rinsed two times in sterile PBS. Mitochondrial
activity was analyzed using a 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium
bromide (MTT) based In Vitro Toxicology Assay Kit (Sigma Aldrich) following the
manufacturer’s protocol with a plate reader (H1 Synergy, BioTek). Absorbance values
were recorded at 570 nm with background absorbance at 690 nm deducted. Average
absorbance values for the experimental samples were compared to positive cell control
values recorded for wells containing media and cells alone.

2.9. Chondrogenic Differentiation
PVA-gelatin hydrogels selected for cell-seeding were coated with type II
collagen using the following protocol. After fabrication and dialysis, PVA-gelatin
hydrogels were formed into cylinders, 3 mm x 2 mm, using a 4mm biopsy punch. The
hydrogels (soft and stiff scaffold groups) were immersed in type II rat collagen (50
mg/mL, Sigma-Aldrich) in phosphate buffered saline (PBS), which was pre-filtered to
obtain cell culture sterile solution, for 1 hour at room temperature.[35] The hydrogel
samples were removed from the collagen solution, rinsed in sterile PBS, and prepared
for cell culture.
Primary bone-marrow derived human MSCs (Lonza), passage 4, were seeded
onto PVA-gelatin hydrogels with or without type II collagen. 38 µL of 700,000 cells
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suspended in standard MSC culture media were placed onto cylindrical hydrogel
scaffolds (3 mm x 2 mm), and the scaffolds were placed in 96-well TCPS plates. Cellseeded scaffolds were incubated at 37 ˚C, 5% CO2 for 30 minutes, and then the wells
were supplemented with 150 µL of chondrogenic media (standard MSC growth media
supplemented with 10 ng/mL of human transforming growth factor beta one (TGF-β1,
Peprotech)).[11]

2.10. Dimethylmethylene Blue (DMMB) Assay
Intracellular sulfated GAG content was quantified using a DMMB assay.[11]
Cell lysate was collected after 4, 7, and 14 days of culture. Scaffolds were removed
from tissue culture plates, trypsin-EDTA was added, and the scaffolds were incubated
for 5 minutes. Equal volumes of standard MSC culture media were added to the cell
suspensions, cell suspensions were placed in micro-centrifuge tubes, and centrifuged at
4000 rpm for 2 minutes. The supernatant was collected and 150 µL of cell lytic solution
was added. Standard chondroitin sulfate solutions with concentrations ranging from 0
to 30 µg/mL were used to form the standard curve. Using a 96-well plate, 25 µL of cell
lysate sample or standard was added to each well. Next, 150 µL of DMMB solution
was added to each well. The absorbance at 525 nm was measured. Controls were MSCs
cultured in chondrogenic media in 96-well tissue culture treated polystyrene plates.
GAG production was normalized to the cell population per sample using
intracellular protein and the Pierce™ Protein Assay Kit (ThermoFisher). Briefly,
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standard bovine serum albumin (BSA) solutions with concentrations ranging from 20 to
2000 µg/mL were used to form the standard curve. Using a 96-well plate, 25 µL of cell
lysate sample or standard was added to each well. Next, 175 µL of working solution
was added to each well. The absorbance at 562 nm was measured. Controls were MSCs
cultured in chondrogenic media in 96-well tissue culture treated polystyrene plates.

2.11. In Vitro Mechanical Testing
MSC-seeded scaffolds were tested in unconfined compression using the same
methods detailed above. Briefly, cylindrical scaffolds (3 mm x 2 mm) were subjected to
uni-axial unconfined compressive strain at 10 µm/s to a final strain of 20%. Samples
were tested after 4, 7, and 14 days of culture with MSCs in chondrogenic media. At day
14, non-seeded PVA-gelatin hydrogel controls were mechanically tested as degradation
controls.

2.12. Statistical Analysis
All experiments were performed in triplicate with results reported as mean ±
standard deviation. Statistical analysis was performed with a GLM procedure using
Statistical Analysis System software. A fixed effect multi-factorial (concentration,
molecular weight, and gelatin concentration, eliminated inside the model if one of the
factor is not significant relevant) model was generated to study the contribution of each
factor to PVA-gelatin hydrogels with a range of compressive elastic moduli, swell ratio
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and weight loss based on ANOVA analysis. The multiple comparisons were performed
with Tukey adjustment. For analyzing cytotoxicity, similar GLM procedures were
preformed to obtain one-way ANOVA results. A p < 0.05 was considered significantly
different for all analysis. GAG assay results were analyzed using a standard student ttest.
3. Results and Discussion
3.1. PVA-Gelatin Theta-Gel Formation
Bio-synthetic hydrogels were obtained from the physical crosslinking of PVA
and gelatin, and the diffusion of PEG for pore formation (Figure 8-1). The thermal
gelation of both PVA and gelatin in the presence of PEG created a macro-porous IPN.
The short-chain, hydrophilic PEG molecules behaved as porogens, aggregating into
large domains. After cooling, the PVA-gelatin hydrogel was dialyzed for 5 days,
allowing the soluble, nucleated PEG molecules to escape the hydrogels, creating a large
interconnected porous structure.
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Figure 8-1. Schematic illustrating the formation of a PVA and gelatin theta-gel, through
the physical crosslinking of PVA (solid black lines) and gelatin (dashed black lines),
respectively, in the presence and subsequent removal of PEG. Areas of hydrogen bonding
(i.e., physical crosslinks) between gelatin and PVA are represented by black rectangles.
Nucleation of PEG porogens (gray lines) during solidification and subsequent removal
through dialysis resulted in a macro-porous network.
To demonstrate the formation of an IPN, soft hydrogels with 18% PVA (high molecular
weight), 1% gelatin and 20% PEG (PVA-PEG-1Gel) were synthesized, in addition to
control samples including 18% PVA (PVA), 1% gelatin (Gelatin), 18% PVA-1% gelatin
(PVA-1Gel) and 18% PVA-20% PEG (PVA-PEG). These samples were tested under
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attenuated total reflectance (ATR) Fourier transform infrared (FTIR) spectroscopy. The
physical crosslinking of PVA and PVA-1Gel controls occurred due to numerous interchain hydrogen bonds between OH groups, formed during crystallization of the polymer
and identified as a peak in the FTIR spectra at 1141 cm-1 (Figure 8-2 C,D).[36, 37] The
intensity of this peak is related to the C-O stretching vibrations of an intramolecular
hydrogen bond was formed between two neighboring OH groups. The C-O peak had a
lower intensity for PVA and gelatin hydrogels, which were solidified in the presence of
PEG porogens – the experimental group PVA-PEG-1Gel (Figure 8-2 B). The control
groups also formed peaks within 1090 – 1150 cm-1, associated with C-O-C stretching
vibrations; these peaks also appeared in the PVA-PEG-1Gel spectrum with lower
intensities. It was hypothesized that crosslinking also occurred due to the increased
polymer concentration at the solidifying regions containing PVA and gelatin, and the
subsequent generation of van der Waals interactions between hydrocarbon polymer
backbones between gelatin and PVA. As a result of introducing PEG into the
solidification process, the PVA and gelatin interacted with each other differently than
simply mixing the two polymers together, illustrated in Figure 8-2.
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Figure 8-2. Top: Chemical structure of PVA; physical crosslinking takes place at OH
groups between PVA molecules. Bottom: fourier transform infrared spectroscopy (FTIR)
spectra of (A) gelatin, (B) PVA-PEG-1Gel, (C) PVA-PEG, (D) PVA-1Gel and (E) PVA
hydrogel films, stretching vibrational bands associated with PVA physical crosslinking
include C-O and C-O-C.
The pore diameters of PVA-gelatin hydrogels (Figure 8-3 D) were approximately ten
times larger than the control PVA hydrogels (Figure 8-3 B), confirmed through scanning
electron micrographs. Large pores may also have been the result of non-crosslinked
gelatin leaving during dialysis, which may result from interference of PVA in the
formation of intra-molecular crosslinks. Van Geison staining qualitatively verified that
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gelatin was retained in the hydrogels after dialysis (gelatin samples stained red, PVA
controls did not; Figure 8-3 E). Qualitatively no differences were seen between groups in
the stained images.

Figure 8-3. SEM images of lyophilized and cryo-fractured surfaces of 18% PVA
211
·

hydrogel samples, fabricated in the presence of PEG alone (A, B) or with the addition of
5% gelatin (C, D). Magnifications at 250x, scale bar = 100 μm (A, C) and 800x, scale bar
= 20 μm (B, D). (E) Van Geison staining qualitatively verified gelatin retention in the
hydrogels, which were fabricated using theta-gel techniques. PVA-gelatin hydrogels
consisting of 18 and 36% PVA, using low or high molecular weight PVA, were
fabricated. Hydrogels also varied in gelatin content; top numbers represent weight
percent of gelatin. Samples containing gelatin displayed a higher intensity of the red
stain.
3.2. Physical Characterization and Mechanical Properties
To demonstrate the formation of an IPN, soft hydrogels with. Rheological
experiments were performed on experimental samples, 18% PVA (high molecular
weight), 1% gelatin and 20% PEG (PVA-PEG-1Gel), in addition to control samples
including 18% PVA (PVA), 1% gelatin (Gelatin), 18% PVA-1% gelatin (PVA-1Gel)
and 18% PVA-20% PEG (PVA-PEG) to examine the effect of PEG porogens on the
mechanical response of PVA-gelatin hydrogels. Polymer hydrogel pre-curser solutions
were autoclaved to dissolve in water and then immediately transferred to a AR2000
stress-controlled rheometer (TA Instrument). A temperature sweep was performed from
60 ºC to 20 ºC. For all samples except 1% gelatin, storage modulus increased as
temperature goes down; the gelatin control remains similar level for the whole tested
time period. With the addition of gelatin in the PVA hydrogel, storage moduli increased
from 24 Pa to 71 Pa. However, storage moduli jumped to 1863 Pa after introducing
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PEG into the PVA hydrogel without gelatin. By having all three components in the
system, the storage modulus increased to 5266 Pa, indicating the positive effect of PEG
porogens on the mechanical response of PVA-gelatin hydrogels (Figure 8-4 A).
After all sample hydrogels were dialyzed against water for one week (the
gelatin control remained in liquid form and was tested directly without dialyzing),
oscillatory time sweeps were performed to examine the mechanical properties of the
hydrogels. PVA and PVA-1Gel exhibited similar mechanical properties overtime
around 500 Pa. However, those hydrogels fabricated in the presence of PEG had a
much higher storage modulus around 4000 Pa. Same as the previous temperate sweep
result, PVA-PEG-1Gel had the highest storage modulus around 6000 Pa. Therefore,
after dialysis, PEG porogens resulted in large porous structures and stiffer scaffolds
(Figure 8-4 B).
Shear storage moduli were also measured to determine the effect of frequency
during dynamic shear application for various different monomers and hydrogels after
dialyzing. Oscillatory frequency sweeps were performed at 1% radial strain and 25 ºC.
The hydrogel exhibited steady-state behavior up to 10 Hz, after which the moduli
increased in response to the increasing shear rate. PVA and PVA-1Gel control groups
exhibited similar storage moduli. Similar with the previous two experiments, the PVAPEG-1Gel revealed the highest storage modulus compared to all of the other groups
(Figure 8-4 C).
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Figure 8-4. Rheological experiments were performed to examine the effect of PEG
porogens on the mechanical response of PVA-gelatin hydrogels. A) Temperature sweep
of single macromers, control solutions (PVA-1Gel, PVA-PEG), experimental solutions
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(PVA-PEG-1Gel); solution from the autoclave was tested from 60 ˚C to 20 ˚C to show
the gelation process of each sample. B) Oscillatory time sweep experiments for control
hydrogels (gelatin, PVA, PVA-1Gel, PVA-PEG), and experimental hydrogels (PVA-PEG1Gel) were tested after dialysis at 25 ˚C. C) Oscillatory frequency sweeps were
performed on hydrogels at 1% radial strain from 0.1 to 100 Hz at 25 ˚C.
PVA hydrogels with and without gelatin swelled > 100% after hydration
(Figure 8-3 A). The PVA molecular weight influenced water content; lower molecular
weight PVA-gelatin hydrogels swelled less compared to higher molecular weight PVAgelatin hydrogels, likely due to an increase in physical crosslinking. A fixed-effect trifactorial model (e.g., PVA concentration, PVA molecular weight, and gelatin
concentration) was generated to study the contribution of each factor to the hydrogel
material properties. All three factors contributed significantly to the equilibrium water
content of the hydrogel. The addition of gelatin increased the overall water content.
Weight loss was calculated to determine polymer mass lost due to hydrolysis.
While some material was lost due to non-crosslinked PVA chains and degraded
polymer during physical crosslinking (< 10%), indicated by the white bars in Figure 83 B, the PVA-gelatin hydrogels, specifically the 18% gelatin samples, black bars in
Figure 8-3 B, lost more weight (2 – 31%). These results correlate with the FTIR data,
which indicated that gelatin interrupted PVA crystallization during cooling, thus
allowing more amorphous species to be lost during hydration (Figure 8-2).
Unconfined compression tests were performed on hydrogels directly after
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dialysis. Increasing the gelatin concentration created a stiffer hydrogel up to 5% (w/v);
concentrations greater than 5% interfered with the formation of a network, resulting in
a more compliant hydrogel (Figure 8-3 C); PVA control hydrogels, fabricated with
PEG, without gelatin, were too compliant to collect compressive moduli values thus
data is not shown. A fixed effect tri-factorial model (e.g., PVA concentration, PVA
molecular weight, and gelatin concentration) was generated to study the contribution of
each factor to the IPN hydrogels with a range of compressive elastic moduli. All three
factors had significant contributions to the resulting moduli, among which PVA
concentration interacted with PVA molecular weight, and PVA molecular weight
interacted with gelation concentration: 18%PVA(H) ranged from 17 to 95 kPa,
36%PVA(H) ranged from 116 to 193 kPa, 18PVA(H) ranged from 26 to 92 kPa, and
36PVA(L) ranged from 189 to 351 kPa. The three factors were also interacting with
each other, and contributing of the compressive moduli of the hydrogels. Overall, the
formation of a crosslinked network of PVA and gelatin, to form a swollen, stiff
hydrogel, was dependent on the PVA concentration and molecular weight, and the
concentration of gelatin.
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Figure 8-5.

The physical and mechanical properties of PVA-gelatin hydrogels,

developed using theta-gel techniques, are reported. PVA-gelatin hydrogels consisting of
18 and 36% (w/v) PVA, using low (L, 95 kDa) or high (H, 145 kDa) molecular weight
PVA, were fabricated. Hydrogels also varied in gelatin content; white = no gelatin, light
gray = 1% gelatin, dark gray = 5% gelatin, black = 18% gelatin. (A) To evaluate
hydration, the equilibrium water content of PVA-gelatin hydrogels and PVA controls was
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calculated; lyophilized hydrogel samples were hydrated in phosphate buffered saline
(PBS), pH 7.4, for 24 hours at room temperature. (B) Weight loss values were calculated
after removal of the hydrogel samples from solution. Measurements were used to
determine the loss of soluble low molecular species and hydrolytic degradation. (C)
Unconfined compression tests were performed and elastic moduli of PVA-gelatin
hydrogels were calculated using a linear regression of the stress-strain curve between 5 –
15% axial compressive strain; average ± standard deviation are reported (n = 4). PVA
samples were left out of the study due to high compliance.

3.3. In Vitro Chondrogenic Differentiation
The bioactive properties of the PVA-gelatin hydrogels were investigated for
cartilage tissue engineering applications. Two different PVA-gelatin hydrogel
formulations were selected for in vitro cell culture based on the physical
characterization and mechanical analysis. Hydrogel formulations were chosen to reflect
differences in elastic moduli, and with or without the addition of a cell-signaling
molecule, type II collagen. Prior to chondrogenic differentiation, an in vitro MTT-based
cytotoxicity assay was used to measure the mitochondrial activity of human MSCs after
24 hours of culture in the presence of PVA-based hydrogels in standard MSC culture
media. All of the PVA-gelatin groups displayed non-cytotoxic effects and maintained
mitochondrial activity levels > 75%. There were no significant results among the
groups; however, the cytotoxicity assay results indicate a dependence on gelatin
content.
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Figure 8-6. (A) Mitochondrial activity was determined using an MTT-based cytotoxicity
assay. The absorbance values for PVA-gelatin and PVA hydrogels were normalized to
non-modified cell controls cultured on tissue culture polystyrene; ethanol (EtOH) was
used as a negative control. Confluent human MSCs were cultured with PVA-based
hydrogels for 24 hours in standard MSC culture medium at 37 ˚C and 5% C02 (n = 4). (B)
Sulfated GAG production was quantified for MSCs cultured in PVA-gelatin scaffolds
and in non-modified treated polystyrene culture plates in chondrogenic media. Hydrogel
experimental groups consisted of: 18PVA(H)-1Gel (soft), 18PVA(H)-1Gel + type II
collagen (soft + T2), and 36PVA(L)-5Gel + type II collagen (stiff +T2); results are
reported as average ± standard deviation (n = 4). (* = p < 0.005 compared to control
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samples at day 14; ** = p < 0.03 compared to day 4 results within the same sample
group.) Unconfined compression tests were performed and the elastic moduli of human
MSC-seeded hydrogels and non-seeded hydrogel controls were calculated using a linear
regression of the stress-strain curve from 5 – 15% axial compressive strain. Hydrogel
experimental groups consisted of: 18PVA(H)-1Gel (soft), 18PVA(H)-1Gel + type II
collagen (soft + T2), and 36PVA(L)-5Gel + type II collagen (stiff +T2); results are
reported as average ± standard deviation (n = 4).

The efficacy of using PVA-gelatin hydrogels, formed using theta-gels
techniques, to support chondrogenic differentiation was evaluated by measuring initial
matrix content production. The chondrogenic differentiation of the MSCs was
measured using a dimethylmethylene blue (DMMB) assay 4, 7, and 14 days postseeding onto PVA-gelatin hydrogels. PVA-gelatin hydrogel groups were selected
according to elastic moduli values and two groups were chosen to reflect high and low
moduli (soft ~ 10 kPa, stiff ~ 100 kPa). The presence of a cartilage matrix protein, type
II collagen, was investigated; hydrogel groups varied in bioactivity (with or without
type II collagen). Reports from the literature suggest that compliant hydrogels promote
and/or enhance chondrogenic differentiation. Therefore, the effect of the bioactive
molecule was investigated in the soft hydrogel groups.
The intracellular sulfated glycosaminoglycan (GAG) content was measured in
primary human MSCs cultured on PVA-gelatin hydrogel scaffolds in chondrogenic
media over a period of 14 days. Soft PVA-gelatin hydrogels, without the addition of
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type II collagen, did not show any significant differences compared to non-modified
cell controls at all three time points (Figure 8-6 B). However, both soft and stiff
hydrogels containing type II collagen significantly increased intracellular GAG content
compared to the controls after 14 days of culture (p < 0.005). In addition, both the soft+
T2 and stiff+ T2 hydrogel groups significantly increased intracellular GAG content
after 14 days compared to 4 days of culture (p < 0.03). The results also suggest that the
soft + T2 hydrogel samples had a greater influence on intracellular GAG production
compared to the stiff + T2 hydrogels. Thus, the combination of both a selective moduli
value and the presence of a bioactive molecule will significantly enhance the ability for
PVA-gelatin hydrogels to support chondrogenic differentiation, and potentially tissue
regeneration. While the two-week duration of the in vitro is a limitation of the study,
the efficacy of using PVA-gelatin hydrogels, which incorporate type II collagen, for
cartilage tissue engineering applications is supported.
Unconfined compression tests were conducted on cell-seeded hydrogels to
determine what effect the cells may have on the mechanical properties of their physical
environment, i.e., the hydrogel scaffold. PVA-gelatin hydrogel controls were incubated
in standard MSC culture media until testing. At day 4, 7, and 14 the elastic moduli of
the MSC-seeded experimental groups were not significantly different compared to the
controls (Figure 8-5, day 4 = light gray bars, day 7 = striped gray bars, day 14 = dark
gray bars, hydrogel controls = black bars). However, a trend showing the decrease in
elastic moduli of cell-seeded hydrogels with time may reflect the cells remodeling the
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hydrogel scaffold during differentiation. Longer time points may reveal significant
data, and future work will examine degradation and the dynamic mechanical properties
of cell-seeded hydrogels.

4. Conclusions
Cell-instructive PVA-gelatin hydrogels were fabricated in the presence of a
PEG porogen to enhance network integrity. Theta-gels with macro-porous structures
formed through the physical interactions of PVA and gelatin, and supported
chondrogenic differentiation and cartilage matrix deposition. Adding gelatin to PVA
hydrogels formed in the presence of PEG porogensw significantly increased the
hydrogel stiffness and pore size.[34] Bio-synthetic IPN hydrogels were formed using
theta-gel techniques and are promising candidates for cartilage regeneration scaffolds
due to their large pore diameters (10 – 50 µm), moderately high compressive elastic
moduli (20 – 400 kPa), and ability to significantly increase chondrogenesis. Future
work will investigate the role of the gelatin during cell culture and longer in vitro
culture time points. In addition, the effect of dynamic culture will be investigated.
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